Caffeine Intake and its Association with Disease Progression, Sleep Quality and Anxiety Symptoms and Nutritional Alterations in People Living with HIV in the Miami Adult Studies on HIV Cohort by Ramamoorthy, Venkataraghavan
Florida International University
FIU Digital Commons
FIU Electronic Theses and Dissertations University Graduate School
10-30-2015
Caffeine Intake and its Association with Disease
Progression, Sleep Quality and Anxiety Symptoms
and Nutritional Alterations in People Living with
HIV in the Miami Adult Studies on HIV Cohort
Venkataraghavan Ramamoorthy
Florida International University, vrama002@fiu.edu
DOI: 10.25148/etd.FIDC000147
Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Human and Clinical Nutrition Commons
This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Recommended Citation
Ramamoorthy, Venkataraghavan, "Caffeine Intake and its Association with Disease Progression, Sleep Quality and Anxiety Symptoms
and Nutritional Alterations in People Living with HIV in the Miami Adult Studies on HIV Cohort" (2015). FIU Electronic Theses and
Dissertations. 2255.
https://digitalcommons.fiu.edu/etd/2255
  
FLORIDA INTERNATIONAL UNIVERSITY 
Miami, Florida 
 
 
 
 
CAFFEINE INTAKE AND ITS ASSOCIATION WITH DISEASE PROGRESSION, 
SLEEP QUALITY AND ANXIETY SYMPTOMS AND NUTRITIONAL 
ALTERATIONS IN PEOPLE LIVING WITH HIV IN THE MIAMI ADULT STUDIES 
ON HIV COHORT  
 
 
 
A dissertation submitted in partial fulfillment of 
the requirements for the degree of 
DOCTOR OF PHILOSOPHY  
in 
DIETETICS AND NUTRITION 
by 
Venkataraghavan Ramamoorthy 
  
ii 
 
To:  Interim Dean Mark Williams      
 Robert Stempel College of Public Health & Social Work  
 
This dissertation, written by Venkataraghavan Ramamoorthy, and entitled Caffeine 
Intake and its Association with Disease Progression, Sleep Quality and Anxiety 
Symptoms and Nutritional Alterations in People Living With HIV in the Miami Adult 
Studies On HIV Cohort, having been approved in respect to style and intellectual content, 
is referred to you for judgment. 
 
We have read this dissertation and recommend that it be approved.  
 
 
_______________________________________ 
Marianna Baum 
 
_______________________________________ 
Juan Liuzzi 
 
_______________________________________ 
Florence George 
 
_______________________________________ 
Adriana Campa, Major Professor 
 
 
 
Date of Defense: October 30, 2015 
 
The dissertation of Venkataraghavan Ramamoorthy is approved. 
 
 
_______________________________________ 
 Interim Dean Mark Williams  
Robert Stempel College of Public Health & Social Work 
 
   
_______________________________________ 
Dean Lakshmi N. Reddi 
University Graduate School 
 
 
 
Florida International University, 2015  
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright 2015 by Venkataraghavan Ramamoorthy 
All rights reserved.  
 
  
iv 
 
 
 
 
 
 
 
 
 
DEDICATION  
I dedicate this dissertation to my parents Meenakshy R and Ramamoorthy K V, 
and Lord Guruvayoorappan. Without their help, timely grace, support, and unconditional 
love, the completion of this work would not have been possible. 
 
 
 
v 
 
ACKNOWLEDGMENTS 
I wish to extend my sincere gratitude to all people who made this dissertation 
possible, especially my committee members who helped me all these years. Dr. Marianna 
Baum, the PI of the twin studies, a special appreciation for her excellent guidance and her 
course Research Concept Development. Dr. Juan Liuzzi, all my admiration for his 
understanding and unrelenting encouragement. Dr. Florence George, my respects for her 
willingness to help and provide hours of unconditional support. Dr. Adriana Campa, my 
Major Professor, my sincere gratitude for her constructive opinions and limitless flow of 
ideas. Dr. Fatma G Huffman, The Chair, her support has been the beacon of hope during 
troubled times. I would like to thank all my fellow Ph.D. students, especially Muni 
Rubens and Christina Fleetwood for their immense support in the entire process of this 
dissertation. Finally, I would also like to acknowledge the University Graduate School for 
Data and Evidence Acquisition Fellowship and Dissertation Year Fellowship. 
 
 
 
 
 
 
 
 
 
  
vi 
 
ABSTRACT OF THE DISSERTATION 
CAFFEINE INTAKE AND ITS ASSOCIATION WITH DISEASE PROGRESSION, 
SLEEP QUALITY AND ANXIETY SYMPTOMS AND NUTRITIONAL 
ALTERATIONS IN PEOPLE LIVING WITH HIV IN THE MIAMI ADULT STUDIES 
ON HIV COHORT 
by 
Venkataraghavan Ramamoorthy 
Florida International University, 2015 
Miami, Florida 
Professor Adriana Campa, Major Professor 
Miami-Dade County has approximately 27,000 people living with HIV (PLWH), 
and the highest HIV incidence in the nation. PLWH have reported several types of sleep 
disturbances. Caffeine is an anorexic and lipolytic stimulant that may adversely affect 
sleep patterns, dietary intakes and body composition.  High caffeine consumption (>250 
mg. per day or the equivalent of >4 cups of brewed coffee) may also affect general 
functionality, adherence to antiretroviral treatment (ART) and HIV care. This study 
assess the relationship of high caffeine intake with markers of disease progression, sleep 
quality, insomnia, anxiety, nutritional intakes and body composition.  
A convenience sample of 130 PLWH on stable ART were recruited from the 
Miami Adult Studies on HIV (MASH) cohort, and followed for three months. After 
consenting, questionnaires on Modified Caffeine Consumption (MCCQ), Pittsburg 
Insomnia Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI), Generalized 
Anxiety Disorder-7 (GAD-7), socio-demographics, drug and medication use were 
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completed. CD4 count, HIV viral load, anthropometries, and body composition measures 
were obtained.  
Mean age was 47.89±6.37 years, 60.8% were male and 75.4% were African-
Americans. Mean caffeine intake at baseline was 337.63 ± 304.97 mg/day (Range: 0-
1498 mg/day) and did not change significantly at 3 months.  In linear regression, high 
caffeine consumption was associated with higher CD4 cell count (β=1.532, P=0.049), 
lower HIV viral load (β=-1.067, P=0.048), higher global PIRS (β=1.776, P=0.046), 
global PSQI (β=2.587, P=0.038), and GAD-7 scores (β=1.674, P=0.027), and with lower 
fat mass (β=-0.994, P=0.042), energy intakes (β=-1.643, P=0.042) and fat consumption 
(β=-1.902, P=0.044), adjusting for relevant socioeconomic and disease progression 
variables. Over three months, these associations remained significant. The association of 
high caffeine with lower BMI weakened when excluding users of other anorexic and 
stimulant drugs such as cocaine and methamphetamine, suggesting that caffeine in 
combination, but not alone, may worsen their action. In summary, high caffeine 
consumption was associated with better measures of disease progression; but was also 
detrimental on sleep quality, nutritional intakes, BMI and body composition and 
associated with insomnia and anxiety. Large scale studies for longer time are needed to 
elucidate the contribution of caffeine to the well-being of PLWH. 
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CHAPTER I: INTRODUCTION AND SPECIFIC AIMS 
General Introduction 
Caffeine is one of the most widely consumed psycho-active substances 
worldwide.1 Caffeine, a white, odorless, crystalline and bitter tasting substance was first 
isolated form coffee beans in the year 1820.1 Over the years a huge body of literature has 
accrued regarding the major sources and quantities consumed as well as the populations 
consuming significant levels.2 Coffee constitutes the single largest source of caffeine and 
contains more caffeine than all other available sources.2,3 Other significant sources 
include tea leaves, cocoa pods, cola nuts, yerba mate, caffeinated drinks and many 
prescription and over the counter medications.2 Many individual studies show that 
athletes, students, young adults, teenagers, and military personnel are the major 
populations consuming significant levels of caffeine.4-6  Some of the major methods of 
caffeine consumption include brewed coffee, brewed tea, carbonated soft drinks, energy 
drinks, energy shots, fruit drinks, fruit flavored beverages and watery beverages.2,3  
Among children carbonated soft drink constitutes the largest source of caffeine 
consumption; whereas brewed coffee constitutes the same among adults.4-6 It is difficult 
to comprehensively summarize average consumption levels across different countries, 
cultures and ethnicities given the diversities in sources and patterns of consumption. The 
predicted average consumption across different coffee/tea consuming nations ranges 
between 80 and 400 mg per person per day.7 A survey done by Faray et al.,3 estimated 
that 87% of Americans consumed caffeine and average consumption approximated 193 
mg per day per person and ranged between 166 mg and 336 mg per day.  In addition to 
caffeine there are many structurally and functionally similar xanthine-alkaloid 
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compounds in coffee and caffeinated products and major ones include theophylline and 
theobromine.8  Tea is primarily rich in theophylline, and contains approximately 50 mg 
of caffeine per 8 oz of black tea.8 Cola-acuminata extracts present in Coca-Cola and other 
soft drinks contain variable amounts of caffeine (35 to 55 mg in 12 oz of soft drinks).8 
Chocolate derived from cocoa pods and cocoa butter is primarily rich in theobromine, but 
also contains trace amounts of caffeine.8 Based on standardized caffeine content of major 
sources (135 mg per 8 oz of coffee, 50 mg per 8oz of black tea and 35-55 mg per 12oz of 
soft drinks), it was estimated in 2014 that an average American consumes 135 mg of 
caffeine from coffee, 30 mg of caffeine from tea and 50 mg of caffeine from soft drinks 
per day.9  According to estimates in late eighties, 75% of total caffeine consumption 
came from coffee, 15% from tea and 10% from caffeinated soft drinks. Chocolates, 
medications and other caffeine containing products contributed very less to the average 
consumption levels.9 Estimates in 2014 still show the same characteristics with coffee 
being the highest source (66%), tea being the second highest (20%) and caffeinated soft 
drinks the third highest source (11%), while all other sources contributed negligibly 
towards the total consumption.9   
            Caffeine shows diuretic properties and stimulates respiratory, cardiovascular and 
neuro-hormonal systems.10 In addition to its consumption as beverages, several 
therapeutic interactions have been identified. This includes its effects on a variety of 
medical conditions like narcolepsy, asthma, sleep apnea, migraine and cluster headaches, 
Parkinsonism, ADHD, fetal asphyxia and major depression states.11-18 Other conditions 
that affect the metabolism and elimination of caffeine include age, pregnancy, 
concomitant medications and liver function levels.19 The half-life of the compound varies 
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between 4-11 hours under normal physiological conditions.19 In acute liver failure states 
caffeine can be significantly toxic as the half-life increases to as high as 90-100 
hours.19,20 Caffeine is metabolized in the liver by the cytochrome P450 oxidase enzyme 
systems into three major metabolites paraxanthine (80-85%), theobromine (10-15%) and 
theophylline (0-5%).19 All these metabolites are dimethyl xanthines and have 
independent actions similar to the parent compound caffeine and are further metabolized 
through the same enzyme system in the liver and excreted through urine.19 Paraxanthine 
has the same potency and nearly all the physiological actions of caffeine.21 In-spite of 
caffeine being considered a therapeutic drug, regulatory agencies have not instituted any 
restriction on the sale and purchase of caffeine: neither is caffeine consumption 
considered any kind of recreational drug use.22 Initial efforts to include it in the list of 
scheduled drugs are evident in studies done by Gilliland and Bullock, and Holtzman.23,24 
Both the studies suggested that caffeine and associated xanthine alkaloids should be 
considered as regulated substances because of their withdrawal, tolerance, dependence 
and addictive potentials.23,24 The median lethal dose of caffeine was 192 milligrams per 
kilogram body weight as estimated in rats.25 Based on estimates from animal studies the 
median lethal dose for humans has been calculated to be about 150 to 200 milligrams per 
kilogram of body weight or roughly 80 to 100 cups of coffee for an average adult, though 
it would also depend upon the individual’s sensitivity and genetic factors affecting 
caffeine metabolism26,27 or the presence of other medications and therapeutic drugs 
affecting the same.28,29 Given these high lethal dose values caffeine consumption is 
generally considered safe for all practical purposes.26  
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            The current study was a prospective observational study (follow-up study) of 
associations between caffeine consumption and immunological and virologic markers of 
disease progression (CD4 counts and HIV viral loads). This study also investigated for 
associations between caffeine consumption and sleep derangements and anxiety 
symptoms through sleep quality and anxiety questionnaires. Similarly, this study 
investigated caffeine consumption and changes in nutrient intakes which included 
carbohydrate intake, protein intake and fat intake. This study also investigated the effects 
of caffeine on body composition measures like BMI, lean body mass (LBM), total fat 
mass and other nutritional status indicators like hemoglobin, hematocrit and serum 
albumin levels. Any adverse effect on these parameters should be considered as adverse 
effects on HIV disease progression as the literature specifies. 
Justification for the Study 
Caffeine intake is very prevalent in this population of HIV infected individuals in 
Miami (MASH cohort). Campa et al.,30 reported that 88.79% of the population sample 
collected for the preliminary study ‘Zinc-supplementation and its effects on disease 
progression in HIV infected patients’ recorded some levels of consumption. The mean 
caffeine intake for this cohort was 115 mg per day.30 As discussed in the literature review 
ahead, consumption of higher levels of caffeine leads to dependency and a variety of 
unpleasant physical and mental conditions including nervousness, irritability, 
restlessness, insomnia, headaches, and heart palpitations. These symptoms collectively 
known as ‘caffeinism’31 was shown to have many adverse health effects in a number of 
studies done in vulnerable populations.32-35  
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There were significant negative associations between caffeine intake and sleep 
quality scores as well as generalized anxiety levels.36,37 These effects were predicted to be 
more pronounced in HIV+ patients with compromised health and immune status.36 Our 
proposed study included PSQI and PIRS questionnaires for estimating sleep quality and 
GAD-7 questionnaires for subjective symptoms of anxiety. Caffeine has been recognized 
as a beneficial stimulant in low to moderate consumption levels (50 mg/day to 250 
mg/day). Increased consumption beyond this limit, however, is associated with 
heightened neuronal burn-outs and lack of adequate sleep.36,37 Our study retested these 
hypotheses in a group of HIV positive participants who were already compromised in a 
number of health and socio-economic parameters. 
There are very few studies about the effects of caffeine consumption on nutrient 
intake especially in HIV positive patients. Research shows that caffeine consumption has 
both positive and negative health outcomes. The positive outcomes were observed mainly 
in diabetic patients. Moderate caffeine intake showed benefits in patients with Type-2 
diabetes and metabolic syndrome, as caffeine intake facilitates weight loss and reduction 
of fat mass.38 Conversely, in people living with HIV, where wasting is a serious problem, 
high caffeine intake could precipitate adverse health outcomes. In a study done by Kent 
et al.39, it was observed that administration of fat lowering agent orlistat was associated 
with higher viral loads compared to subjects not using this medication. Similarly another 
study done by Shor-Prosner et.al.,40 on HIV positive participants from Miami showed 
that body mass index (BMI) was inversely associated with progression to AIDS as well 
as mortality; suggesting mild-to-moderate obesity having better immune function and 
better survival rates in this cohort.  Loss of fat mass as well as lean body mass, have 
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always been reported to have detrimental effects on HIV disease progression. Both HIV41 
and caffeine42 increase fat and protein catabolism and decrease appetite, and their 
combined interactions have not been well studied. Based on these previous literatures, 
our study investigated whether caffeine was associated with changes in body composition 
measures, nutritional indicators and in nutrient consumption levels.   
Significance of the Study  
The study is particularly relevant for many reasons. This study aimed to 
determine the effect of caffeine consumption on disease progression in HIV positive 
patients. Though there are many studies on the effects of caffeine on healthy persons, 
ergogenics, diabetes, pregnancy, liver failure and other medical conditions, to the best of 
our knowledge, the literature on HIV positive participants is limited. The information 
obtained through this study will be helpful for development of targeted interventions for 
people living with HIV (PLWH). Future studies that estimate the effects of different 
levels of consumption as well as standardized consumption limits in this population will 
contribute to the development of adequate nutritional recommendations for caffeine in 
PLWH.  
This study also looked for the effects of caffeine on sleep quality, anxiety and 
nutritional parameters. The majority of the participants enrolled in this study are 
marginalized and disempowered. Their living conditions are plagued by food scarcity, 
homelessness, drug abuse and criminalization.  Because of these harsh living conditions 
they are already susceptible to a variety of anxiety states and sleep disorders as well as 
poor nutrient intakes.43-51 Caffeine consumption at high levels further contributes to these 
conditions. Such effects will definitely increase the rate of disease progression in this 
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population. Many studies have shown that adequate nutrition and sufficient sleep are 
inseparable components of healthy living initiatives.52,53 Educating this marginalized 
population about healthy living can never be accomplished without understanding their 
caffeine consumption, its impact on sleep quality and nutrient consumption, as well as the 
inter-relationships between these variables.  
Specific Aims and Hypotheses 
Specific aim 1: Examine the effect of caffeine on HIV disease progression  
Rationale: Caffeine intake in higher than regular doses (>250 mg/day) has been 
associated with decreased CD4 counts (adverse effect) as well as decreased viral loads 
(beneficial effect). Our study looks for the net impact of caffeine over these opposing 
effects on disease progression. 
Hypothesis 1A: HIV+ adults with caffeine intake >250 mg/day have lower CD4 cell 
counts compared with those who do not consume caffeine or do so in moderation (<250 
mg/day) measured over 3 months.  
Hypothesis 1B: HIV+ adults with caffeine intake >250 mg/day have higher viral loads 
compared with those who do not consume caffeine or do so in moderation (<250 mg/day) 
measured over 3 months. 
Hypothesis 1C: Caffeine consumption as a continuous variable is associated with 
decreased CD4 cell counts, CD4 counts<200 cells/μL and increased viral loads or lack of 
viral load control, measured over 3 months. 
Instruments/Tools/Observations: Caffeine Consumption questionnaires, CD4 cell count 
and viral loads transcribed from medical records submitted by the participants. 
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Confounding Variables: Age, gender, income, race/ethnicity, grades, time from 
diagnosis of HIV, drug use, alcohol consumption, smoking status, BMI, total body fat 
percentage. 
Specific Aim 2: Examine the effect of caffeine on sleep disorders in HIV 
Rationale: Caffeine intake >250 mg/day is associated with poor quality of sleep and 
increased episodes of insomnia. 
Hypothesis 2A: HIV+ adults with caffeine intake >250 mg/day have decreased quality of 
sleep measured by the PSQI scores, and increased periods of insomnia measured by the 
PIRS over a period of 3-months. 
Hypothesis 2B: Caffeine consumption as a continuous variable is associated with 
decreased quality of sleep measured by the PSQI scores, and increased periods of 
insomnia measured by the PIRS over a period of 3-months. 
Instruments/Tools/Observations: Caffeine consumption questionnaires, Pittsburg Sleep 
Quality (PSQI) questionnaire, Pittsburg Insomnia Rating Scale (PIRS) questionnaire.  
Confounding Variables: Age, income, race/ethnicity, time from diagnosis of HIV, drug 
use, alcohol consumption, smoking status, sleep medications and types of ART 
medications. 
Specific Aim 3: Examine the effect of Caffeine on Anxiety Symptoms 
Rationale: Caffeine intake >250 mg/day has been associated with increased anxiety and 
restlessness. 
Specific Aim 3: Examine the effect of Caffeine on anxiety symptoms 
Rationale: Caffeine intake >250 has been associated with increased anxiety and 
restlessness. 
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Hypothesis 3A: HIV+ adults with caffeine intake >250 mg/day have increased anxiety 
symptoms measured by the GAD-7 scores over a period of 3-months. 
Hypothesis 3B: Caffeine consumption as a continuous variable is associated with 
increased anxiety symptoms measured by the GAD-7 scores over a period of 3-months. 
Instruments/Tools/Observations: Caffeine consumption questionnaires, Generalized 
Anxiety Disorder-7 (GAD-7) questionnaire.  
Confounding Variables: Age, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
Specific Aim 4: Examine the effect of Caffeine on Body composition measures and 
nutritional indicators such as hemoglobin, hematocrit and serum albumin levels 
Rationale: Caffeine is associated with decreased caloric intakes as well as increased 
energy expenditures thereby leading to nutritional deficiency states. 
Hypothesis 4A: HIV+ adults with caffeine intake >250 mg/day have decreased lean body 
mass and body fat mass estimated by Bio-impedance analysis (BIA) over a period of 3-
months. 
Hypothesis 4B: HIV+ adults with caffeine intake >250 mg/day have decreased BMI 
estimated by BIA over a period of 3-months. 
Hypothesis 4C: HIV+ adults with caffeine intake >250 mg/day have lower than normal 
hemoglobin measured over a period of 3-months. 
Hypothesis 4D: HIV+ adults with caffeine intake >250 mg/day have lower than normal 
hematocrit measured over a period of 3-months. 
Hypothesis 4E: HIV+ adults with caffeine intake >250 mg/day have lower than normal 
serum albumin levels, measured over a period of 3-months. 
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Instruments/Tools/Observations: Caffeine consumption questionnaires, Bio-impedance 
analysis (BIA), Hemoglobin levels, Hematocrit and serum albumin levels. 
Confounding Variables: Age, gender, income, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status and types of ART medications. 
Specific Aim 5: Examine the effect of caffeine on caloric and nutrient intake and food 
security status 
Rationale: Caffeine is associated with decreased nutrient intakes and deficiency states. 
Hypothesis 5A: HIV+ adults with caffeine intake >250 mg/day have decreased total 
caloric intakes estimated by 24-hour dietary recall over a period of 3-months. 
Hypothesis 5B: HIV+ adults with caffeine intake >250 mg/day have decreased caloric 
intakes from proteins estimated by 24-hour dietary recall over a period of 3-months. 
Hypothesis 5C: HIV+ adults with caffeine intake >250 mg/day have decreased caloric 
intakes from carbohydrates estimated by 24-hour dietary recall over a period of 3-
months. 
Hypothesis 5D: HIV+ adults with caffeine intake >250 mg/day have decreased caloric 
intakes from fats estimated by 24-hour dietary recall over a period of 3-months. 
Instruments/Tools/Observations: Caffeine consumption questionnaires, 24-hour dietary 
recall, Nutribase-9 analysis reports of daily nutrient intake, food security questionnaire 
(FSQ).  
Confounding Variables: Age, gender, income, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status and types of ART medications. 
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Table 1: Summary of Hypotheses and Statistical Methods  
 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 1A :HIV+ 
adults with caffeine 
intake >250 mg/d have 
lower CD4 cell counts 
compared with those 
who do not consume 
caffeine or do so in 
moderation (<250 
mg/day) measured over 
a period of 3 months. 
CD4 count 
square root 
Total Caffeine 
intake  
age, income, race 
ethnicity, time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use, BMI and 
total body fat percent. 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations 
Hypothesis 1B: HIV+ 
adults with caffeine 
intake >250 mg/d have 
higher viral loads 
compared with those 
who do not consume 
caffeine or do so in 
moderation (<250 
mg/day) measured over 
a period of 3 months. 
Log10 viral 
load 
Total Caffeine 
intake 
age, income, race 
ethnicity, time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use, BMI and 
total body fat percent. 
 
 
 
 
 
 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 1C: 
Caffeine consumption as 
a continuous variable is 
associated with 
decreased CD4 cell 
counts, CD4 counts<200 
cells/μL and increased 
viral loads or lack of 
viral load control, 
measured over a period 
of 3 months. 
CD4 count 
square root, 
Log10 viral 
load 
Total Caffeine 
intake 
age, income, race 
ethnicity, time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use, BMI and 
total body fat percent. 
Linear and logistic 
regressions were used to 
understand whether caffeine 
consumption is associated 
with changes in CD4 cell 
counts and viral loads. 
Linear Mixed Models were 
used for overtime changes in 
these relationships. 
Hypothesis 2A: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased quality of 
sleep measured by the 
PSQI scores, and 
increased periods of 
insomnia measured by 
the PIRS over a period 
of 3-months. 
 
 
 
 
 
 
PSQI 
variables, 
PIRS 
variables 
Total Caffeine 
intake 
age, income, race 
ethnicity, time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use, sleep 
medications and 
types of ART 
medication. 
 
 
 
 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations.* 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 2B: 
Caffeine consumption as 
a continuous variable is 
associated with 
decreased quality of 
sleep measured by the 
PSQI scores, and 
increased periods of 
insomnia measured by 
the PIRS over a period 
of 3-months. 
PSQI 
variables, 
PIRS 
variables 
Total Caffeine 
intake 
age, income, race 
ethnicity, time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use, sleep 
medications and 
types of ART 
medication. 
Linear and logistic 
regressions were used to 
understand whether caffeine 
consumption is associated 
with changes in quality of 
sleep measured by PSQI 
scores and severity of 
insomnia measured by the 
PIRS. Linear Mixed Models 
were used for overtime 
changes in these 
relationships. 
Hypothesis 3A: HIV+ 
adults with caffeine 
intake >250 mg/d have 
increased anxiety 
symptoms measured by 
the GAD-7 scores over a 
period of 3-months. 
GAD-7 scores Total Caffeine 
intake 
age, income, and time 
from diagnosis of 
HIV, drug, tobacco 
and alcohol use and 
different types of 
ART medications 
 
 
 
 
 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 3B: 
Caffeine consumption as 
a continuous variable is 
associated with 
increased anxiety 
symptoms measured by 
the GAD-7 scores over a 
period of 3-months.  
GAD-7 scores Total Caffeine 
intake 
age, income, and time 
from diagnosis of 
HIV, drug, tobacco 
and alcohol use and 
different types of 
ART medications 
 
Linear and logistic 
regressions were used to 
understand whether caffeine 
consumption is associated 
with changes in levels of 
anxiety measured by GAD-7 
scores. Linear Mixed Models 
were used for overtime 
changes in these 
relationships. 
 
 
Hypothesis 4A: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased lean body 
mass and body fat mass 
estimated by Bio-
impedance analysis 
(BIA) over a period of 
3-months. 
Lean body 
mass(LBM), 
fat mass 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
 
 
 
 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 4B: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased BMI 
estimated by BIA over a 
period of 3-months.  
Body mass 
index (BMI) 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
Hypothesis 4C: HIV+ 
adults with caffeine 
intake >250 mg/d have 
lower than normal 
hemoglobin measured 
over a period of 3-
months.   
Hemoglobin 
levels 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
Hypothesis 4D: HIV+ 
adults with caffeine 
intake >250 mg/d have 
lower than normal 
hematocrit measured 
over a period of 3-
months. 
Hematocrit Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 4E: HIV+ 
adults with caffeine 
intake >250 mg/d have 
lower than normal 
serum albumin levels, 
measured over a period 
of 3-months. 
Serum 
albumin 
levels 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
Hypothesis 5A: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased total caloric 
intakes estimated by 24-
hour dietary recall over 
a period of 3-months. 
Total caloric 
intake 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
Hypothesis 5B: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased caloric 
intakes from proteins 
estimated by 24-hour 
dietary recall over a 
period of 3-months. 
Calories from 
proteins 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications  
 
 
 
 
 
 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
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Table 1. Continued… 
Hypotheses Dependent 
Variables 
Independent 
Variables 
Control Variables Statistical Analysis  
Hypothesis 5C: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased caloric 
intakes from 
carbohydrates estimated 
by 24-hour dietary recall 
over a period of 3-
months. 
Calories from 
carbohydrates 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
Hypothesis 5D: HIV+ 
adults with caffeine 
intake >250 mg/d have 
decreased caloric 
intakes from fats 
estimated by 24-hour 
dietary recall over a 
period of 3-months. 
Calories from 
fats 
Total Caffeine 
intake 
age, gender, income, 
and time from 
diagnosis of HIV, 
drug, tobacco and 
alcohol use and 
different types of 
ART medications 
T-test and linear and logistic 
regressions were used to 
analyze baseline cross-
sectional data and Linear 
Mixed Models were used for 
over time changes in these 
associations. 
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CHAPTER II: LITERATURE REVIEW 
There are many recent instances of adverse events due to caffeine abuse and a 
number of television and newspaper reports suggest a pandemic of caffeine overuse in 
United States in the current decade.1 There have also been many reports of energy drinks 
related deaths and concerns about rising levels of caffeine consumption especially 
amongst many vulnerable populations.1 In spite of such alarming rates of increased 
adverse events due to caffeine, the extent to which these reports are scientific and 
evidence-based has always been disputed and repeatedly challenged by the scientific 
community.1 In lieu of these conflicting evidence, concerns over safety and permissible 
levels of caffeine consumption needs to be addressed and researched amongst different 
population groups. We need to understand the reasons for peaking levels of caffeine 
consumption in many vulnerable populations, as well as the characteristics that place 
these populations at higher risk. Many studies have linked caffeine intake to various 
physical benefits, such as increased strength, endurance and stamina, making caffeine-
containing beverages a favorite amongst athletes and sports personnel.1-5 There are many 
reports which show that caffeine is associated with mental faculties like increased 
alertness, cognition and performance, thereby increasing its overuse potentials among 
students and professionals.1-5 Many studies report the advantages of consuming caffeine 
on increased duration and quality of work, increased working capacity at hours that 
interfere with the biological rhythm, as well as increased work efficiency at the cost of 
reducing the number of hours of sleep recommended per day.1-5 Vulnerable populations 
according to numerous studies include students, business personnel, athletes, night shift 
workers, population with chronic diseases, military personnel, geriatric population, 
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frequent travelers as well as professionals in college and university settings.6 It is 
particularly relevant that we research caffeine consumption as a phenomenon and 
understand the effects in the general population before we focus on the effects in our 
cohort of PLWH in Miami.  
Daily Reported Caffeine use in United States 
Secondary analyses of NHANES data collected between 2001 and 2010 showed 
that the general levels and patterns of caffeine consumption have not significantly 
changed over the last ten years.6-8 The average recorded consumption was 200 mg/day for 
all the entire survey.6-8 All the age groups consumed highest amounts of caffeine through 
coffee and average consumption through different beverages included, 135 mg/day form 
coffee, 65 mg/day from energy drinks, 60 mg/day form tea and 35 mg/day from soda.6-8 
Results also showed that highest caffeine consumptions (average caffeine intake recorded 
beyond the 90th percentiles for the entire sample) were recorded in the age group of 50-59 
years with average daily levels exceeding 500 mg/day, and in the 50-59 years group with 
slightly less than 500 mg/day.6-8 There was also a statistically significant increase of 8 
mg/day of caffeine from energy drinks during the past ten years (P<0.001).6-8 Another 
large scale study done in US in the year 2011 with 37,604 participants showed similar 
caffeine consumption characteristics to the ones reported by the NHANES data.9  The 
largest caffeine source was coffee followed by energy drinks, tea and soda.9  
Safe Levels of Caffeine Consumption 
Over the last fifty years caffeine has been widely researched. Several studies have 
been conducted by regulatory agencies for determining the safe levels of consumption as 
well as levels producing side effects and adverse effects for different populations.10-15  
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The U.S. Food and Drug Administration (USFDA) has different recommendations based 
upon whether caffeine is consumed through naturally available sources like coffee, tea 
and cocoa products or artificially added in caffeinated beverages and energy drinks.11,14 
USFDA has classified natural sources as Generally Recognized as Safe (GRAS) category 
while artificially added caffeine has been concluded to be safe, within the current average 
levels of consumption (200 mg/day).11 Further research was recommended to confirm the 
safety limits of artificially added caffeine.11 For both naturally occurring and artificially 
added caffeine sources, FDA considers 400 mg/d to be generally safe and not associated 
with any dangerous side effects.10,11  The World Health Organization (WHO) defines 
caffeine overuse as daily consumption beyond 500 mg/d.12,13  Beyond this level caffeine 
produces visible adverse effects collectively known as ‘caffeinism’. The World Health 
Organization (WHO) has also cautioned that these adverse effects could be precipitated at 
much lower doses depending on the physiological profiles of individuals as well as the 
genetic makeup of the population.12,13 The International Classification of Diseases (ICD) 
manual considers caffeine consumption beyond 250 mg/day to be associated with many 
mental and behavioral disorders though it is inconclusive whether such effects would be 
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally 
safe and beyond this level to be associated with many adverse effects such as withdrawal, 
addiction, irritability and craving.15 Thus we can conclude that consumption below 250 
mg/day, irrespective of the sources is generally safe and devoid of adverse effects after 
comparing and summarizing the recommendations of these individual regulatory bodies.  
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Caffeine-Biological Actions-Adenosine Receptors (A1, A2a, A2b and A3) 
 Caffeine affects a number of physiological and biochemical processes.16 The 
main action includes the blockade of a number of related adenosine receptor family 
subtypes.16,17 Caffeine at plasma levels of 0.001-0.1 millimoles/ml produces significant 
blockade of all adenosine receptor subtypes.16 Other biochemical effects include 
inhibition of phosphodiesterases, blockade of GABA-A receptor subtypes, and release of 
intracellular calcium.16 These actions are accomplished at higher plasma levels of 0.1-10 
millimoles/ml.16 A number of other interactions including ion channel blockade and 
enzyme inhibitions have also been reported.16 Four different adenosine receptor subsets 
exist in mammals, which include A1, A2a, A2b and A3.17 When considered the order of 
importance (in humans), in terms of relative concentrations and effects in the body, A2a 
receptors stand the first, A1 the second and A2b the third.17 At A3 receptors caffeine is a 
‘partial agonist’ with both agonist and antagonist like actions or in practical terms ‘no 
significant effects’.17 Caffeine is primarily an antagonist at A1, A2a & A2b receptor 
subtypes.17 To be antagonized, the receptors should be already acted upon by endogenous 
adenosine.  Caffeine has no CNS effects unless the receptors are already acted upon by 
endogenously produced adenosine. Under normal physiological conditions, adenosine 
acts on A1 and A2a receptors in both the Central Nervous System (CNS) and Peripheral 
Nervous System (PNS) and produces inhibition of the neuronal circuitry.17 Adenosine 
acts on A2b and A3 receptor during abnormal conditions like ischemia and necrosis, or 
during increased firing states like convulsions and seizures.17 Blockade of A1 and A2b 
receptor seem to be the most possible mechanism for pharmacological actions of caffeine 
under normal resting physiological conditions.17 A number of drugs of abuse have the 
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potentials to change the endogenously and constitutionally expressed levels of 
adenosine.17 These endogenously expressed levels of adenosine show much ‘inter species 
variability’ between different biological species and ‘intra-species variability’ between 
different individuals.16 This is the likely mechanism for different levels of tolerance to the 
effects of caffeine between different individuals, as well as different life forms.16 This 
also accounts for the different set of responses when caffeine is co- administered with 
other drugs of abuse.16 This is also responsible for different sets of biphasic responses 
between animals and humans thereby delimiting the comparability between animal and 
human studies.18 Caffeine also stabilizes these receptors to the normal circadian 
fluctuating levels of adenosine expressed constitutionally thereby explaining the 
phenomenon of reinforcement.18 In addition to inhibiting adenosine, caffeine also inhibits 
phosphodiesterase enzymes and thereby increases the G-protein stimulation, increases 
adenylyl cyclase enzyme activity and increases cyclic AMP levels in the cells.19 It has not 
been possible to classify and isolate the effects of caffeine (e.g CNS stimulation, anti-
depressant, and somnolytic effects) specifically to its action on any of the individual 
receptor subtypes. All these actions are accomplished through various levels of receptor 
antagonism involving all the three receptors.19 Various ‘receptor sub-type specific 
analogs’ of adenosine have been employed to study the individual receptor subtypes. But 
these analogs have additional actions on many other receptor, which may or may not be 
related to caffeine and adenosine, thus obscuring the results.19  Research has shown there 
are many such dormant receptor subtypes that are not affected by endogenously produced 
adenosine. These receptors are species specific and hence again, animal studies do not 
produce comparable results.19 This is further complicated by the findings in many animal 
 28 
 
studies which show receptor ‘up-regulations’ and ‘down-regulations’ by caffeinated 
products. In a study done on mice, chronic treatment with caffeine resulted in ‘up-
regulation’ of A1-adenosine receptors, serotonin receptors, GABA-A receptors, 
muscarinic receptors, and δ-opoid receptors.20 Similarly it produced ‘down-regulation’ of 
β-adrenergic receptors and ‘desensitization’ of nicotine receptors.20 Dopamine receptors 
were not showing any such changes and hence the actions on dopaminergic receptors can 
be considered unaffected by acuteness or chronicity of caffeine consumption, in both 
humans and animals.21 These findings suggest that the biological effects of caffeine are 
complex and variable (individual to individual variability), because of the differences in 
the mechanism of action and variability in the types of receptors involved. Many studies 
on acute and chronic caffeine use fail to yield adequate test-retest reliability due to these 
variable levels of receptor-regulations.21  
Caffeine and A1 Adenosine Receptors in the Central Nervous System (CNS) 
A1 receptors are abundant in the cerebral cortex, cerebellar cortex, hippocampus, 
substantia nigra, and thalamic nuclei.22 These receptors are located on synaptic clefts and 
axo-dendritic buttons.22 When endogenous adenosine acts on these receptors it produces 
substantial inhibition of the release of a number of neuro-transmitters. It is not well 
known how these inhibitory actions are accomplished. Under normal physiological 
conditions adenosine produces inhibition of only certain neuronal circuits while others 
remain unaffected. These mechanisms too, are not fully understood. Caffeine has a dual 
role when it comes to antagonism of adenosine at A1 receptors. It produces reversal of 
the inhibition produced by Adenosine which is the most important and acute action. But 
in the long term these receptors are also up-regulated by chronic caffeine use.23 Up-
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regulation occurs both by the process of desensitization to caffeine as well as increase in 
the number of constitutionally synthesized receptors.23 Caffeine also increases the rate of 
recycling of these receptors.23 Adenosine decreases the rate of firing of many CNS 
neurons with nor-adrenergic, dopaminergic, cholinergic, and glutamatergic activity 
through A1 receptor-mediated activation of fast potassium channels.24 Thus adenosine 
produces hyper-polarization of the cells and thereby inhibition of neuronal circuitry. 
Certain studies show that open chloride channels are also responsible for these actions. 
This process is known as tonic inhibition of A1 receptors by adenosine.24 This tonic 
inhibition is competitively antagonized by caffeine.24 A number of animal studies have 
documented that caffeine increases the levels of acetylcholine in the cholinergic neurons 
of meso-pons, hippocampus and amygdala and mesolimbic nuclei. 25 These are the 
centers responsible for mood, aggression, locomotion, learning, memory and behavior. 
This acetylcholine via stimulation of nicotinic receptors in Ascending Reticular 
Activation System (ARAS) produces behavioral arousal. Actions of caffeine have also 
been recorded in nigro-straital pathways, thus enhancing jitteriness and loss of fine motor 
coordination skills.25 Caffeine also increases the levels of dopamine and glutamine in the 
cortical neurons that innervate the thalamus and striatum.21 This is responsible for 
locomotor stimulation and hyper-excitability states. An animal study done on mice 
showed that both D1 and D2 receptors are involved in the locomotor stimulatory effects 
of caffeine. Antagonists that blocked both D1 and D2 receptors inhibited the increased 
locomotor stimulation induced by caffeine.21 Selective antagonists of D2 receptors 
produced inhibition of rotational activity also induced by the same doses of caffeine.21 
These processes are very complex and shows inter species and intra species variations. 
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Irrespective of these complexities it is very convincing that caffeine produces a variety of 
adverse effects through antagonism of Adenosine at A1 receptors. These biochemical 
alterations can have serious effects in chronic disease states like HIV where brain cells 
are constantly attacked and destroyed the virus. 
Caffeine Effects on A2a and A2b Adenosine Receptors  
A2a receptors are abundant in caudate nucleus, putamen, nucleus accumbens, 
tuberculum olfactorium26 as well as the gabaminergic neurons of striatum.27 These nuclei 
are mainly associated with D1 and D2 receptor mediated release of encephalins which are 
natural endorphins that act as potent analgesics and mood elevators. D1 receptors are also 
associated with release of other neurotransmitters like substance P and dynorphins which 
have similar euphoric actions. Though both the dopaminergic receptors D1 and D2 are 
positively modulated by caffeine, the effects of D1 predominate.28 These A2a receptors 
stimulate Adenylyl cyclase, increase cyclic AMP levels, similar to A1 receptors. But 
strikingly, D2 receptors decrease the levels of cyclic AMP. Caffeine antagonizes the 
actions of endogenous adenosine at A2b receptors, thereby potentiating endogenous 
dopaminergic effects on D2 receptors. This decreases the levels of cyclic AMP in the 
neuronal cells. Thus caffeine acts as a depressant in some neuronal circuitry.29 These A2a 
receptors are located on the dendritic spines and are virtually absent in the synaptic 
buttons or clefts. 29 It is well established that inhibition of adenosine at A2a receptors by 
caffeine, potentiate the inhibitory effects of GABA. 29 Caffeine blocks the striatal A2a 
receptor activity tonically activated and controlled by adenosine. This would decrease the 
effects of endogenous dopamine on D2 receptors. 29 This produces major changes in 
circuitry associated with reward /arousal systems. Adenosine by its action on A1 
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receptors produces some levels of physiological self-antagonism to its actions on A2a 
receptors.29 These actions confuse the role played by caffeine both in acute and chronic 
doses.29 Furthermore, this self-antagonism shows inters-species and intra-species 
variations.29 Any findings from animal studies therefore need to be validated with human 
studies and no acceptable levels of homogeneity and comparability exists. Caffeine 
therefore has both effects; stimulating effects on certain neuronal circuitry and depressant 
effects on others.30 Furthermore some nuclei like striato-pallidal and striato-nigral, are 
inhibitory to the Globus pallidus and substantially higher concentrations of A2a receptors 
are found to be active in these nuclei.31 Caffeine by blocking the constitutive inhibitory 
effects of endogenous adenosine decreases the inhibitory effects on Globus pallidus and 
thereby symptomatically ameliorates the progression of Parkinson’s disease.31 But this 
effect is at the costs of increased activity in other neuronal circuits like those in cerebral 
and cerebellar cortex which leads to increased burnout damages in these neurons. Thus, 
we have an open question ‘Whether the beneficial effects of caffeine could be at the costs 
of potential known or unknown side-effects?’  
Biphasic Effects of Caffeine  
Both human and animal studies have shown biphasic behavioral effects of 
caffeine. Low to moderate doses elicited a stimulatory effect described by many as 
desirable: high doses elicited undesirable effects like anxiety, nervousness, shakiness, 
jitteriness and lack of concentration. 32 Very high doses have shown to induce 
convulsions in animal models. The cluster of undesirable effects of high and very high 
doses of caffeine is collectively known as ‘caffeinism’.32 Low doses of caffeine (<4 
mg/kg body weight/day) stimulated a frenzy of motor activity in rodents. This is 
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measured in terms of ‘open-field locomotion activity scores’ in normal mice and 
‘rotational activity scores’ in mice with induced unilateral dopaminergic lesions. Low 
doses elicited ‘conditioned place preference’ an indicator of desirable effects in mice.32 
High doses on the contrary, elicited ‘place aversion’ an indicator of undesirable effects.32 
High doses have also shown major depression like symptoms in these animals.32  Another 
study suggested that high doses of caffeine produced profound suppression of motor 
activity in knockout mice with absent A2A-adenosine receptor.33 This shows that the 
stimulatory effects are prominent until fullest saturation of these and other structurally 
similar receptors and once these receptors are saturated depressive effects begin to 
predominate. Mumford and Holtzman34 did an experiment in which the mice were trained 
to identify drugs with similar effects as that of caffeine upon temporary withdrawal of 
regularly administered doses of caffeine. The regularly administered doses were different 
for different groups of mice and are referred to as ‘priming doses’. They were primed 
initially either for low or high doses of caffeine and subsequently given choices of a 
number of other test drugs. These experiments used extensive behavioral techniques in 
order to derive exact cues from rodent behaviors. Mice that were primed with low doses 
of caffeine chose dopaminergic drugs such as amphetamine and cocaine. Mice that were 
primed for high doses of caffeine chose CNS depressants which included benzodiazepine 
inverse agonists such as phencyclidine, pentylenetetrazole and papaverine. This study 
reflects the biphasic response to caffeine, where the mice primed with low doses showed 
euphoric effects and mice primed for high doses showed many complex effects, which 
were behaviorally non-routine but definitely not euphoric and tended towards coping 
mechanisms for depressive effects.34 These experiments cannot be generalized to human 
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beings because humans show different sets of responses for both high and low doses of 
caffeine. Furthermore, other xanthine alkaloids like theobromine have virtually no 
responses in humans but are comparably active as caffeine in rodent populations.34 To 
add to the limitations of this animal study, all sources of caffeine metabolize to three 
xanthine alkaloid products in the human body and the metabolic products of caffeine 
show many differences in types as well as levels between humans and animals.18 These 
three xanthine alkaloid products are also naturally present in differing concentrations in 
various caffeinated products.18 There are no unified cutoff points for high and low doses 
of caffeine in human beings, as the effects may vary from individual to individual and in 
the same individual from one time to another, depending on the intakes of other 
substances and their regular intakes.18 Paraxanthine a biological metabolite of caffeine is 
also as potent as caffeine in humans and this complicates the mechanisms further.18 Thus, 
we see that caffeine produces biphasic responses in both humans and animal models, 
although the exact signs and symptoms may be variable due to intra-species and inter-
species biological dissimilarities. Most of these biphasic responses can elevate the levels 
of stress in chronic disease states such as HIV infected patients, which can further 
aggravate disease progression. These biphasic effects are also correlated with increased 
consumption of alcohol due to delay in attaining the euphoric effects, and thereby 
exacerbating the adverse effects of both alcohol and caffeine in combination.35  
Caffeine-Adverse Effects Outweigh Apparent Beneficial Effects 
 A number of studies done during the early nineties have documented that 
caffeine increases mental and physical alertness. These effects have been wrongly 
interpreted as the beneficial effects of caffeine.  The majority of them have been 
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documented in situations of compromised alertness, like patients on benzodiazepines36 
early morning shift workers37 night shift workers38 and persons on cold medications and 
sleep loss39. Lieberman40 stated that some of these beneficial effects can increase 
neuronal burnouts when administered  under normal wakeful conditions. Caffeine in 
single bolus dose infusion of 300 mg/day or higher, triggered acute anxiety states.41 This 
heightened anxiety has been described by many healthy volunteers under normal 
physiological conditions to increase their mental and physical capacities. A number of 
healthy volunteers scored better in self-rated depression questionnaires when 
administered 300 mg/d of caffeine per day.41 Caffeine reduces fatigue and produces 
increased tension and nervousness, and human physiology perceives this as a pleasurable 
experience.41 In a study done amongst apparently healthy volunteers, it was observed that 
subjects who were administered 300 mg/d of caffeine showed increases jitteriness and 
nervousness, and fine motor coordination scores were adversely affected.42 A number of 
stress related physiological and neuro-hormonal changes have also been documented and 
include increased levels of excitatory neuro-hormones like nor-epinephrine and 
epinephrine, increased calcium mobilization into the cells, increased prostaglandin 
antagonism and increased phosphodiesterase enzyme inhibition.43  Caffeine infusions 
produced better performance in both simple reaction time and choice reaction time 
scores; both indicators of increased stress and alertness.40 Caffeine facilitated 
performance in jobs involving impulsive maneuverings, and reduced performance in 
those involving complex cognitive skills.44 This finding is also supported by another 
study in which caffeine in doses of 400 mg/day increased anxiety when paired up with a 
stressful task requiring increased cerebral functions.45 Though many of these early studies 
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record the beneficial versus adverse effects, they used fairly large doses of caffeine (>400 
mg/day) in single administered doses and do not consider regular consumption levels of 
caffeine. These studied are virtually inconclusive about the long term effects of regular 
small to medium doses of caffeine on human behavior. Furthermore, these studies were 
done on apparently healthy volunteers and the health related impacts could be many folds 
higher in chronic disease states like HIV, and can be further adverse in those on Anti-
retroviral medications. Thus we can say that caffeine produces a number of adverse 
effects masked by perceived beneficial effects. 
Adverse Effects of Caffeine Withdrawal  
Caffeine withdrawal as a topic has been widely researched and there exist 
adequate evidences in literature on the addictive potentials and development of 
dependence in regular users.46 Caffeine shows all the three criteria for labeling it as a 
reinforcing drug, which includes dependence, tolerance and withdrawal.46 However the 
reinforcing potentials of caffeine are much lesser that than other psychomotor stimulants 
such as cocaine and amphetamines.46 Both the acute stimulating effects and undesirable 
withdrawal effects contribute to the reinforcing potentials, but withdrawal effects 
predominate in making it an additive substance.46 Many studies report the reinforcing or 
addictive potentials but are inconclusive whether these are physiological or psychological 
responses to decreasing serum caffeine levels. The most widely reported symptoms 
include headache, body ache and mood changes.46 In a study done by Ratcliff-Crain et 
al.,47 it was shown that caffeine deprivation leads to increased reporting of stress and 
anxiety by regular caffeine consumers. This is further confirmed by another study done 
by Schuh et al.,48 in which participants reported feelings of fatigue and decreased 
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alertness on caffeine deprivation. Silverman et al.,49 reported that about 52% of 
volunteers with low to moderate daily intakes of caffeine (mean=235 mg/day), reported 
moderate to severe headaches, 11% reported increased depression, 8% reported increased 
anxiety symptoms, 11% reported low vigor and 8% reported increased fatigue when their 
regular doses were acutely substituted with placebo solutions. Some studies confirm that 
even regular doses of caffeine (≤250 mg/day) produces tolerance as well as ill effects of 
withdrawal due to habituation.42 This is very well confirmed by a double blind study 
done by Goldstein et al.,42 in which both habitual and non-habitual caffeine consumers 
were challenged with overnight caffeine deprivation. Habitual caffeine consumers 
reported higher rates of caffeine withdrawal symptoms than non- habitual caffeine 
consumers, which included decreased alertness, decreased feeling of content and 
wellbeing, increased sleepiness, irritability and mild to moderate headaches.42 
Consequent to the caffeine deprivation test, the participants were randomly divided into 
three groups and each group received single dose pills of either 0 mg (placebo), 150 mg 
or 300 mg of caffeine with approximately equal number of habitual and non-habitual 
consumers in each of the three groups. This study showed that habitual caffeine 
consumers showed significant reversal of the negative symptoms of caffeine withdrawal, 
within minutes after administration of 150 or 300 mg of caffeine, but non-habitual 
consumers did not show such responses. This study confirms the re-enforcing potentials 
of caffeine.42 With regards to the beneficial effects such as increased cognitive acuity, 
increased wakefulness and increased sense of well-being, both habitual and non-habitual 
consumers showed no significant differences for both 150 mg and 300 mg doses; on the 
contrary, the non-habitual consumers reported higher rates of negative symptoms such as 
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nervousness, jitteriness and increased gastric acidity.42 Strikingly, non-habitual 
consumers who were administered placebo pills (0 mg) also reported equivalent increase 
in negative symptoms such as nervousness, jitteriness and increased gastric acidity, 
indicating the role of placebo responses in these individuals.42 Habitual consumers who 
received 0 mg of caffeine did not show significant reversal of negative symptoms 
indicating the existence of physiological mechanisms for caffeine withdrawal and 
reinforcements.42 This study very well documents the addictive potentials of caffeine. 
This also shows that both physiological and psychological mechanisms are involved in 
withdrawal reactions. A number of other possibilities should have been considered in 
analyzing these responses, which include the preexisting differences in personalities, 
possibilities of mood disorders in these volunteers, the number of hours of sleep, and the 
number of hours of caffeine deprivation. These factors were not adequately considered in 
the study and hence the conclusions are not entirely reliable. Another study done by 
Bruce et al.,50 showed that negative symptoms of caffeine withdrawal like tiredness, 
drowsiness, anger and depression successively increased and peaked in volunteers 
deprived of caffeine for 24 hours, and beyond this time interval these effects started to 
subside, and by the end of 7 days were completely resolved. Thus we can see that 
caffeine withdrawal and dependence are associated with time elapsed since consumption 
of habitual doses of caffeine.50 Furthermore it can be inferred that caffeine withdrawal 
symptoms occur regularly in caffeine addicted individuals and force them to consume 
regular or higher doses to overcome these symptoms.42 Caffeine withdrawal also 
facilitates increasing doses in a vicious cycle. These increasing doses of caffeine would 
lead to marginal weight loss even in normal subjects due to serially increasing levels of 
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consumption.51 Such addictive and withdrawal effects can have increased adverse effects 
on HIV positive patients who are already compromised in a variety of health related 
parameters. 
Caffeine is Associated with Changes in CD4 levels as well as Plasma Viral Loads  
A study was done amongst HIV infected clinically stable (except for oral 
Candidiasis in some participants) patients in order to quantify the variations in CD4 cell 
counts that could be ascribed to laboratory and physiological factors. There was 15% 
reduction in CD4 counts due to laboratory factors (alcohol, caffeine and tobacco) after 
controlling for factors like age, gender, ART compliance, presence of opportunistic 
infections and measurement errors.52 Though caffeine was considered one of the 
laboratory factors in this study, it was clustered with many other factors like exercise, 
tobacco and alcohol consumption.52 In addition, this study recruited a small sample size 
of 30 participants and results are not generalizable.52  Another study was done amongst 
clinically stable HIV positive individuals to establish the effects of caffeine consumption 
on CD4 and CD8 cell counts after exercise (cycling for about 90 minutes). The 
participants were asked to abstain from consumption of caffeine for 60 hours prior to the 
experiment. Half of the subjects were administered 6 mg/kg/day of caffeine, while the 
remaining subjects were administered placebo before the exercise. There was 54% 
decrease in circulating CD4 cell counts and 55% decrease in circulating CD8 cell counts 
post exercise in subjects administered caffeine when compared to placebo after 
controlling for factors like fluid input levels, age, gender, BMI, lean body mass and fluid 
output levels. 53 This study also reports that post exercise plasma catecholamine levels 
were significantly higher in those administered caffeine when compared to placebo 
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indicating increased stress levels in participants administered caffeine.53 This study also 
reported that caffeine produced alterations in lymphocyte subset trafficking as well as 
expression of CD69 molecules which are important intermediate steps in generating and 
recruiting inflammatory cells.53 Through this process caffeine decreased production and 
recruitment of inflammatory cells to the targeted areas of inflammation which included 
decreased circulating CD4 and CD8 cells.53  
In contrast to the findings that caffeine intake produces adverse effects on HIV 
disease progression; an in-vitro tissue culture study showed that caffeine suppresses 
replication of infectious HIV-1 strains in cultures of human peripheral mononuclear cells. 
Caffeine in 100 millimoles/ml concentrations exerted these effects by inhibiting the 
integration step of the HIV-1 viral replication cycle. This study also shows that other 
methyl-xanthines like theophylline, theobromine, and paraxanthine, in 100 millimoles/ml 
doses act through the same process to inhibit HIV-1 viral replication. They observed a 9-
fold reduction in HIV-1 p24 antigen values in samples treated with caffeine, 
theobromine, paraxanthine or theophylline when compared to control solutions.54 These 
analysis were controlled for confounding factors like solvents (Water vs 0.1% NaCl 
solution) used for different xanthine compounds, rate of growth of human peripheral 
mononuclear cells, differences in viral replications per unit time for different HIV-1 
strains as well as the differences in reagents used for the experiment.54 Adjustments were 
also made to account for variations in reverse transcriptase-polymerase chain reaction 
procedures (RT-PCR), southern blotting assays for HIV gag sequences, as well as the 
primer-probes SK38, SK39, and SK19.54  In another tissue culture study it was found that 
caffeine in doses of 10 µgm/liter significantly inhibited retroviral transduction of dividing 
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Human Neuronal Precursor (hNT-2) cells thereby blocking post integration repair of 
HIV-1 viral strains. These effects have been postulated to a cellular target- ‘The Ataxia 
Telangiectasia-Mutated And Rad3-Related (ATR) kinase’.55 Caffeine inhibits viral DNA 
repair at the DNA damage-activated checkpoints.55 These results were adjusted for 
different dosages of retinoic acid used for maturation of hNT-2 cells, different levels of 
Nocodazole used for cell cycle arrest, differences in HIV-1vectors like vpr, vif, vpu, and 
nef genes, as well as differences in western blot procedures for detecting levels of PCNA 
(Proliferating Cell Nuclear Antigen) proteins and viral integrase.55 
 In summary, we can say that here are very few studies that document the direct 
effect of caffeine on CD4 cells and viral load. The studies investigating viral loads are 
tissue culture in-vitro studies. Furthermore, these effects are opposing one another in 
terms of disease progression as caffeine inhibits viral replication as well as decreases the 
number of CD4 cells.  Therefore a question remains-whether caffeine is beneficial to HIV 
infected individuals due to decreased viral replications or harmful due to depletions in 
CD4 cell counts.  
Caffeine Adversely Affects Sleep Quality and Precipitates Anxiety Disorders   
In a study done amongst pre-AIDS seropositive men and women, it was observed 
that increasing psychological distress scores were associated with increasing viral load 
and lowering CD4 cells after controlling for age, medication use and HIV 
symptomatology.56 In an animal study, it was observed that even mild acute stressors 
produced increased plasma corticosterone levels and a significant decrease in the 
numbers and percentages of all circulating lymphocytes, and these changes were rapidly 
reversed upon removal of the stressors.57 Oral administration of 480 mg of caffeine 
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provoked acute stress responses like panic attacks and heightened anxiety levels in a 
sample of regular non HIV subjects with various forms of anxiety disorders, recruited in 
a randomized double-blind experiment conducted on two occasions 7 days apart.58 
General stress levels estimated by the number of anxiety symptoms and panic attacks, 
were substantially higher in subjects administered 480 mg of caffeine when compared to 
control solutions after adjusting for gender, age, educational level, marital status, 
occupation, different sources of caffeine and previous psychiatric treatments if any. Four 
hundred and eighty mg of caffeine on each of the two test dates precipitated panic attacks 
in 60.7% all of the participants in experimental arm of the study while none of the 
participants in control arm showed any such symptoms. This study concluded that higher 
doses of caffeine precipitated anxiety and panic attacks even in regular non-HIV 
volunteers with some levels of anxiety disorders.58  According to a review paper, caffeine 
in higher than regular levels (>250 mg/day) worsened mental stress and precipitated acute 
events in healthy subjects after controlling for many covariates such as sedative 
medications, presence or absence of psychiatric symptoms, age, gender, lifestyle factors, 
exercise and alternative therapies.59  In a case report, it was also observed that chronic 
caffeine consumption in doses of 400 mg/day precipitated delusions and paranoia in a 
schizophrenic patient undergoing treatment, with symptoms controlled through 
medications. Lowering the doses of caffeine serially to end with the eventual cessation of 
caffeine caused the delusions and paranoia to subside completely. This case study shows 
the effects of caffeine in increasing neuronal excitability and stress, however the study 
was very limited because the patient is a single isolated case with psychiatric 
abnormalities.60 In a study that investigated the effects of day-long consumption of tea, 
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coffee and water on cognitive and psychomotor performance, and of sleep quality at 
night, it was observed that caffeine in doses of 35 to 150 mg/day, irrespective of sources, 
significantly decreased the initial Critical Flicker Fusion Threshold (CFFT) which 
signifies higher levels of neuronal excitability after controlling for age, BMI, exercise, 
gender, body composition measures and lifestyle factors.61 This study also reports that the 
caffeine in coffee produced significantly greater sleep disturbances than in tea, in the 
form of altered sleep patterns after controlling for several cognitive and psychomotor 
adverse effects for both the beverages and dose adjustments for different levels of 
caffeine in both the beverages.61  
In a cross-sectional survey conducted in 1514 men and 1528 women, men who 
consumed more than 200 mg/d of caffeine had 50% higher interleukin 6 (IL-6), 30% 
higher C-reactive protein (CRP), 28% higher tumor necrosis factor- (TNF- )  and 3% 
higher white blood cell (WBC) counts . Women who consumed greater than 200 mg/d of 
caffeine similarly showed 54% higher IL-6, 38% higher CRP, 28% higher TNF-   and 
4% higher WBC counts.62 These findings were significant even after controlling for 
interactions between caffeine consumption and age, sex, smoking, body mass index, 
physical activity, and other covariates. This study shows that caffeine consumption and 
related physiological stress is associated with increased inflammatory states and thereby 
wasteful immune functions.   
HIV patients already report deteriorated sleep quality, increased periods of 
insomnia and post morning sleepiness, cognitive impairments, and increased tiredness.63-
67 In a study done amongst HIV positive participants it was found that sleep quality 
measured by the Pittsburgh Sleep Quality Index (PSQI) was significantly poorer after 
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adjusting for underlying pathologies and medications(over-the-counter drugs, vitamins 
and herbal products, and mood-altering substance).65  Another study was done to examine 
the correlates of sleep quality in HIV-infected persons using the ‘Symptom Experience 
Dimension’ of the revised ‘UCSF Symptom Management conceptual model’.  According 
to this study the variables significantly related to sleep quality included employment 
status, trait anxiety, general well-being, length of time living with HIV disease, 
depressive symptoms, state anxiety, severity of symptoms, daytime sleepiness, and 
functional status of the participants.66 The length of time living with HIV disease was 
significantly associated with poor sleep quality measured by the PSQI after controlling 
for other covariates mentioned above.66  Another study done amongst 146 clinically 
stable HIV positive participants showed that physical pain, stress and social support 
variables were significantly associated with deteriorated sleep quality after controlling for 
covariates like age, sex, marital status, compliance with ART, other medications, 
concurrent drug use, alcohol and tobacco use as well as income.68  Similarly, a study 
done amongst clinically stable HIV positive patients shows that that higher sleep quality 
measured by the Pittsburgh Sleep Quality Index (PSQI) and Pittsburg Insomnia Rating 
Scale (PIRS) was associated with  better cognitive performance on tasks of attention, 
frontal/executive function, and psychomotor/motor speed after controlling for the effects 
of medications, alcohol consumption and drug abuse.67 However this study also reports 
that more than 40% of the participants were chronically and severely sleep deprived.67  In 
addition, another study done on injection drug users reported that general well-being 
scores estimated by the HIV Assessment Tool (HAT) and the State-Trait Anxiety 
Inventory(STAI), was significantly associated with sleep quality measured by Pittsburg 
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sleep quality index (PSQI) after controlling for age, gender ethnicity, injection drug use, 
employment status, income, sleep medications, day time dysfunction and alcohol 
consumption.64 
Side Effects of Caffeine in Non–sleep-deprived Volunteers 
In a study done on non-sleep-deprived volunteers, caffeine was administered in 
doses of 0, 100, 200, 400, and 600 mg and the biological effects were measured four 
hours after this administered dose.69 This study found a dose dependent increase in 
subjective symptoms of jitteriness, nervousness and shakiness with increasing dosages 
after controlling for many co-factors like age, gender, number of hours of sleep and 
physiological and psychological stressors. Even the lowest dose of 100 mg showed 
statistically significant differences when compared to placebo for ratings in subjective 
distress scores. There was also a statistically significant as well as dose dependent 
increase in the ratings  for “dislike effects” for caffeine doses of 400 mg and 600 mg after 
controlling for the same co-factors mentioned earlier.69 Another study was done in a 
group of non–sleep-deprived volunteers who were habitual smokers and drug users.70 
This study looked for the side effects of 0 mg (placebo), 200, 400 and 800 mg doses of 
caffeine on ratings of subjective distress scores. There was a dose dependent increase in 
tension-anxiety ratings and this increase was statistically significant for all the doses of 
caffeine when compared to placebo. In addition there was also a statistically significant 
increase in scales associated dysphoric and somatic symptoms in participants 
administered 800 mg doses when compared to placebo. There was also a significant 
increase in ratings for drug induced euphoria in the participants administered 800 mg 
doses. Although this study controlled for many covariates, such as stress, hours of sleep, 
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age and physiological impairments, changes in subjective assessments could have been 
affected by other drugs like nicotine and amphetamines which were prevalent in this 
cohort.  The study included only six subjects and a repeated–measures design was used. 
There would have been many carryover effects affecting the results of the study. The 
subjects were not restricted from smoking after caffeine consumption, and the subjective 
symptoms could have been due to both nicotine and caffeine. Irrespective of the 
limitations of these studies, we can infer that caffeine is associated with many subjective 
sensations of anxiety, distress and discomfort which could affect sleep quality as well as 
wellbeing even in non-sleep-deprived participants.69,70  
Side Effects of Caffeine in Sleep-Deprived Volunteers 
There are many recent studies that have mixed findings about the impact of 
caffeine on performance and alertness in sleep-deprived volunteers. Sizeable amounts of 
caffeine consumption are directed to overcoming the subjective effects of tiredness and 
irritability due to insufficient sleep. In a study conducted amongst fifty healthy, 
nonsmoking males between the ages of 18 and 32 years, caffeine was administered in 
doses of 150, 300, or 600 mg after 48 hours of sleep deprivation.71 Mental alertness was 
measured through Stanford Sleepiness Scale (SSS), and Visual Analog Scale (VAS). 
Caffeine even in low doses of 150 mg/day produced reversal of sleep deprivation-induced 
lack of alertness measured through SSS and VAS. In this study the highest doses of 600 
mg/day produced complete reversal of sleepiness and the values of SSS and VAS were 
close to fully rested physiological conditions with recommended number of hours of 
sleep. Thus, this study reports the benefits of caffeine consumption in terms of increased 
alertness during physiologically challenged condition such as sleep deprivation. However 
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this study also suggests that these subjective feelings of increased alertness could be at 
the cost of many health related parameters such as impaired immune functions, impaired 
cognition and other indicators of healthy living.71  In the same study, it was also reported 
that there was a dose dependent increase in frequency of sleepiness, anxiousness, 
irritability, jitteriness, talkativeness, increased heart rate, headache, sweatiness, stomach 
discomfort and other subjective symptoms.71 However, the  doses at which these 
subjective symptoms started to appear was not clearly mentioned in this study.71 In 
another study to test the efficacy of modafinil versus caffeine on fifty sleep deprived 
volunteers, it was found that 600 mg doses of caffeine produced increased subjective 
symptoms of palpitations, irritability and nausea following 41 hours of forceful sleep 
deprivation.6 In the same study it was also observed that 2 volunteers vomited 
approximately after two hours of administration of 600 mg of caffeine.6 In the same 
study, caffeine in doses beyond 100 mg was associated with increased blood pressure 
tracings, though the increase was not significant. (Approximately 1mm Hg per 100 mg 
increase in doses of caffeine).6 Thus we can summarize that, though many studies 
discussed the adverse effects of caffeine in sleep deprived volunteers, none of them 
reported any hospitalizations or other adverse events beyond subjective symptoms. 
However, it should also be noted that the majority of these studies employed a convenient 
sample of healthy volunteers, and that adverse events due to the administered doses of 
caffeine were criteria for discontinuation of study participation. Furthermore these studies 
did not look for the adverse effects of chronic levels of caffeine consumption.   
In addition, caffeine intake affects sleep quality as demonstrated in a study done 
amongst 88 HIV positive participants.72 In this study sleep quality was measured by the 
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Revised Pittsburg Sleep Quality Index (R-PSQI). Mean caffeine intake of the entire 
sample was 476 mg/day, which was 2.4 times the national US consumption average of 
200 mg caffeine/day. This study showed that subjects having higher caffeine 
consumption levels (>400 mg/day) showed decreased sleep quality index scores.72 Within 
one month subjects who reduced their baseline caffeine consumption by 90% or higher, 
showed significant improvements in sleep quality index scores after controlling for other 
covariates like liver function tests, CD4 cell counts, viral loads, smoking, alcohol 
consumption and recreational drug use. However this study had several limitations 
because the average caffeine intake of the sample was very high, sample size was small, 
and this study did not look for dose-based adverse effects of caffeine.  
Thus, we see that caffeine consumption could be responsible for decreased sleep 
quality, altered sleep patterns as well as increasing stress levels and anxiety symptoms. 
All these factors could be responsible for accelerated disease progression in PLWH. Our 
study aims at understanding whether such mechanisms would have existed in our 
population of HIV positive participants from Miami-Dade County. We also aim at 
estimating the share of caffeine in adverse effects on sleep quality and anxiety symptoms, 
after controlling for covariates such as age, gender, drug abuse, alcohol consumption, 
tobacco use and types of ART, as well as explore the effects of moderate (<250 mg/day) 
and high (>250 mg/day) doses of caffeine on these outcome variables.  
Caffeine Intake is Associated with Significant Nutritional Alterations 
A long-term follow-up study from 1980 to 1998, that recruited 1333 males and 
4085 females having type -2 diabetes, showed that there was a strong association between 
increased caffeine consumption (> 4 cups/day which is approximately >240 mg 
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caffeine/day) and weight loss (approximately 5.5 kg/ year) and this weight loss produced 
significant reduction in risk factors for diabetic complications after controlling for age, 
weight status, insulin administration, anti-diabetic drugs, physical activity and lifestyle 
factors.73 Further analysis also revealed that there was decreased risk for diabetes in those 
who lost weight, and that there was a positive dose–response relationship between 
caffeine intake and weight loss when caffeine was considered as a continuous variable.73  
In a systematic review of twenty studies on the protective effects of caffeine in diabetes, 
twelve studies reported that the protective effects were due to weight loss induced by 
caffeine.74  This review also mentions an estimated 100kcal/day increased energy 
expenditure due to habitual consumption of 6 cups of coffee (400 mg caffeine/d).74 This 
review states that caffeine is the primary, and possibly the sole, ingredient responsible for  
the negative energy balance observed in several studies.74 Eight studies of these twenty 
studies also reported a dose-response relationship between caffeine intake and weight 
loss.74  Caffeine intake is also associated with decreased feeding in animal models. In a 
vertebrate study on Wistar rats, it was observed that rats administered 1gm/liter caffeine 
solutions in their drinking water for forty days showed significant aversions to palatable 
rat foods, when compared to the rats administered 0.3g/liter caffeine solutions or plain 
water control solutions after controlling for baseline weights and feeding behaviors.75 
This study also showed that such effects were more profound in the female rats, when 
compared male rats, after controlling for the differences in catecholamine levels, baseline 
weights, and baseline calorie consumption levels, in all groups of animals.75 In another 
study done in young healthy women, caffeine was responsible for increasing basal energy 
expenditures (BEE), even in the presence of genetic abnormalities predisposing to 
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decreased BEE. The Arg allele in the beta-3 adrenergic receptor gene (beta-3-AR) is a 
marker for obesity-related traits, and mutations in this gene make an individual 
susceptible to decreased BEE.76 In a group of women showing beta-3-AR Trp64Arg 
abnormalities, and consequently decreased basal energy expenditures, an average early 
morning dose of caffeine (4 mg/kg body weight/day) produced significant increase in 
energy expenditures, measured through indirect open-circuit calorimetric studies at four 
intervals during the day, after controlling for age; physical activity; height; blood 
pressure; dietary intakes of fat, proteins, carbohydrates, cholesterol, fiber; BMI; and 
lifestyle factors.76 This study showed that caffeine, independent of genetic predispositions 
to gain weight, increased resting energy expenditure leading to significant weight loss. 
However, the study was limited because it included a convenient sample of healthy 
young women with an average age of 21±1 years, and men and subjects from other age 
groups are not included.76  
Jones et al.77 showed that increased fat mass was associated with lower rates of 
disease progression, and fat loss produced faster progression to CD4 counts less than 200 
cells/μl.77 The HIV Epidemiology Research (HER) Initiative enrolled 871 HIV positive 
women for an observational study of three years. Cross sectional analysis, survival 
analysis and longitudinal analysis were done on the data obtained from this cohort. All 
five study outcomes, (which included CD4 cell count and viral load; time to ﬁrst 
occurrence of CD4 cell count ≤200 cells/mm3; ﬁrst occurrence of CD4 cell count ≤100 
cells/mm3; ﬁrst occurrence of  other Infection/malignancy; and HIV-related death), were 
significantly delayed in women who were in the obese group (BMI≥35 kg/m2) after 
controlling for ART status, BMI changes, baseline CD4 cell counts, attrition due to death 
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and progression to AIDS, age and lifestyle factors.77 This study established the need to 
prevent weight loss; especially loss of fat mass in HIV positive patients.  
Deficiencies of several essential micronutrients in HIV-infection have been 
reported to accentuate disease progression and mortality risks.78 Several altered metabolic 
pathways are responsible for such nutrient depletions in these patients. One such pathway 
is chronic anti-oxidant depletion, including a drastic depletion of cysteine from the 
glutathione pool, and a progressive decline in serum selenium levels.79 There is 
significant correlation between caffeine intake and depletion of antioxidants, although 
this relationship is controversial, with some studies reporting an anti-oxidant effect80 
while others reporting a pro-oxidant effect for caffeine itself.81 In a laboratory study done 
with chemical equivalents of naturally produced biological oxidative species, it was 
observed through Electron Spin Resonance (ESR) trapping that caffeine, in 
concentrations of 1 mmols/L, acted as an antioxidant with efficient free radical 
scavenging rates of  5.9 x 109 M-1 sec-1,  which is comparable to the scores of other 
naturally occurring antioxidants such as vitamin C, vitamin E, Selenium, and Zinc.80  
However this study is a measure of reductive behavior of the chemical named 1,3,7-
trimethylxanthine (caffeine) and may or may not correlate with the biological effects of 
caffeine.80 Such disclaimers about the antioxidant capacities of caffeine and other 
xanthine alkaloids in living animals and humans, in spite of laboratory evidences for 
antioxidant effects, was also reported in recent study done by Tsoi et al.,82 where he 
recommends better technologies such as Oxygen Radical Absorbance Capacity (ORAC) 
and Cellular Antioxidant Activity Assay (CAAA), for comparing biological versus 
laboratory antioxidant capacities of caffeine and other xanthine compounds. Caffeine 
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consumption in higher than normal doses (>250 mg/day) has also been reported to lower 
the plasma levels of antioxidant trace elements such as zinc and selenium after 
controlling for dietary intakes, age, physical activity, smoking, alcohol use and drug 
use.26 This relationship also shows a dose-response, with lower caffeine consumption 
associated with decreased depletion of antioxidant elements.26 Thus, the net effect of 
caffeine on total antioxidant status has not been elucidated, and remains questionable.  
In summary, we see that caffeine can accentuate weight loss which may be useful 
for diabetic patients as shown in several studies, but extremely detrimental to PLWH. It 
also produces nutritional changes such as lower serum selenium levels and decreased 
plasma zinc levels. However, the effects on total antioxidant capacity in PLWH are 
controversial and need further research.  
Caffeine Intake and its Effects on Fluid-Electrolyte Balance and Blood Pressure 
Caffeine and other methyl -xanthene compounds have significant diuretic 
properties. Consumers are often cautioned to avoid these beverages when their fluid-
electrolyte balance is jeopardized due to various medical conditions. Acute ingestion of 
caffeine in doses of 250-300 mg (equivalent to 2-3 cups of coffee or 5-8 cups of tea) is 
associated with short-term stimulation of urine output. But these effects are observed 
only in subjects deprived of caffeine for few days before the study. There is profound 
tolerance to these effects in regular and frequent coffee drinkers. As such there is no 
concrete relationship between caffeine intake in regular doses (≤ 250 mg/d) and fluid 
losses in excess of the volume ingested under normal physiological conditions.83 But this 
is not the same for stressful or non-physiological states. Recreation enthusiasts and 
athletes are often advised to decrease the consumption of coffee or caffeine containing 
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carbonated drinks to avoid dehydration, electrolyte imbalance, and potential 
complications.84 A number of contrary evidences also exist. One study supports that 
caffeine intake is associated with only 0.03% higher diuretic capacity than plain water 
itself and hence it is advisable to administer caffeinated beverages to athletes.85 Thus 
there is no general consensus as to whether caffeine produces or does not produce 
dehydration and electrolyte imbalance. Furthermore tolerance to caffeine reduces the 
likelihood of any serious fluid electrolyte imbalance.84 Abstaining from caffeine has a 
protective effect on hypertension. Caffeine, even in moderate doses (250 mg/day) 
produces small elevation in blood pressure (8-10 mm hg). Many other substances present 
in brewed coffee like poly-phenols and soluble fibers may reverse the adverse effects of 
pure caffeine.86 Coffee and caffeine containing beverages produce similar increases in 
Muscle Sympathetic Activity (MSA) Scores and blood-pressure in non-habitual coffee 
drinkers; but in habitual coffee drinkers there is no comparable increase in blood pressure 
even when there is MSA activation.84 This could be attributed to the homeostatic 
mechanisms of the cardio-vascular system. This can also be attributed to ingredients 
other than caffeine, such as poly-phenols and chlorogenic acids and hunic acid, but the 
mechanism still remains unclear.84 In a study done amongst hypertensive patients, it was 
observed that caffeine through ‘acute presser response’ significantly increased both 
systolic and diastolic blood pressure levels.87 This study concludes with a word of caution 
for hypertensive patients to restrict their caffeine consumption. It also states that the 
hemodynamic effects of chronic caffeine consumption should be studied through 
prospective longitudinal studies. This report also proposes the inhibition of 
phosphodiesterases as the probable mechanism for these responses.87 Thus, we see that 
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caffeine definitely has some role in altering the fluid-electrolyte balance and systemic 
blood pressure tracings, though not clinically significant to produce visible adverse 
effects. Partly, this phenomenon is due to the increased tolerance of the body to the 
diuretic effects of caffeine. Some other constituents of coffee, other than caffeine, can 
also be suspected, but the mechanism remains unclear. But it is definite that caffeine can 
have adverse effects in HIV infected patients, because of their already jeopardized fluid-
electrolyte balance, which is secondary to nutritional inadequacies and intermittent 
diarrheal episodes. 
Caffeine is Associated with Smoking, Alcohol Consumption and Drug Abuse  
A British study consisting of 376 young adults suggested that estimated daily 
caffeine consumption increased with age, and was associated with increased smoking and 
greater alcohol consumption.88 This study, however, does not show any correlation 
between caffeine consumption and drug abuse.88 Other studies have also shown that 
caffeine intake is higher in smokers than in nonsmokers. A secondary analysis of data 
from adults who participated in the Second National Health and Nutrition Examination 
Survey showed that subjects who ingested caffeine from tea had lower alcohol 
consumption.89 In comparison to this, the subjects who ingested caffeine from coffee and 
caffeinated beverages were more likely to be heavy alcohol consumers and chain 
smokers.89 There was also a positive correlation between income and caffeine intake; 
caffeine intake and alcohol consumption, and caffeine intake and smoking.89 Smokers 
were much more likely to drink caffeinated coffee, and a significant dose-response 
relationship between caffeine intake and smoking was observed.89 These studies also 
show a definite linear relationship between caffeine intake and alcohol consumption.89 
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The relationship between caffeinated beverages, alcohol consumption and smoking, was 
also researched in a group of chronic alcoholics from Israel. There was a significant 
linear relationship between caffeine intake and alcohol consumption & smoking.90  In 
addition, the subgroup of subjects with a family history of alcoholism revealed significant 
correlations between alcohol and caffeine consumption, between alcohol intake and 
smoking, as well as caffeine use and smoking.90 The subjects without a family history of 
alcoholism also showed similar linear relationships between alcohol and caffeine use, but 
no relationship between caffeine intake and smoking.90 A review article on the 
relationships between caffeine, alcohol and drugs of abuse concluded that many studies 
show positive correlations between caffeine consumption, alcohol intake and drugs of 
abuse such as cocaine, amphetamines and marijuana.91 In a Sardinian study, conducted 
amongst patients with bipolar disorders, it was observed that smoking, alcohol 
consumption and illicit drug abuse synergistically increased the levels of stress in 
subjects consuming high amounts of caffeine, and the collective effects of these factors 
increased suicidal tendencies.92 A study assessing the combined biological influence of 
coffee, smoking, and alcohol showed that caffeine consumption from coffee showed 
inverse correlations with biological markers of heavy drinking, after controlling for 
baseline alcohol consumption levels, the number of cigarettes smoked per day, as well as 
number of years of smoking.93 This study shows that in addition to adverse health effects, 
these addictive substances also show associations with nutritional deficiencies such as 
vitamin B12 depletion and anemic states.93 Alcohol intake can be indirectly measured 
through a number of markers.  γ-Glutamyltransferase is one such widely used marker. 
Coffee intake was significantly (P< 0.01) and negatively related to γ-Glutamyltransferase 
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activity. This study contradicts other studies presented earlier in this section, and shows 
that caffeine consumption reduces alcohol intake.94 Caffeine also influences the actions 
of other dependence producing drugs such cocaine and amphetamines.95 An animal study 
conducted in rats showed that there are significant interactions between caffeine and 
cocaine on many behavioral paradigms related to drug abuse.95 Caffeine was responsible 
for reinstating cocaine consumption behavior in rats that were forced to abstain from 
cocaine after initial priming. In this study, rats were administered either normal saline, 
cocaine in different doses (5.0, 10.0, or 20.0 mg/kg) through foods and caffeine in 
different doses (5.0, 10.0, 20.0, 40.0 mg/kg) through injections. There was a dose-
dependent increase in cocaine consumption behaviors with increasing doses of injected 
caffeine.95 This study confirms that caffeine can modulate the drug seeking tendencies 
and provoke drug reinstating response to dopaminergic drugs such as cocaine and 
amphetamines.95 Caffeine affects the dopaminergic reward circuitry, and hence, it is 
responsible for altering the addictive potentials of many dopaminergic drugs.95 In another 
study conducted on cocaine addicted individuals, it was found that caffeine consumption 
was significantly higher in cocaine dependent individuals when compared to matched 
controls.96 The same study also found that habitual caffeine consumption was associated 
with lower cocaine use within the cocaine dependent group, and that caffeine deprivation 
tends to increase the abuse of cocaine in these individuals.96 In summary, we can say that 
caffeine intake shows significant associations with alcohol, tobacco and drug use levels, 
patterns and behaviors. There could be many behavioral, physiological and genetic 
mechanisms responsible for these observations. Through these mechanisms, caffeine 
consumption can have a number of adverse effects in these HIV-infected subjects, among 
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whom drug use, alcohol and smoking are frequent. Drug abuse, along with alcohol 
consumption and smoking, can quickly and synergistically deteriorate their health status 
and contribute to HIV disease progression. Because of these interactions, we have 
decided to control for tobacco, drug and alcohol use in all our analysis related to the 
adverse effects of caffeine on several health related parameters. 
Caffeine and its Metabolites and Their Collective Role in Metabolic Alterations  
              Cardiovascular diseases and diabetes are a major health problem in HIV infected 
patients. A large number of these diseases can be traced back to their roots in metabolic 
syndrome. A longitudinal study done by Balk et al.,97 examined the relationship between 
caffeine consumption and the components of the metabolic syndrome. This study used 
the data from “Amsterdam Growth and Health Longitudinal Study (AGAHLS)” for 
analyzing these associations. All the earlier studies on the benefits of caffeine in 
metabolic syndrome are challenged by this study, as the study shows no significant 
improvements in any of the parameters used to assess the severity of metabolic 
syndrome.97 This study questions the very benefits of caffeine in metabolic syndrome, 
and rather discusses the adverse effects. All the analyses were adjusted for other 
confounding variables such as physical activity, energy intake, alcohol consumption, 
smoking behavior etc., thus, eliminating many confounders clouding the validity of these 
observations.97 Coffee is a complex mixture of cholrogenic acid, cafestol, kahweol, 
diterpines and caffeine. 98 These other components significantly alter the serum levels of 
both healthy and non-healthy lipids. These components are implicated in increasing 
several risk factors associated with cardiovascular health such as blood pressure and 
plasma homocysteine levels.98 High consumption of unfiltered coffee such as French 
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press and boiled house brew have been reported to increase the levels of LDL and VLDL 
fractions of serum lipid profile.99 People with hypertensive disorders, children, 
adolescents, and the elderly are at the highest risks for these adverse effects. There is 
compelling evidence to decrease caffeine consumption in pregnant women and women of 
reproductive age groups. Caffeine is also associated with several cases of spontaneous 
abortions, sudden fetal death syndromes and impaired fetal growth.100 A recent study has 
established the existence of genetic polymorphisms in the process of metabolism and 
actions of caffeine.101 Thus, caffeine may be beneficial to certain sets of genetically 
privileged individuals. But in individuals with genetic weakness, caffeine could 
exacerbate the adverse effects. Diterpines present in caffeine have been strongly 
associated with adverse cardiac events.102 Caffeine is also associated with increased 
levels of fibrinogen and C-reactive proteins, both individually potent and significant risk 
factors for a number complications such as stroke, myocardial infarction, diabetes, renal 
disorders, and thrombo-embolic sequels.103 Habitual caffeine consumption is also 
associated with accelerating the adverse effects of mental stress on vascular inflammatory 
response as evidenced by a dietary study done amongst eighty-five healthy non-smoking 
men with various levels of caffeine consumption.104  This study found that caffeine was 
positively associated with baseline systolic blood pressure, increased heart rate and 
increased inflammatory markers such as C-reactive protein (CRP) and Von Willebrand 
factor antigen (vWF), after controlling for age, body mass index and consumption of tea, 
red wine, fruit, vegetables, oily fish and dietary supplements.104 These adverse effects 
could be more pronounced in HIV positive subjects who experience dyslipidemias due to 
ART medications. Such adverse effects could also affect their general health status.  
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Inference  
In summary, evidence to date indicates that caffeine intake is associated with 
depletion of circulating CD4 cells. It is also associated with weight loss and wasting. It is 
implicated for altered sleep patterns , decreased intervals of sleep, decreased sleep quality 
scores, decreased perceptional wellbeing scores, increased neuronal excitability and 
increased plasma levels of inflammatory markers such as interleukein-6, C-reactive 
proteins and tumor necrosis factor-α . All these factors can have a bearing in hastening 
disease progression in HIV infected patients. Moderate caffeine intake produces small 
elevations in blood pressure. Caffeine also produces minor non-significant electrolyte 
imbalances in healthy subjects. This, however, can have accentuated effects in HIV 
infected patients, because of their already jeopardized fluid-electrolyte balance secondary 
to nutritional inadequacies and intermittent diarrheal episodes.  Caffeine intake is 
associated with increased smoking, greater alcohol consumption and increased 
recreational drug abuse. Drugs along with alcohol consumption and smoking can 
synergistically deteriorate the health status of HIV-positive patients. Chronic caffeine 
consumption may have irreversible effects on palatability and food consumption. There 
exists strong evidences for caffeine producing significant weight loss. There is significant 
correlation between caffeine intake and depletion of antioxidants. It reduces the plasma 
levels of anti-oxidant trace elements like selenium and zinc. Such weight changes, loss of 
appetite and antioxidant depletion can have adverse effects on the health status of these 
HIV infected patients. Caffeine produces many metabolic alterations like increased levels 
of LDL and VLDL fractions of serum lipid profile, increased plasma homocysteine 
levels, increased fibrinogen and C-reactive protein, all signifying increased stressful 
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states and chronic inflammation. These markers of chronic inflammation are already 
aggravated in HIV infected patients due to the disease as well as the medications. 
Caffeine can accentuate these adverse effects. It is associated with altered dopaminergic 
neurotransmission and consequent heightened neuronal excitability and potential loss of 
brain cells due to neuronal burnouts. Caffeine also precipitates fluid and electrolyte 
imbalances. Our proposed study aims at elucidating the net combined effects of these 
adverse reactions of caffeine consumption on HIV disease progression in PLWH. 
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CHAPTER III: METHODOLOGY 
Preliminary Study   
A preliminary study was conducted to understand the relationship between 
caffeine consumption and CD4 cell counts and viral loads in 231 HIV positive 
participants.1 This study was a secondary analysis of data collected by the parent study 
“Zinc-supplementation and HIV disease progression in HIV infected adults in Miami” 
also known as the Zinc study.1,2 For this study, HIV positive adults were recruited 
between March, 2002 and December, 2005 from several outreach sites in Miami-Dade 
County. The procedures included an informed consent, medical history, physical 
examination, blood collection for various disease related parameters; several standardized 
and validated questionnaires and standardized 24-hr dietary recalls using NUTRIBASE-7 
diet-analysis program. Participants were eligible, if HIV infection was documented, had 
low plasma zinc levels (<0.75 μg/ml), were ≥18 years, and did not have history of 
endocrine or psychiatric disorders; women were excluded if pregnant or had intention to 
become pregnant. Participants with plasma zinc levels ≤0.35 μg/ml at any time during the 
study were excluded for scientific and ethical reasons. HIV-viral load, complete blood 
counts and chemistries were monitored at baseline and every 6 months and any abnormal 
value communicated to the primary care physician. The study protocol was approved by 
the Florida International University (FIU) Internal Review Board.    For this analysis only 
the baseline measures were used for 231 HIV+ adults. About 78% were African-
American, 62% received ART and 73.2% were men. The mean age was 42.7±7.0 years. 
The mean caffeine intake was 115 mg/day and about 10% recorded zero mg caffeine 
intakes in the past month. There was a positive correlation between caffeine intake and 
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viral load (r=0.3, p<0.008) in patients who were not on ART (N=87), but no relationship 
was found in those on ART (N=144). This association also showed a dose response 
relationship which strengthened after controlling for several associated variables like age, 
drug use, smoking and alcohol consumption (β=739, p=0.004).   This study served as a 
preliminary data to calculate sample size and for the current observational study on the 
effects of caffeine consumption on potential risk factors for HIV disease progression.  
Figure 1: Regression Analysis Scatter Plot with Line of Fit for Caffeine Intake and HIV 
Viral Load 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Caffeine Intake and Viral Load using Mixed Models 
 
Variable Coefficients 
Viral Load* β=739  P=0.004  
*Controlled for age, drug use, smoking and alcohol consumption      
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Overview of the Current Study 
The current study was a prospective observational study (follow-up study) of data 
collected over a period of three months.  It also included secondary analysis of relevant 
variables collected from the Miami Adult Studies on HIV (MASH) cohort which 
included a total of 803 HIV positive and 78 uninfected participants followed from 2002 
to 2014, for two NIH sponsored grant studies, co-infection study and alcohol study, 
described elsewhere in this chapter. It included a baseline visit and a follow-up visit at 
three months. This study collected data from February to June of 2014. One hundred and 
thirty HIV+ adults (sample size calculations given in page 28) were recruited from the 
participants who were already enrolled in the MASH cohort. This study was approved by 
the Florida International University Institutional Review Board. The initial screening 
included detailed explanation of the current study as well as obtaining informed voluntary 
written consent for participation. To obtain a study sample of 130 patients (65 consuming 
≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) a total of 150 patients were 
screened. Outreach personnel from the parent grants collaborated in scheduling of 
appointments and establishing contacts with the participants. All data collected during the 
baseline and 3-month visits were used for data analysis and inferences.  
Parent Studies 
At the time of recruitment from MASH, there were two active NIH sponsored 
studies for which we had already screened more than 800 HIV positive participants. 
These two studies were ‘HIV and HIV/HCV co-infection, Disease Progression, Oxidative 
Stress and Antioxidants’ also known as Co-infection study and ‘Alcohol & 
Antiretrovirals in HIV infection, Oxidative Stress and Liver Disease’ also known as 
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Alcohol study. Co-infection study looked for the adverse effects of HCV co-infection on 
oxidative stress and plasma levels of antioxidant micronutrients as well as the net effects 
of these variables on HIV disease progression. The “Alcohol study” similarly examined 
the effects of alcohol consumption on oxidative stress, mitochondrial DNA damage and 
hepatocellular injury as well as the combined effects on HIV disease progression. The 
majority of the participants in both the studies were receiving antiretroviral therapy 
(ART). They were interviewed every three months at Borinquen Health Center, and at the 
semiannual and annual visits blood and urine were collected for laboratory values. Both 
the studies had stringent eligibility criteria, meticulous recruitment and retention 
protocols and safety and confidentiality procedures. 
Inclusion Criteria for Co-Infection Study 
1) HIV/HCV co-infected or HIV mono-infected participants with HBV infection 
ruled out and documented in the medical chart. HIV mono-infected participants 
will have qualitative HCV-RNA analysis by PCR to rule out HCV infection also 
documented in the medical chart 
2) Identified from the Borinquen Healthcare Center 
3) HIV/HCV co-infected patients determined with biopsy or another accepted non-
invasive method of staging to be either F0-F5 fibrosis grading or its equivalence 
4) Age 40-60 years 
5) BMI >18, but < 40 kg/m2 
6) Compliant, as determined by regular visits to the clinic and adherence to 
treatment 
7) Free of significant active psychiatric conditions 
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8) Free of co-morbid diseases (uncontrolled diabetes, symptomatic cardiovascular 
disease) 
9) Willingness to provide consent for a second biopsy if clinically indicated 
10) Signature on a consent form 
11) Willingness to participate in a study for 4 years (monthly contact with the clinic 
for follow-up, assessment visits at baseline and every 3 months thereafter for 48 
months) 
12) English speaking 
Exclusion Criteria for Co-Infection Study 
1) HBV infection 
2) BMI <18, or > 40 kg/m2 
3) Chronic inflammatory diseases 
4) Age<40, or >60 years 
5) Elevated liver enzymes > than grade 2 according to ATCG criteria, in HIV mono-
infected participants 
6) Ishak score F6 or end stage liver disease defined by clinical criteria of hepatic 
encephalopathy, esophageal varices, ascites, or hepatocellular carcinoma 
7) Receiving HCV treatment 
8) Pregnancy or the intent to become pregnant. Although the proposed study is 
observational, CD4 cell count increases in pregnancy, and pregnant women need 
to be referred to the obstetrics clinics where they are given micronutrient 
supplementation, which may confound the micronutrient and the oxidative stress 
findings 
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Inclusion Criteria for Alcohol Study 
1) HIV status documented in the medical chart 
2) HIV-positive adults identified from the Borinquen clinics where the participants 
are followed medically and we will have access to their medical charts with 
written permission of the participant 
3) ART naïve or treatment experienced 
4) For Groups 1 and 2, CD4 cell count <350, initiating ART and achieving 
undetectable HIV viral load within 6 months, just prior to baseline. The ART will 
be a tenofovir based regimen 
5) For Groups 3 and 4 (CD4 cell count > 450, and viral load < 50,000), not yet 
eligible for ART 
6) For Group 5 (85 HIV-negative participants) participants will have a documented 
seronegative test in the last year 
7) Willing to respond to questionnaires on alcohol use pattern, frequency and type of 
beverages consumed 
8) Age 18 – 60 years old 
9) BMI >18, but < 40 kg/m2 to control for malnutrition or obesity 
10) Compliant, as determined by regular visits to the clinic and adherence to 
treatment 
11) Controlled co-morbid diseases (diabetes, symptomatic cardiovascular disease, 
hyperlipidemia, and metabolic syndrome). Free of HBV and HCV (as confirmed 
by test results) 
12) Free of heavy tobacco smoking (defined as >20 cigarettes/day) 
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13) Signature on a consent form 
14) Willingness to participate in a study for 2 years (monthly contact with the clinic 
for follow-up, assessment visits at baseline and every 3 months thereafter) 
Exclusion Criteria for Alcohol Study 
1) HBV and HCV infected as confirmed by testing or medical records 
2) BMI <18, or > 40 kg/m2 
3) Chronic inflammatory diseases 
4) Pregnancy or the intent to become pregnant. Although the proposed study is 
observational, CD4 cell count increases in pregnancy. Pregnant women will be 
referred to the obstetrics clinics 
Additional Inclusion Criteria for The Current Study 
1) Enrolled in the MASH cohort 
2) History of ART 
3) Willing to participate in a study that is at least 3 months duration  
Additional exclusion criteria for the current study 
1) Any major cardiovascular abnormalities or implanted pacemakers 
2) Any morbid medical conditions such as uncontrolled hypertension, anemia, mal-
absorption syndromes or AIDS defining opportunistic infections during the course 
of the study 
Characteristics of the MASH Cohort 
For the two NIH grant sponsored studies, co-infection study and alcohol study, a 
total of 803 HIV positive and 78 uninfected participants were followed from 2002 to 
2014, for a period of twelve years. This constituted the Miami Adult Studies on HIV 
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(MASH) cohort and included a specimen repository and database for a number of 
clinical, laboratory, socio-demographic, substance abuse and behavioral data collected at 
regular intervals during the studies. The mean age of the cohort was 45.13 ± 7.9 years. Of 
these participants, 74.73% were African American, 6.8% were non-Hispanic White, 
19.92% were Hispanic, and 1.55% belonged to other races. Males constituted 68.95% of 
all participants. The mean family income for the entire cohort was 439 ± 638.4 $ per 
month. The average time from diagnosis of HIV was 12.2 ± 8.7 years. About 33.62% 
reported adequate control over disease progression represented by undetectable HIV viral 
loads, while 23.4% reported inadequate control over disease progression represented by 
CD4 counts less than 200 cells per microliter. About 54.41% of the cohort reported some 
form of recreational drug use. The mean CD4 cell count for the entire cohort was 470.81 
± 444.81 cells per microliter. The mean log10 HIV viral load was 3.23 ± 1.33 copies of 
HIV viral RNA.  
Human Subjects and Institutional Review Board (IRB) 
This study was approved by the Institutional Review Board at Florida 
International University. According to the eligibility criteria of the parent studies, all the 
participants recruited for the current study were under standard medical care prior to the 
recruitment, as well as during the entire period of the study. All the data collected were 
entered into a de-identified database where visits were linked only by a coded ID. All the 
software used for data storage and retrieval procedures were password protected to ensure 
safety and confidentiality.  
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Recruitment of Study Subjects 
All the study participants were recruited from the MASH cohort followed at the 
FIU-Borinquen Research Clinic. Participants were a consecutive convenience sample of 
130 people (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) 
living with HIV (PLWH).  We recruited participants from both genders and major racial 
and ethnic characteristics. To ensure compliance with the current study, the participants 
were provided incentives such as reimbursement for their time and effort, nutritional 
education and counseling.  
Initial Screening and Enrollment 
During the screening, participants were explained the details of the study and the 
eligibility criteria; if they were eligible and willing to participate, they were enrolled in 
the study. The participants were also assured confidentiality of the data obtained from 
them, as well as voluntary withdrawal from the study without any penalization. The 
consent forms are currently maintained at FIU in a locked cabinet only accessible to 
investigators for audit purposes.  
Pilot Testing of the Questionnaires, Logistics and Instruments 
Though all the questionnaires and instruments used in the current study were 
already validated in original studies and publications, we additionally pilot tested all 
questionnaires and instruments in a subset of 15 participants to assess the understanding 
of the questions by the participants. We evaluated the wording, understandability and 
schematic and grammatical layout of the administered questionnaires, and develop an 
efficient clinic logistic to administer them. No changes to the questionnaires and logistics 
were made throughout the duration of the study.  
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Baseline and 3-month Visits 
All eligible participants were screened and enrolled into the study and the baseline 
visits were scheduled at their earliest convenience, including the dates when the 
participants were screened for the current study. The baseline visits included the Caffeine 
Consumption Questionnaire (CCQ), Pittsburg Insomnia Rating Scale (PIRS) 
questionnaire, Pittsburg Sleep Quality Index (PSQI) questionnaire and Generalized 
Anxiety Disorder-7(GAD-7) questionnaire. Participants were interviewed at the three-
month visits with the same set of questionnaires and assessments. At the end of the study 
we followed all the study termination procedures enlisted in the Good Clinical Practice 
protocol. We also ensured that the data collected did not include any personal identifiers 
and were transported safely to a secure storage location within the premises of Florida 
International University ensuring their confidentiality.  
Compliance 
Compliance with the assigned schedule of visits and eligibility requirements was 
closely monitored. A variety of factors such as non-compliance to ART medications, 
inappropriate nutritional practices, self-supplementations, self-medications and types and 
frequency of substance abuse were assessed every three months in the MASH cohort. We 
tried to overcome potential barriers to compliance through meticulous efforts such as 
calling and reminding the participants a month and a week before the scheduled visit, 
reimbursing costs for their time spent with us, reducing wait time through organized 
appointments, and provisions for free parking through collaborations with the 
administration at Borinquen Health Care Center. We also tried to achieve higher 
compliance by assuring that the participants were interviewed by the same staff on every 
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successive visit, and by trying to contact the participants for rescheduling on the same 
day, third day, a week, a month and two months after no show for the scheduled visits. 
During the visits, we established rapport before asking uncomfortable questions such as 
the reasons for their missing appointments, failure to follow study requirements, as well 
as other factors affecting compliance, so as to understand and take necessary steps to 
maximize compliance for the study. For those participants who did not show up for the 3-
month visit, we also searched the incarceration records and vital statistics. In-spite of 
these efforts to ensure compliance with follow-up visits, when we had missing values, we 
imputed them during the analysis of data. 
Safety Monitoring 
The majority of the safety-monitoring procedures were already in place in the 
MASH cohort when we collected data for the current study. Viral loads and CD4 counts 
were scrupulously monitored for signs of disease progression beyond healthy levels. 
Though there were no adverse events recorded during the current study, as this was not 
an intervention study, all protocols were in place for prompt intervention and resolution 
of adverse events. In case of adverse events severe enough to warrant prompt medical 
attention, we also had provisions for referrals to the nearby hospitals and emergency 
services. The MASH cohort was already monitored for signs of medical illness or 
nutritional deficiencies during follow-up visits of the parent studies. 
Outcomes and Assessments 
The primary outcomes of the study were changes in the markers of HIV disease 
progression which included changes in CD4 counts and viral loads. The outcomes 
collected during the current study included variables gathered from Caffeine 
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Consumption Questionnaire (CCQ), Pittsburg Insomnia Rating Scale (PIRS) 
questionnaire, Pittsburg Sleep Quality Index (PSQI) questionnaire and Generalized 
Anxiety Disorder-7(GAD-7) questionnaire. Several variables such as age, gender, 
race/ethnicity, education, income, smoking, alcohol consumption, drug use, ART 
medications, CD4 counts, plasma viral load, 24-hour dietary intakes, body mass index 
(BMI), lean body mass (LBM), total fat mass, hemoglobin, hematocrit, serum albumin 
levels, and food security questionnaire (FSQ) scores were collected as part of the MASH 
cohort requirements and were used for secondary analysis in the current study. The 
following table provides a brief description of variables collected during the study as well 
as variables transcribed from the MASH cohort. 
Table 2: Outcomes and Assessments Collected During the Current Study  
Assessments  Visits 
Baseline 3-month 
Caffeine Consumption Questionnaire (CCQ)   
Pittsburg Insomnia Rating Scale (PIRS) questionnaire   
Pittsburg Sleep Quality Index (PSQI) questionnaire    
Generalized Anxiety Disorder-7(GAD-7) questionnaire    
 
Caffeine Consumption Questionnaire (Appendix-1): We used the Modified Caffeine 
Consumption Questionnaire (MCCQ) developed by Preston et al in the year 1998.3 This 
questionnaire is easy to understand, compact, organized and reported adequate 
compliance, validity and reliability.3 This questionnaire was field tested and validated in 
many large scale studies and adequately reflected average daily caffeine consumption 
levels.4 It includes a total of 21 sources of caffeine classified in to three groups, 
‘beverages’, ‘over the counter medications’ and ‘prescription medications’. This 
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questionnaire also included ‘total caffeine consumption per day’ by adding these 
individual sources. Caffeine consumption was analyzed both as a continuous variable and 
a categorical variable. Caffeine categories included low (≤250 mg/day) and high (>250 
mg/day) based on previous studies5 and recommendations by regulatory bodies like 
World Health Organization (WHO) 6,7, International Classification of Diseases (ICD) 
manual13 and The Diagnostic and Statistical Manual of Mental Disorders (DSM-V).8 
The Pittsburg Insomnia Rating Scale (PIRS): The PIRS (Appendix-1) is a 66-item 
self-report questionnaire that measures the subjective levels of insomnia experienced over 
the past seven days.9 This questionnaire consists of four components: Distress Score; 
Sleep Parameter Score; Quality of Life Sore; and Total Insomnia Score. The ‘Distress 
Score’ equals the total of first 46 questions each rated on a 0-3 scale and higher scores 
indicate increased levels of subjective distress symptoms experienced by the participants. 
Similarly, the ‘Sleep Parameter Score’ totals questions 47 to 56 each rated on a 0-3 scale 
and higher scores signify poor sleep quality. The ‘Quality of Life Score’ adds questions 
57 to 65 and higher scores signify poor quality of life.  The ‘The Global PIRS Score’ 
sums all the 65 questions and higher scores represent increased subjective reports of 
insomnia. The original study of the questionnaire also recommends scores 0-50 as ‘No 
Insomnia’, scores 51-100 as ‘Moderate Insomnia’ and scores greater than 100 as ‘Severe 
Insomnia’.9 The questionnaire also contains an ‘Overall Sleep Quality’ estimator with 
scores from 0% to 100%, and serves as a simplified summary of overall sleep. In 
opposition to the other components and the global score, increasing scores in ‘Overall 
Sleep Quality’ signify lower levels of insomnia. The PIRS questionnaire showed 
excellent internal consistency, test-retest reliability and discriminative validity in a mixed 
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sample of 456 normal adult participants between 18 and 85 years in the original study. 
The original study also reported a Cronbach's alpha coefficient of 0.88 indicating high 
internal consistency and an intra-class correlation of 0.89 indicating good test-retest 
reliability.9 The original study also reported a sensitivity of 83.4% and a specificity of 
88.6% for the questionnaire.9 In the present study the global PIRS scores were analyzed 
as both continuous and categorical variables. The global PIRS score categories included: 
≤50 (No Insomnia), 51-100 (Moderate Insomnia), and >100(Severe Insomnia) as 
recommended in the original study.9 
The Pittsburg Sleep Quality Index Questionnaire (PSQI):The PSQI (Appendix-1) is a 
19-item self-report questionnaire that measures self-reported quality of sleep over the 
past 30 days.10 This questionnaire includes seven individual components: Sleep Duration; 
Sleep Disturbance; Sleep Latency; Days Dysfunction due to Sleepiness; Sleep Efficiency; 
Overall Sleep Quality; and Need Meds to Sleep. Each component is rated on a 0–3 scale 
with higher scores signifying worsening outcomes. ‘Sleep Duration’ is calculated using 
question 4 and represents the total number hours slept per day. ‘Sleep Disturbance’ is 
calculated by summarizing individual scores in questions 5b to 5j and represents various 
factors like bad dreams, pain, breathing problems etc. that have impaired the quality of 
sleep. ‘Sleep Latency’ represents the total time spent awake on bed trying to sleep each 
day and is calculated using the questions 2 and 5 with necessary re-coding. ‘Days 
Dysfunction due to Sleepiness’ is calculated from questions 8 and 9 and represents daily 
problems related to sleep, such as having trouble staying awake or having enough 
enthusiasm to get things done. ‘Sleep Efficiency’ is calculated from questions 1 and 3 
and represents the ratio of actual number of hours of sleep, given the number of hours 
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spent in bed. ‘Overall Sleep Quality’ is calculated from question 6 and represents general 
sleep quality over the past month.  ‘Need Meds to Sleep’ is calculated from question 7 
and represents use of sleep medications over the past month. These seven component 
scores are added to obtain a global PSQI score which ranges from 0 to 21 and higher 
scores represent worsening sleep quality. According to the original study a global PSQI 
score of 5 or greater represents poor sleep quality.10 However other studies recommend 
scores 0-5 as good sleep quality, 6-10 as poor sleep quality and greater than 10 as worst 
sleep quality.11,12 This questionnaire had good internal consistency, test-retest reliability, 
and discriminative validity in the original study with a sample of 168 participants aged 19 
to 83 years.10 The original study also reported a Cronbach's alpha coefficient of 0.83 
indicating high internal consistency and an intra-class correlation of 0.85 indicating good 
test-retest reliability.10,13 The original study also reported a sensitivity of 89.6% and a 
specificity of 86.5% for the questionnaire.10,13 In the current study the global PSQI scores 
were analyzed as both continuous and categorical variables. The global PSQI score 
categories included: ≤5 (Good Sleep Quality), 6-10 (Poor Sleep Quality), and >10 (Worst 
Sleep Quality).23,24 
The Generalized Anxiety Disorder-7 (GAD-7) Questionnaire: The GAD-7 
(Appendix-1) is a 7-item self-reported questionnaire for screening and evaluating the 
severity of generalized anxiety symptoms over the past two weeks.14 Although primarily 
developed for measuring generalized anxiety disorder, studies have also reported good 
sensitivity and specificity for many other anxiety and panic disorders.15 There are seven 
questions about anxiety symptoms each rated on a 0-3 scale representing the options ‘not 
at all’, ‘several days’ , ‘more than half the days’ , and ‘nearly every day’. The total scores 
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range from 0 to 21 and higher scores represent greater anxiety levels. GAD-7 had shown 
good internal consistency, test-retest reliability, and discriminative validity in the original 
study of 2470 participants aged 19 to 95 years.14 The original study of this questionnaire 
reported a Cronbach's alpha coefficient of 0.92 indicating very high internal consistency 
and an intra-class correlation of 0.83 indicating good test-retest reliability.14 The original 
study also reported a sensitivity of 89% and a specificity of 82% for the questionnaire.14 
In the current study the GAD-7 scores were analyzed as both continuous and categorical 
variables. The GAD-7 score categories included: ≤5 (Minimal Anxiety), 6-10 (Mild 
Anxiety), 11-15 (Moderate Anxiety) and >15 (Severe Anxiety) as recommended in the 
original study.14 
Table 3: Assessments Variables Collected by the MASH Cohort  
Assessments  Visits 
Baseline 3-month 
Demographic and Socioeconomic information  × 
24-hour dietary recall    
Bio-impedance analysis (BIA)    
CD4 cell count    
Viral loads    
Alcohol, tobacco, and illicit drugs   
Food Security Questionnaire (FSQ)   
Hemoglobin   
Hematocrit   
Serum Albumin levels   
 
Demographic and socioeconomic information: The parent studies collected 
demographic and socioeconomic information for all participants. Information used for the 
present study included age, gender, race/ethnicity, education and income levels. A 
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number of health and lifestyle related factors like tobacco use, alcohol consumption, drug 
use and types of antiretroviral (ART) medications were also transcribed from the MASH 
cohort data.  
24-hour dietary recall: All research personnel in the parent studies were trained to 
obtain 24-hour dietary recalls which were used to estimate dietary and nutrient 
consumption by the participants. During each visit participants were queried about foods 
and beverages consumed on the day prior to the visit. All details including cooking 
methods, amount consumed, additional ingredients and seasonings and food brands were 
recorded to ensure the comprehensiveness of the obtained information. We also used 
props like food models and measuring cups to ensure accuracy of the amounts and 
volumes recalled as well as providing cues for better recall of consumed foods. We used 
Nutribase Professional Software Version 9 (Cybersoft Inc, 2011), into which all the 
collected information were entered to obtain estimation of several nutrients consumed by 
the participants.  
Bio-impedance analysis (BIA): In the parent studies after screening the participants, 
height was recorded immediately using a stadiometer, calibrated according to the 
instruction manual. Height was recorded to the nearest 0.5 inch after removing shoes, 
socks and other footwear. Height was recorded only once to ensure that it was uniform 
and there were no minor variations during every successive visit. Weight was measured 
every visit to the nearest 0.1 lbs. using a standard weighing machine which was calibrated 
and maintained throughout the study and the participants were requested to remove, their 
watches, shoes, mobile phones or other heavy materials possessed by them. The data so 
obtained along with age were entered into the bio-impedance machine (Biodynamics-
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450)16 to obtain several body composition measures such as, body cell mass, extracellular 
mass, lean body mass (LBM), fat mass, body mass index (BMI) and intracellular and 
extracellular fluid levels. In addition we also obtained the waist-to-hip ratio using a non-
stretchable tape to measure the waist and hip circumference at the narrowest levels of the 
waist and widest levels of the hip. 
CD4 counts and viral load: The BHCC provides a variety of comprehensive health 
services for HIV/AIDS patients which include quarterly check-up visits, laboratory 
services, nutritional counseling and emergency services. Based on requests from their 
primary health care physicians or their HIV/ STD consultant at BHCC, CD4 counts, viral 
loads and other clinical variables are measured every six months for all HIV infected 
patients. The parent grant collected and documented these reports after appropriate 
medical release forms signed by the participants. The parent grants also paid a 
compensation of $15 every six month to motivate participants towards timely submission 
of medical records and lab reports which included CD4 counts and viral load. We took 
meticulous efforts to ensure that lab reports submitted by the participants were timely and 
done within the interval between two six monthly follow-up visits in the parent study. 
The CD4 counts and viral loads were analyzed as both continuous and categorical 
variables. In analyses where CD4 counts and viral load were used as continuous variables 
they were transformed into CD4 square root and log10 viral load to ensure normal 
distribution and better model fit criteria. In analysis where CD4 counts and viral loads 
were used as categorical variables both the variables were divided into three groups of 
adequate control on disease progression (CD4 count >500 and viral load < 75 copies of 
HIV RNA); moderate control over disease progression (CD4 count between 200-499 and 
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viral load between 76-9999 copies of HIV RNA); and inadequate control over disease 
progression (CD4 count <200 and viral load >10,000 copies of HIV RNA), based on 
immunological and viroloigc stratification  of HIV disease progression by the World 
Health Organization (WHO).17,18  
Alcohol, tobacco, and illicit drugs: A trained interviewer administered alcohol, tobacco, 
and drug abuse questionnaires. The alcohol use questionnaires include information on 
frequency and type of alcohol use over time collected by the Lifetime Alcohol History 
(LAH),19 and history of alcohol binging and prolonged heavy exposure utilizing the 
validated and standardized Alcohol Use Disorders Identification Test (AUDIT).19 
Hemoglobin, hematocrit and serum albumin: Two chemistry panels and complete 
blood counts (CBC) from visits that tallied closest to the baseline and 3-month visit of the 
current study were transcribed form the laboratory reports of blood samples collected 
from the MASH cohort for the two parent studies. We obtained nutritional indicators like 
hemoglobin; hematocrit and serum albumin form these lab reports.    
Data Collection for the Study 
To reduce observer bias, we used standardized procedures with uniform protocols. 
All equipment, questionnaires and instruments were calibrated according to the 
instructions in user’s manual and the requirements of the MASH cohort. We also assured 
that these procedures were done prior to the commencement of the study to reduce wait 
time, as well as the time taken to administer the questionnaires and assessments. Each 
visit lasted approximately 30 minutes and was primarily devoted towards answering and 
filling out the forms and questionnaires. Participant responses were recorded and 
maintained in the paper based research charts for each study visit. Every chart included a 
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checklist of activities and the questionnaires were arranged according to the specific aims 
of the current study. The consent forms were maintained separately to ensure better levels 
of confidentiality as well as availability for audit purposes. All the research charts were 
quality assured at least twice during the course of the study to avoid missing data and 
non-rectifiable errors.  
Sample Size Calculation 
G-Power is a common software used for power analysis in social and behavioral 
research.20 G-Power 3 has incorporated several improvements over previous versions and 
is adapted to run on several interfaces like Windows XP, Windows Vista, and Mac OS X 
10.4. This software covers many different statistical tests of the t, F and χ2 categories.20  
G-Power 3 provides improved effect size calculations and graphic options, supports both 
distribution-based and design-based input models. This software comes handy in several 
types of power analysis with adjustments according to the study designs and sample size 
limitations.20 Hypothesis 1A was used for calculating the sample size for the study. The 
input parameters for the sample size calculations included a two tailed t-tests to 
determine difference between two independent means or two group means. The effect 
size was set at 0.5. Cohen et al.,21 has described three effect sizes: 0.3 for strong 
associations, 0.5 for moderate associations, and 0.8 for strong associations. Considering 
the associations between caffeine and CD4 cells to be moderate as evident in the 
preliminary study, we had decided 0.5 as the effect size.  We set the probability of alpha 
error at 0.05 and statistical power levels at 0.80 i.e. 80 percentage. We obtained an actual 
power of 0.801 for a total sample size of 128 participants for the study. We rounded this 
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figure to 130 participants (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day 
of caffeine) for the study. 
Statistical Methods Used in the Study 
SPSS-21 for windows was used for analyzing the relationship between caffeine 
intake and outcome variables in the study. Standard statistical methods were used to 
calculate the rates, describe the demographic characteristics and show basic summary 
statistics. Caffeine intake was analyzed as a as a categorical variable by splitting into two 
groups of <250 mg (low intake) and >250 mg (high intake) based on the studies that 
classify the dosage based adverse effects of caffeine.4-8,22 T-tests and chi-square tests 
were used for significant differences between the two caffeine groups with respect to all 
the outcome variables in the study. Multinomial logistic regressions were used to 
estimate the associations between different levels of caffeine consumption and several 
categorical outcome variables. Linear Mixed Models were used for over time changes in 
these associations. Caffeine intake was also considered as a continuous variable for 
several analyses.  Correlation analyses were used to find significant associations between 
caffeine intake and several continuous outcome variables. Correlation matrices helped to 
understand the existence of these associations. Linear regressions were used to analyze 
baseline cross-sectional data and report the strength and predictability of the associations 
between caffeine intake and continuous outcome variables. Linear Mixed Models were 
used for overtime changes in these associations. The results were considered significant 
for p <0.05 
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Quality Control 
We took several steps to ensure that data collected during the study were accurate 
and free from errors. All the procedures were done according to the ‘Good Clinical 
Practice’ protocols for quality control. We meticulously strived to ensure that there was 
no breach of protocol and we had adequate procedures to resolve them and take effective 
measures if we found any such occurrences. The Doctoral Candidate, Dr. Ramamoorthy’s 
responsibilities included monitoring every visit along with immediate perusal of all the 
data collected in charts as well as data entered into the software programs.  He was also 
assisted by other staff members in quality assurance procedures. The PI, Dr. Marianna 
Baum, PhD, and the committee members were constantly consulted to discuss logistic 
issues as well as sufficient supply of binders, folders, forms, questionnaire, copies and 
other supplies. The gathered data were regularly monitored through standardized 
procedures to ensure validity as well as reliability. All activities done during each week 
were discussed in weekly meetings to get feedback on the progress of the project as well 
as technical issues. A weekly review of performance, protocol compliance, and 
recommendations was done by the major professor, Dr. Adriana Campa, PhD, during the 
entire period of data collection and data entry. The security and confidentiality of data 
were ascertained through scrupulous and meticulous coding procedures. An elaborate 
system of patient identification numbers and study identification numbers were already in 
place for the parent study and were used for the current project. The data form charts 
were entered into databases by trained personnel with sufficient experience in data entry 
and retrieval procedures. All the working steps were intermittently scrutinized to ensure 
adequate quality control. The confidentiality and security of the data was further 
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strengthened by assigning appropriate password protections and accessibility codes for all 
the software used in the current study. All the instruments, logistics as well as the 
questionnaires were pilot tested to ensure the continuation of established standards of the 
parent study. To the best of our knowledge we took adequate steps to ensure the validity 
as well as reliability of the data collected during the current study as well as secondary 
analysis variables from the parent studies. 
Proposed Benefits of the Study 
This prospective study would serve as the basis for further large clinical trials for 
understanding the effects of caffeine consumption on disease progression levels. Several 
other factors that could not be covered in this study can be progressively determined, 
measured and analyzed. These researches can further help in instituting studies on 
standardized dietary recommendations on the consumption of coffee and other caffeine 
containing beverages in HIV infected patients. This can alleviate the already immuno-
compromised states in these patients, contribute to immune recuperation and bring 
significant changes in their general wellbeing. 
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CHAPTER IV: CAFFEINE INTAKE AND ITS ASSOCIATION WITH DISEASE 
PROGRESSION IN MIAMI ADULT STUDIES ON HIV (MASH) COHORT – AN 
OBSERVATIONAL STUDY 
ABSTRACT 
Introduction: In the year 2013, Miami-Dade County reported about 26,760 people living 
with HIV (PLWH). Though there are many studies on adverse health effects of alcohol, 
recreational drugs and tobacco use in this population, similar studies about caffeine 
consumption are few. In this study we investigated for the effects of caffeine on 
immunological and virologic markers of disease progression.  
Methods: A convenience sample of 130 consecutive, clinically stable HIV-positive 
participants on ART, (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of 
caffeine) were recruited from the Miami Adult Studies on HIV (MASH) cohort. This 
prospective study included a baseline and a follow-up visit after 3 months. After 
obtaining written consent, the Modified Caffeine Consumption Questionnaire (MCCQ), 
CD4 cell count, HIV viral load, demographics, anthropometries, Body Mass Index 
(BMI), bio impedance measures, substance abuse and types of ART were obtained. Data 
were sequentially entered in secure databases and analyzed using SPSS-21 for windows. 
T-tests and chi-square tests were used to describe demographics and health and lifestyle 
characteristics of the participants. Linear regressions were used to analyze baseline data 
for relationships between caffeine consumption and parameters of HIV disease 
progression. Linear Mixed Models were used to understand the effect of caffeine 
consumption on these parameters over time.  
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Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were male and 
75.4% were African-Americans. All participants were on ART during both the visits. 
Mean caffeine intake at baseline was 161.26 ± 194.95 mg/day (3-8 cups of coffee) 
(Range: 0 mg-1498 mg/day) and did not change significantly at the 3-month follow-up 
visit. Linear regression analysis showed significant associations between higher caffeine 
consumption and higher CD4 cell count (β=1.532, P=0.049) and lower HIV viral load 
(β=-1.067, P=0.048), after adjusting for age, gender, education, income, and time from 
diagnosis of HIV, drug use, smoking status, alcohol use and different types of ART 
medications. Linear mixed model analysis showed that higher caffeine consumption was 
associated with higher CD4 cell count (β=1.720, P=0.042) and lower HIV viral load (β= -
1.389, P=0.033), in a dose-response manner, after adjusting for the same covariates.  
Conclusion: Higher caffeine consumption was associated with higher CD4 cell counts 
and lower HIV viral loads indicating beneficial effects on HIV disease progression. 
Future studies examining bio-chemical effects of caffeine on CD4 cell counts and viral 
replication are needed to shed light on the mechanisms of these potential beneficial 
effects.  
Keywords: Caffeine, HIV infection, CD4 cell count, HIVviral load. 
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INTRODUCTION 
HIV/AIDS is a leading cause of morbidity and mortality worldwide.1 According 
to CDC estimates in 2013, about 1.2 million people were living with HIV/AIDS in 
United States.2  In Miami-Dade County, there were 26,760 people living with HIV/AIDS 
(PLWH), in the same year.3 In the year 2013, it  was also estimated that one in 99 Miami-
Dade resident was living with HIV infection which included one in 36 African American, 
one in 123 White, and one in 163 Hispanic.4 HIV/AIDS has also successively been in the 
list of ten leading causes of death among African Americans in Florida.5 This 
epidemiological evidence shows that Miami-Dade County and the State of Florida suffer 
increased burden of the disease compared to the national average. 
Antiretroviral therapy (ART) has significantly improved survival rates and 
decreased morbidity and mortality in PLWH and constitutes the single most effective 
strategy to prevent HIV-1 transmission rates.6   Combination ART has decreased the 
numbers of patient entering health-care centers from 75,486 in the year 2000 to 24,780 in 
the year 2010.15 The estimated cumulative survival benefits of combination ART therapy 
was 2,813,892 years between the years 2000 and 2010.15  Due to recent improvements in 
availability and accessibility of combination ART medications, currently, HIV/AIDS 
constitutes a chronic disease with decreasing incidence, increasing prevalence and 97% 
decrease in progression to AIDS and death as of the year 2014.16       
 Many factors contribute to faster HIV disease progression, such as homelessness, 
illegal commercial sex, drug abuse, alcohol addiction and criminalization of the disease 
which contribute to barriers in access to effective ART and compliance with the 
medications.17-21 Most of the PLWH live in marginalized neighborhoods with limited 
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resources.22 Though the majority of the MASH cohort, from which our participants were 
recruited, receive social security benefits and some forms of food assistance, many of 
them experience poverty and some experience food insecurity.23 Food insecurity, poverty 
and poor living conditions are associated with accelerated disease progression and poor 
health outcomes, as reported in other studies.24,25 There is  a large body  of literature on 
associations of alcohol,26 illicit drugs27 and tobacco use28 with a variety of health related 
outcomes in this population. However, there are very few studies that relate caffeine 
consumption to health related outcomes in HIV infected populations.   
In a study done by Raboud et al.,29 CD4 cell counts were significantly lower in 
consumers of moderate amounts of caffeine (<250 mg/day) compared to non-consumers 
(0 mg/day). Another study done among clinically stable HIV positive individuals showed 
that administration of caffeine (<250 mg/day) decreased  CD4 cell counts by 54% and 
CD8 cell counts by 55%  compared to placebo (0 mg/d) .30 In contrast, an in-vitro study 
showed that caffeine suppressed replication of infectious HIV-1 strains in cultures of 
human peripheral mononuclear cells.31 This study demonstrated greater than 9-fold 
reductions in HIV-1 p24 antigen values in samples treated with caffeine or caffeine 
metabolites such as theobromine, paraxanthine or theophylline when compared to control 
solutions.31 Similar findings were reported in another tissue culture study where caffeine 
in concentrations of 10 µgm/liter significantly inhibited retroviral transduction of 
dividing Human neuronal precursor (hNT-2) cells, thereby, blocking post integration 
repair of HIV-1 viral strains and inhibiting viral replication cycles. 32 These effects have 
been hypothesized to be related to a cellular target: the ataxia telangiectasia-mutated 
Rad3-related (ATR) kinase.32   
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Studies in HIV-seronegative populations have implicated caffeine use in a variety 
of health problems. High caffeine intake (>400 mg/day) adversely affected the quality of 
sleep and general well-being scores in healthy subjects,33,34  and precipitated anxiety 
disorders in apparently healthy volunteers.35  High caffeine intake (480 mg/day), 
adversely affected gabaminergic (inhibitory) neurotransmission, exacerbated mental 
stress, and produced irreversible psychological derangements in apparently healthy 
participants with anxiety disorders controlled through medications.36,37  Caffeine intake 
(<250 mg/day) was also associated with nutritional losses such as cysteine-depletion and 
decreased plasma levels of anti-oxidant trace elements such as zinc and selenium thereby 
increasing susceptibility to oxidative damage of neuronal cells.38,39 Caffeine in doses of 
300 mg/day was also associated with irregularities in blood pressure tracings and cardiac 
function tests in susceptible populations.40,41  
Excessive caffeine intakes were also associated with higher levels of 
inflammation. In a cross-sectional survey conducted in 1514 men and 1528 women, men 
who consumed more than 200 mg/day of caffeine had 50% higher interleukin 6 (IL-6), 
30% higher C-reactive protein (CRP), 28% higher tumor necrosis factor- α (TNF-α)  and 
3% higher white blood cell (WBC) counts. Similarly women who consumed more than 
200 mg/day of caffeine reported 54% higher IL-6, 38% higher CRP, 28% higher TNF-α 
and 4% higher WBC counts.42  
Caffeine (<250 mg/day) was associated with moderate weight loss in many 
groups of healthy volunteers.43,44 This could be detrimental to HIV-infected patients 
because higher body weight and fat-mass are associated with higher CD4 cell counts, 
lower viral load and better health outcomes in participants receiving ART.45-47  
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Since studies have found associations between excessive caffeine consumption 
and many adverse effects in non-HIV infected populations, it is possible that some of 
these effects may be more pronounced in HIV infected subjects, who are already 
compromised in a variety of health related parameters. There are very few studies that 
document the associations of caffeine and CD4 cells and HIV viral load. Existing studies 
on the effects of caffeine on viral loads are in-vitro studies conducted in tissue cultures, 
while the ones investigating CD4 counts have several shortcomings, including small 
sample sizes and inadequate control for several variables associated with HIV disease 
progression.  Furthermore, some studies show adverse associations between caffeine and 
immunological markers but potentially beneficial associations with virologic markers. 
Therefore, a question remains on whether caffeine is beneficial or detrimental to PLWH. 
The specific aim of this study was to investigate the immunological (CD4 cell counts) 
and virologic (HIV viral load) measures of disease progression in association with 
caffeine consumption in a group of PLWH on stable ART.  
METHODS 
Study Design and Setting 
The present study recruited a convenience sample of 130 participants (65 consuming ≤ 
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which 
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10 
years at the FIU research clinic in the Borinquen Health Care Center (BHCC).  The 
BHCC provides comprehensive range of health and social services to a culturally diverse 
low income community. The recruitment for the present study took place from February 
to July 2014. The present study included a baseline and 3-month follow-up visits, and 
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participants received $5 as partial reimbursement for their time and efforts, for each of 
the two visits. The initial screening included detailed explanation of the study as well as 
obtaining informed voluntary written consent for participation. In order to obtain a study 
sample of 128 participants as estimated in our sample size calculations, we screened a 
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants. 
The present study also included secondary analysis of relevant variables collected for the 
MASH cohort studies. Data collected during the baseline and 3-month visits were used 
for the analyses of descriptive and inferential statistics. The inclusion and exclusion 
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable 
to our current study. The additional inclusion criteria for participants in the present study 
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a 
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion 
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical 
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or 
mal-absorption syndromes. The Institutional Review Board at Florida International 
University approved the study protocol and research procedures. 
Measures 
The questionnaires used in the present study were previously field tested and 
validated in several large scale studies.48-51 However, we pre-tested these questionnaires 
on 15 participants from the MASH cohort to ascertain their applicability and we 
determined that revisions were not necessary for the questionnaires.  
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Caffeine consumption questionnaire: We used the Modified Caffeine Consumption 
Questionnaire (MCCQ) developed by Preston et al in the year 1998.52 This questionnaire 
is easy to understand, compact, organized and reports adequate compliance, validity and 
reliability.52 This questionnaire was field tested and validated in several large scale 
studies and adequately reflected average daily caffeine consumption levels.48 It includes a 
total of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the 
counter medications’ and ‘Prescription medications’. This questionnaire also included 
‘Total caffeine consumption per day’ by adding these individual sources. Caffeine 
consumption was analyzed both as a continuous variable and a categorical variable.  
             For both naturally occurring and artificially added caffeine sources, FDA 
considers 400 mg/d to be generally safe and not associated with any dangerous side 
effects.53,54  The World Health Organization (WHO) defines caffeine overuse as daily 
consumption beyond 500 mg/d.55,56  Beyond this level caffeine produces visible adverse 
effects collectively known as ‘caffeinism’. The World Health Organization (WHO) has 
also cautioned that these adverse effects could be precipitated at much lower doses 
depending on the physiological profiles of individuals as well as the genetic makeup of 
the population.55,56 The International Classification of Diseases (ICD) manual considers 
caffeine consumption above 250 mg/day to be associated with many mental and 
behavioral disorders though it is inconclusive whether such effects would be uniformly 
applicable in the general population.13 The Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) considers consumption below 250 mg/day to be generally safe and 
above this level to be associated with many adverse effects such as withdrawal, addiction, 
irritability and craving.57 Summarizing these cutoffs, we concluded that caffeine 
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consumption below 250 mg/day that is equivalent to 4 cups of coffee, irrespective of the 
sources is generally safe and not associated with adverse effects. In this study, caffeine 
categories included low (≤250 mg/day, within safe levels) and high (>250 mg/day, 
beyond safe levels) based on these recommendations. 
CD4 counts and viral load: The BHCC provides a variety of comprehensive health 
services for HIV/AIDS patients which include quarterly check-up visits, laboratory 
services, nutritional counseling and emergency services. Based on requests from their 
primary health care physicians or their HIV/ STD consultant at BHCC, CD4 counts, viral 
loads and other clinical variables are measured every six months for all PLWH. The 
MASH cohort studies collected and documented these reports after appropriate medical 
release forms were signed by the participants. The CD4 counts and viral loads were 
analyzed as both continuous and categorical variables using clinically meaningful cutoff 
points. In analyses where CD4 counts and viral load were considered as continuous 
variables, they were transformed into CD4 square root and log10 HIV viral load to ensure 
normal distribution and better model fit criteria. In analysis where CD4 counts and HIV 
viral loads were considered as categorical variables both variables were divided into three 
groups with clinically meaningful cutoff points based on immunological and virologic 
stratification  of HIV disease progression by the World Health Organization (WHO).58,59 
CD4 cell counts were stratified as  >500 cells/μL , ≤500 and >200cells/μL , and < 200 μL 
.58,59HIV viral load was stratified as undetectable HIV viral load <21; between 21 and 
9,999 copies/mL, considered moderately controlled HIV viral load; and >10,000 
copies/mL, considered uncontrolled viral load, based on the clinical cutoffs 
recommended by the World Health Organization.50,51 
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Control Variables 
Demographic and socioeconomic information: Demographic and socioeconomic 
information used in this study were collected by the MASH studies. Information used for 
the current study included age, gender, ethnicity, education and income levels. A number 
of health and lifestyle related factors such as tobacco use, alcohol consumption, and illicit 
drug use were also gathered from the MASH data repository. All these variables were 
adjusted in our analysis based on studies associating these variables with HIV disease 
progression.26-28 
Bio-impedance analysis (BIA): In the MASH cohort studies, after screening the 
participants, height was recorded immediately using a stadiometer, calibrated according 
to the instructions in user manual. Height was recorded to the nearest 0.5 inch after 
removing shoes, socks and other footwear. Height was recorded only once to ensure that 
it was uniform and there were no minor variations during every successive visit. Weight 
was measured every visit to the nearest 0.1 lbs. using a standard weighing machine which 
was calibrated and maintained throughout the study and the participants were requested 
to remove  their watches, shoes, mobile phones or other heavy materials. The data so 
obtained along with age were entered into the bio-impedance machine (Biodynamics-
450)60 to obtain  body cell mass, extracellular mass, lean body mass (LBM), fat mass, 
body mass index (BMI) and intracellular and extracellular fluid levels. In addition we 
also obtained the waist-to-hip ratio using a non-stretchable tape to measure the waist and 
hip circumference at the narrowest levels of the waist and widest levels of the hip. While 
estimating the effects of caffeine on immunological and virologic markers of HIV disease 
progression, we adjusted for BMI and fat mass, based on studies associating these 
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variables to better immunological and virologic profiles.45,61-63 
ART medications: All participants enrolled in the study were on some form of ART. 
Information about different types of antiretroviral medications prescribed by their 
physicians was obtained during the MASH cohort visits. All analyses were adjusted for 
these variables because all antiretroviral medications have profound effects on markers of 
HIV disease progression. 
Statistical Analysis 
Field data were collected in paper based questionnaires and later entered into 
RedCap database, imported into SPSS version 21 for Windows (Armonk, NY: IBM 
Corp) and merged into a single dataset for analysis. Descriptive statistics were used to 
understand the population characteristics and were expressed in terms of means, standard 
deviations and percentages. The characteristics of the population were shown for all the 
participants and separated based on low and high intakes of caffeine using the cutoff 
points: >250 mg/day for high intake; and ≤250 mg/day for low or no intake. T-tests and 
chi square tests were used to describe differences in demographics, health and lifestyle 
characteristics and CD4 and viral load categories with respect to low and high levels of 
caffeine consumption. Paired sample t-tests were used to measure differences in levels of 
caffeine consumption between baseline and the follow-up visit for major sources, as well 
as total levels of caffeine consumption. Linear regression was used to estimate the 
strength of association between caffeine consumption and markers of HIV disease 
progression, CD4 counts and viral load. Assumptions of linear regression were followed 
prior to analyses. Linear mixed models (LMM) were used to determine over time changes 
in the strength of these associations. For parameter estimation in LMM models, 
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Restricted Maximum Likelihood (REML) was used. Multinomial logistic regressions 
were used to determine the associations between high and low caffeine intake groups 
with respect to different levels of disease progression (different categories of CD4 counts 
and viral load). For liner and logistic regressions, as well as linear mixed model analysis, 
we initially used crude models and subsequently adjusted for associated covariates 
already described in Methodology. These covariates were also tested for significant 
associations with the outcome variables using bivariate analysis before being 
incorporated into the models. To increase the validity of the models, multicollinearity 
among covariates was tested prior to the analyses. Adjusted models included non-missing 
values for all independent variables included in the models. Statistical significance was 
set at P<0.05 for all the analyses.  
RESULTS 
Demographic and Socio-economic Characteristics  
A total of 130 participants were included in the study and 79 (60.8%) were men. 
The mean age was 47.89 ±SD 6.37 years. Most of the participants were African 
Americans (75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and other 
races constituted 4.6 percent. About 24% of the participants had college education, while 
45.4% were high school graduates and 30.8% had some form of primary education. All 
participants had incomes under the level of poverty and the mean income was $495.91± 
465.887. There were no significant differences in any socio-demographic variables 
between low and high levels of caffeine consumption in both baseline and follow-up 
visits (Table-1A, 1B). 
 
 107 
 
Health/lifestyle Characteristics  
Sixty one percent of the participants reported smoking within the past six weeks 
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive 
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and 
65.8% tested positive for illicit drug use during the follow-up visit.  
All participants were on ART during both the visits. Antiretroviral therapy took 
many forms, 58.5% were on NRTI, 13.1% were on NNRTI and 47.7% were on PI in 
several combinations, 26.2% of the participants were using a one-pill multi-drug 
combination such as Atripla, Truvada and Combivir during the baseline visit. At the 3-
month visit, 63.8% were on NRTI, 13.8% were on NNRTI and 47.7% were on PI, and 
25.4% were on a one-pill multi-drug combination during the follow-up visit. There were 
no significant differences in the distribution of these variables between low and high 
levels of caffeine consumption in both baseline and follow-up visits (Tables 2 and 3). 
Caffeine Consumption 
Total caffeine consumption was 337.63 ± 304.97 mg/day at baseline (Range: 0-
1,498 mg/day), and 281.04 ± 260.85 mg/day (Range: 0-1,175 mg/day) at the 3-months 
follow-up. Coffee constituted the largest source of caffeine and mean consumption levels 
were 161.26± 194.95 mg/day at baseline, and 190.40 ± 205.03 mg/day at follow-up. 
Caffeinated soft drinks constituted the second largest source of caffeine and mean 
consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66 ± 83.78 mg/day at 
follow-up. There were no significant differences between baseline and follow-up visits 
with respect to total caffeine consumption or caffeine from most of the sources. However, 
there was significant decrease in consumption of caffeinated soft drinks (63.23 ± 92.98 
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vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs. 9.61 ± 65.32, P=0.005) 
and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the baseline to the follow-up 
visits (Table-4).  For all other sources of caffeine in the questionnaire, except the ones 
enlisted in Table 4, participants reported none to negligible levels of consumption at both 
the visits. 
Caffeine Consumption and Immunological And Virologic Markers of HIV Disease 
Progression 
Caffeine intake was significantly associated with CD4 cell count (β=1.532, 
P=0.049) and log10 viral load (β= -1.067, P=0.048) after adjusting for age, gender, 
race/ethnicity, education, income, and time from diagnosis of HIV, drug use, smoking 
status, alcohol use, different types of ART medications, BMI and total fat mass (Table-5). 
Linear mixed model analysis for the effect of caffeine intake on changes in parameters of 
HIV disease progression between the two study visits, showed higher CD4 cell count 
(β=1.720, P=0.042) and lower log10 HIV viral load (β= -1.389, P=0.033)  with increasing 
caffeine consumption, in a dose-response manner, after adjusting for the same covariates 
(Table-6).  
 Multinomial logistic regression showed that the odds of having CD4 counts < 
200 cells/mm3 were 69% higher in participants who consumed less than 250 mg of 
caffeine per day when compared to participants who consumed greater than 250 mg, after 
adjusting for the same covariates (OR=1.690, 95% CI: 1.123 -3.879, P=0.047). Similarly 
the odds of having CD4 counts 200-499 cells/mm3 were 53% higher in participants who 
consumed less than 250 mg of caffeine per day when compared to participants who 
consumed greater than 250 mg, after adjusting for the same covariates (OR=1.537, 95% 
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CI: 0.522 -5.136, P=0.198). The odds of presenting HIV viral loads greater than 10,000 
copies of HIV viral RNA/mm3 were 93% higher in in participants who consumed less 
than 250 mg of caffeine per day when compared to participants who consumed greater 
than 250 mg after adjusting for covariates (OR=1.933, 95%CI: 1.254 -6.192, P=0.048). 
However caffeine consumption did not affect the odds of presenting HIV viral loads 21-
9,999 copies of HIV viral RNA/mm3 (OR=0.964, 95%CI: 0.317 -3.444, P=0.437).  To 
summarize, the participants who consumed less caffeine had lower CD4 and higher viral 
loads. All the significant odds continued overtime and retained significant when 
associations over the three month period were considered (Table 7, 8, 9 and 10).  
DISCUSSION 
The characteristics of our population were epidemiologically similar to those 
described by others in Miami-Dade County.64,65 More than half of the participants were 
consuming alcohol and smoking cigarettes, and 48.2% used illicit drugs confirmed by 
urine toxicology, therefore, we adjusted for these variables in the analyses, to evaluate the 
independent effect of caffeine.  The  apparent beneficial effects of high consumption of 
caffeine on HIV disease progression was unexpected, although there is evidence from in-
vitro studies on caffeine decreasing the replication of the HIV virus in tissue cultures.31,32  
In our study, only after adjusting for other relevant variables affecting HIV disease 
progression, caffeine consumption became significantly associated with both 
immunological and virologic markers of disease progression. This suggests a complex 
and moderate impact of caffeine on parameters of HIV disease progression. Our findings 
need to be confirmed by larger studies, as they could be incidental findings. Furthermore, 
there are very few studies that explore the relationship between caffeine and HIV disease 
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progression, and there is lack of scientific consensus on this topic, probably due to the 
general acceptance of caffeine as a safe consumer product.53  
A study conducted by Raboud  et al.29 among clinically stable HIV-infected 
patients  showed significant reductions in CD4 counts among caffeine consumers 
compared to non-consumers, after adjusting for age, gender, medications, presence of 
opportunistic infections (oral candidiasis) and potential measurement errors. However, 
this study had several limitations and differences from our study. The study was 
conducted before the advent of combined ART; caffeine consumption was considered a 
categorical variable with subjects either reporting or not reporting caffeine consumption; 
and the study had a small sample size of 30 participants, which limited its external 
validity.29 Because of these shortcomings, this study could have missed the beneficial 
effects of caffeine. Furthermore, the findings in our study could be more relevant because 
of the larger sample size and adjustments for several covariates that have significant 
confounding effects on immunological and virologic parameters.   
          Bishop et al.,30 conducted a study in clinically stable PLWH to establish the effects 
of caffeine consumption and exercise on CD4 and CD8 cell counts. The participants were 
asked to abstain from consumption of caffeine for 60 hours prior to the experiment. Half 
of the subjects were administered 350 mg/day of caffeine, while the remaining subjects 
were administered placebo. There was 54% decrease in circulating CD4 cell counts and 
55% decrease in circulating CD8 cell counts post exercise in subjects administered 
caffeine compared to the placebo group, after adjusting for factors such as age, gender, 
BMI, lean body mass and fluid input and output levels.30 This study also reports that post 
exercise plasma catecholamine levels were significantly higher in those administered 
 111 
 
caffeine when compared to placebo.30 This study hypothesized that caffeine produced 
alterations in lymphocyte subset trafficking as well as expression of CD69 molecules 
which are important intermediate steps in generating and recruiting inflammatory cells.30 
Through this process, caffeine decreased production and recruitment of inflammatory 
cells to the targeted areas of inflammation which included decreased circulating CD4 and 
CD8 cells.30 It is not clear whether these results were produced by caffeine itself or the 
stress hormones such as catecholamines that are associated with exercise and caffeine 
consumption.66-69 
         Our study found mostly beneficial effects of caffeine consumption. The 
beneficial findings in our study are supported by two in-vitro studies. The first in-vitro 
study showed that caffeine suppressed replication of infectious HIV-1 strains in cultures 
of human peripheral mononuclear cells.31 Caffeine in 100 millimolar concentrations 
exerted these effects by inhibiting the integration step of the HIV-1 viral replication 
cycle. This study also showed that other methyl-xanthines such as theophylline, 
theobromine, and paraxanthine, in 100 millimolar doses act through the same processes 
to inhibit HIV-1 replication. They observed a 9-fold reduction in HIV-1 p24 antigen 
values in samples treated with caffeine, theobromine, paraxanthine or theophylline when 
compared to control solutions.31 The second in-vitro study found that caffeine in 
concentrations of 10 µgm/liter significantly inhibited retroviral transduction of dividing 
human Neuronal Precursor (hNT-2) cells thereby blocking post integration repair of HIV-
1 viral strains. These effects have been postulated to a cellular target- ‘the ataxia 
telangiectasia-mutated and Rad3-related (ATR) kinase’.32 Caffeine inhibits viral DNA 
repair at the DNA damage-activated checkpoints, thereby inhibiting viral replication 
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cycle.32  Our study observed an inverse association between caffeine consumption and 
viral load which might be ascribable to these mechanisms.  
            Nevertheless, we should also note that tissue culture studies and studies on human 
beings are not comparable. Many confounders associated with the lifestyle, dietary and 
other confounding factors could have influenced the findings in our study. Our sample 
size was also very limited due to the feasibility and constraints of the study settings. 
Large scale studies with controlled intake of nutrients and health and lifestyle factors and 
adequate sample size should be planned in the future to ascertain the findings in our 
study. 
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption 
Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables   
 
 
 
 
 
 
 
 
 
Variables 
Baseline 
Total 
 
Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 47.57±6.81 48.00±6.15 0.706 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
40 (61.5%) 
25 (38.5%) 
 
39 (60.0%) 
26 (40.0%) 
0.857 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
3 (4.6%) 
7 (10.8%) 
55 (84.6%) 
0 (0.0%) 
 
4 (6.2%) 
15 (23.1%) 
43 (66.2%) 
3 (4.6%) 
0.057 
Education in 
years, N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
24 (36.9%) 
29 (44.6%) 
12 (18.5%) 
 
 
16 (24.6%) 
30 (46.2%) 
19 (29.2%) 
0.202 
Income in dollars 
per month 
 
495.91 ± 
465.887 
464.00 ± 
419.667 
527.34 ± 
508.637 
0.442 
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Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption 
Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables   
 
Variables 
Follow-up 
Total Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 46.63±7.33 48.87±5.38 0.490 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
43 (68.3%) 
20 (31.7%) 
 
36 (53.7%) 
31 (46.3%) 
0.090 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
4 (6.3%) 
9 (14.3%) 
50 (79.4%) 
0 (0.0%) 
 
3(4.5%) 
13 (19.4%) 
48 (71.6%) 
3 (4.6%) 
0.285 
Education in 
years, N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
21 (33.3%) 
29 (46.0%) 
13 (20.6%) 
 
 
19 (28.4%) 
30 (44.8%) 
18 (26.9%) 
0.670 
Income in dollars 
per month 
 
495.91 ± 
465.887 
498.80 ± 
511.708 
492.89 ± 
416.619 
0.943 
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Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables 
ART: Antiretroviral therapy.  
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
 P-value 
Smoking 
cigarettes 
Yes 
No 
 
80 (63.5%) 
46 (36.5%) 
 
39 (60.9%) 
25 (39.1%) 
 
41 (66.1%) 
21 (33.9%) 
0.582 
Alcohol use 
Yes 
No 
 
73 (57.9%) 
53 (42.1%) 
 
36 (56.3%) 
28 (43.8%) 
 
37 (59.7%) 
25 (40.3%) 
0.721 
Drug use 
Yes 
No 
 
53 (48.2%) 
57 (51.8%) 
 
25 (43.9%) 
32 (56.1%) 
 
28 (52.8%) 
25 (47.2%) 
0.445 
Marijuana 
Yes 
No 
 
44 (33.8%) 
86 (66.2%) 
 
21 (32.3%) 
44 (67.7%) 
 
23 (35.4%) 
42 (64.6%) 
0.853 
Cocaine 
Yes 
No 
 
41 (31.5%) 
89 (68.5%) 
 
19 (29.2%) 
46 (70.8%) 
 
22 (33.8%) 
43 (66.2%) 
0.706 
Other Drugs 
Yes 
No 
 
10 (9.1%) 
100 (90.9%) 
 
6 (10.5%) 
51 (89.5%) 
 
4 (7.5%) 
49 (92.5%) 
0.744 
ART     
Multi-
combination 
Yes 
No 
 
34 (26.2%) 
96 (73.8%) 
 
22 (33.8%) 
43 (66.2%) 
 
12 (18.5%) 
53 (81.5%) 
0.072 
NRTI 
Yes 
No 
 
76 (58.5%) 
54 (41.5%) 
 
40 (61.5%) 
25 (38.5%) 
 
36 (55.4%) 
29 (44.6%) 
0.594 
NNRTI 
Yes 
No 
 
17 (13.1%) 
113 (86.9%) 
 
10 (15.4%) 
55 (84.6%) 
 
7 (10.8%) 
58 (89.2%) 
0.604 
PI 
Yes 
No 
 
62 (47.7%) 
68 (52.3%) 
 
34 (52.3) 
31 (47.7%) 
 
28 (43.1%) 
37 (56.9%) 
0.380 
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Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests all variables. 
ART: Antiretroviral therapy.  
 
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-
value 
Smoking 
cigarettes 
Yes 
No 
 
79 (63.2%) 
46 (36.8%) 
 
41 (68.3%) 
19 (31.7%) 
 
38 (58.5%) 
27 (41.5%) 
0.271 
Alcohol use 
Yes 
No 
 
76 (60.3%) 
50 (39.7%) 
 
34 (56.7%) 
26 (43.3%) 
 
42 (63.6%) 
24 (36.4%) 
0.469 
Drug use 
Yes 
No 
 
79 (65.8%) 
41 (34.2%) 
 
45 (75.0%) 
15 (25.0%) 
 
34 (56.7%) 
26 (43.3%) 
0.054 
Marijuana 
Yes 
No 
 
67 (55.8%) 
53 (44.2%) 
 
38 (63.3%) 
22 (36.7%) 
 
29 (48.3%) 
31 (51.7%) 
0.141 
Cocaine 
Yes 
No 
 
48 (40.0%) 
72 (60.0%) 
 
29 (48.3%) 
31 (51.7%) 
 
19 (31.7%) 
41 (68.3%) 
0.093 
Other drugs 
Yes 
No 
 
13 (10.9%) 
106 (89.1%) 
 
6 (10.0%) 
54 (90.0%) 
 
7 (11.9%) 
52 (88.1%) 
0.496  
ART     
Multi-
combination 
Yes 
No 
 
33 (25.4%) 
97 (74.6%) 
 
20 (31.7%) 
43 (68.3%) 
 
13 (19.4%) 
54 (80.6%) 
0.113 
NRTI 
Yes 
No 
 
83 (63.8%) 
47 (36.2%) 
 
40 (63.5%) 
23 (36.5%) 
 
43 (64.2%) 
24 (35.8%) 
1.000 
NNRTI 
Yes 
No 
 
18 (13.8%) 
112 (86.2%) 
 
9 (14.3%) 
54 (85.7%) 
 
9 (13.4%) 
58 (86.6%) 
1.000 
PI 
                  Yes 
                   No 
 
62 (47.7%) 
68 (52.3%) 
 
28 (44.4%) 
35 (55.6%) 
 
34 (50.7%) 
33 (49.3%) 
0.488 
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Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
 
 
Table 5:  Linear Regression of the Effect of Caffeine Consumption on Immunological 
and Virologic Markers of Disease Progression  
 
Disease 
progression 
variables 
Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
CD4 square root a 1.215 0.099 0.465 1.532 0.241 0.049* 
Log10 Viral load b -1.023 0.043 0.588 -1.067 0.081 0.048* 
aModel R2 = 0.135, F (17) = 15.313, P = .047.   
bModel R2 = 0.174, F (17) = 16.379, P = .047.   
†Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status, BMI, total body fat percentage. 
*Significant 
 
Food source Baseline Follow-up P-value 
Coffee 161.26 ± 194.95 190.40 ± 205.03 0.206 
De-Caffeinated 
coffee 
0.83 ± 9.21 0.03 ± 0.43 0.329 
Expresso 14.40 ± 64.35 13.92 ± 57.82 0.942 
Tea 34.70 ± 64.32 31.58 ± 59.36 0.640 
Green tea 7.34 ± 62.93 4.20 ± 21.62 0.594 
Energy drinks 46.32 ± 134.42 9.61 ± 65.32 0.005* 
Hot cocoa 1.03 ± 5.00 0.00 ± 0.00 0.020* 
Caffeinated soft 
drinks 
63.23 ± 92.98 29.66 ± 83.78 <0.0001* 
Chocolate candy 
bars 
3.69 ± 13.81 2.00 ± 17.93 0.402 
Anacin  0.24 ± 2.80 0.00 ± 0.00 0.319 
Appetite control 
pills  
4.61 ± 39.10 0.00 ± 0.00 0.181 
Total 337.63 ± 304.97 281.04 ± 260.85 0.890 
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Table 6: Linear Mixed Model Analysis of Overtime Changes in the Effects of Caffeine 
Consumption on Immunological and Virologic Markers of Disease Progression  
aModel: -2 Restricted Log Likelihood = 1055.823; Akaike’s Information Criteria (AIC) = 
1059.823; Schwarz’s Bayesian Criteria (BIC) = 1065.910. 
bModel: -2 Restricted Log Likelihood = 2597.274; Akaike’s Information Criteria (AIC) = 
2601.274; Schwarz’s Bayesian Criteria (BIC) = 2607.36. 
†Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status, BMI, total body fat percentage. 
*Significant 
 
 
Table 7: Baseline: CD4 count and Viral Load Categories by Levels of Caffeine 
Consumption† 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables. 
aInadequate control over disease progression 
bModerate control over disease progression 
cAdequate control over disease progression 
†World Health Organization. Who Case Definitions of HIV for Surveillance and Revised 
Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and 
Children. 2007; http://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf. 
Accessed September 30, 2014. 
Disease progression 
variables 
Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
CD4 square root a 0.900 0.3011 0.402 1.720 0.901 0.042* 
Log10 Viral load b -0.9774 0.8002 0.777 -1.389 0.786 0.033* 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-value 
CD4 count  
≤199a 
200-499b 
≥500c 
 
15 (13.0%) 
53 (46.1%) 
47 (40.9%) 
 
8 (13.8%) 
25 (43.1%) 
25 (43.1%) 
 
7 (12.3%) 
28 (49.1%) 
22 (38.6%) 
0.811 
HIV viral load  
≤21c 
21-9999b 
≥10000a 
 
32 (28.6%) 
55 (49.1%) 
25 (22.3%) 
 
16 (28.6%) 
27 (50.0%) 
13 (21.4%) 
 
16 (28.6%) 
28 (50.0%) 
12 (21.4%) 
0.971 
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Table 8: Follow-up CD4 count and Viral Load Categories by Levels of Caffeine 
Consumption† 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables. 
aInadequate control over disease progression 
bModerate control over disease progression 
cAdequate control over disease progression 
*Significant 
†World Health Organization. Who Case Definitions of HIV for Surveillance and Revised 
Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and 
Children. 2007; http://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf. 
Accessed September 30, 2014.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
 P-value 
CD4 count43,44 
≤199a 
200-499b 
≥500c 
 
17 (15.5%) 
41 (37.3%) 
52 (47.3%) 
 
6 (11.1%) 
27 (50.0%) 
21 (38.9%) 
 
11 (19.6%) 
14 (25.0%) 
31 (55.4%) 
0.024* 
HIV viral 
load43,44≤21c 
21-9999b 
≥10000a 
 
34 (31.5%) 
50 (46.3%) 
24 (22.2%) 
 
18 (34.0%) 
22 (41.5%) 
13 (24.5%) 
 
16 (29.1%) 
28 (50.9%) 
11 (20.0%) 
0.616 
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Table 9: Baseline Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on CD4 and Viral Load Categorical Levels  
 
 Unadjusted Adjusted† 
 OR 95% CI P-
value 
OR 95% CI P-
value 
Caffeine 
intake 
CD4 count >500 versus ≤199 (High risk for disease progression) 
High 
Low  
Ref 
0.994 
Ref 
(0.310 - 3.188) 
 
0.992 
Ref 
1.690 
Ref 
(1.123 -3.879) 
 
0.047* 
 CD4 count >500 versus 200-499 (Moderate risk for disease 
progression) 
High 
Low 
Ref 
1.237 
Ref 
(0.579 - 2.795) 
 
0.548 
Ref 
1.537 
Ref 
(0.522 -5.136) 
 
0.198 
 HIV viral load ≤21 and 21-9999 (Moderate risk for disease 
progression) 
High 
Low 
Ref 
0.874 
Ref 
(0.367 - 2.079) 
 
0.761 
Ref 
0.964 
Ref 
(0.317 -3.444) 
 
0.437 
 HIV viral load ≤21 and ≥10000 (High risk for disease progression) 
High 
Low 
Ref 
0.857 
Ref 
(0.332 - 2.214) 
 
0.750 
Ref 
1.933 
Ref 
(1.254 -6.192) 
 
0.048* 
R2 = 0.213 (Cox and Snell), 0.219 (Nagelkerke). χ2 (36) = 47.638, P =0.029 
†Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status, BMI, total body fat percentage. 
*Significant 
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Table 10:  Overtime Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on CD4 and Viral Load Categorical Levels 
R2 = 0.216 (Cox and Snell), 0.215 (Nagelkerke). χ2 (36) = 45.478, P=0.020 
†Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use, 
alcohol consumption, smoking status, BMI, total body fat percentage. 
*Significant 
 
 Unadjusted Adjusted† 
Caffein
e intake 
OR 95% CI P-
value 
OR 95% CI P-
value 
 CD4 count >500 versus ≤199 (High risk for disease progression) 
High 
Low 
Ref 
1.242 
Ref 
(0.398 -  3.878) 
 
0.709 
Ref 
1.876 
Ref 
(1.216 - 8.763) 
 
0.047* 
 CD4 count >500 versus 200-499 (Moderate risk for disease 
progression) 
High 
Low 
Ref 
0.351 
Ref 
(0.150 - 1.822) 
 
0.159 
Ref 
1.375 
Ref 
(0.094 - 2.500) 
 
0.066 
 HIV viral load ≤21 and 21-9999 (Moderate risk for disease 
progression) 
High 
Low 
Ref 
1.057 
Ref 
(0.772 - 4.470) 
 
0.167 
Ref 
1.186 
Ref 
(0.288 - 4.878) 
 
0.113 
 HIV viral load ≤21 and ≥10000 (High risk for disease progression) 
High 
Low 
Ref 
1.300 
Ref 
(0.274 - 5.674) 
 
0.900 
Ref 
1.863 
Ref 
(1.217 - 7.894)  
 
0.048* 
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CHAPTER-V: CAFFEINE INTAKE AND ASSOCIATIONS WITH SLEEP 
QUALITY AND GENERALIZED ANXIETY SCORES IN MIAMI ADULT 
STUDIES ON HIV (MASH) COHORT—AN OBSERVATIONAL STUDY 
ABSTRACT 
Introduction: People living with HIV (PLWH) report deteriorated sleep quality, 
increased periods of insomnia, post morning sleepiness, cognitive impairment, and 
chronic fatigue. Caffeine consumption adversely affects sleep quality and anxiety 
symptoms in many vulnerable populations. Although there are many studies on caffeine 
consumption and sleep and anxiety symptoms in HIV non-infected populations, 
inadequate information is available in PLWH.  
Methods: We examined caffeine intake and sleep quality, insomnia levels, and anxiety 
symptoms in a convenience sample of 130 clinically stable HIV positive participants (65 
consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) recruited from the 
Miami Adult Studies on HIV (MASH) cohort. This study included a baseline and a 
follow-up visit at 3 month. After obtaining written informed consent, caffeine 
consumption, sleep quality, insomnia levels and anxiety symptoms were determined 
using Modified Caffeine Consumption Questionnaire (MCCQ), Pittsburg Insomnia 
Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI) and Generalized Anxiety 
Disorder-7 (GAD-7) questionnaires. Information on demographics, anthropometries, 
body composition measures, substance abuse and antiretroviral therapy (ART) were 
collected from the MASH cohort database.  T-tests and chi-square were used to describe 
demographics and health and lifestyle characteristics. Linear regressions were used to 
analyze baseline data for relationships between caffeine consumption, insomnia, sleep 
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quality and anxiety symptoms. Linear Mixed Models were used to understand the effect 
of caffeine consumption on these parameters over time.   
Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were male 
participants and 75.4% were African-Americans. All participants were on ART 
throughout this study. Mean caffeine intake at baseline was 161.26 ± 194.95 mg/day (3-8 
cups of coffee) (Range: 0 mg-1498 mg/day) and did not change significantly at 3-month 
follow-up visit.  Linear regressions showed significant associations between higher 
caffeine consumption and higher global PIRS scores (β=1.776, P=0.046), higher global 
PSQI scores (β=2.587, P=0.038) and higher GAD-7 scores (β=1.674, P=0.027) after 
adjusting for associated covariates. Linear mixed model analysis showed that higher 
caffeine consumption was associated with higher global PIRS scores (β=1.678, P=0.047), 
higher global PSQI scores (β=2.594, P=0.006) and higher GAD-7 scores (β=0.937, 
P=0.048), in a dose-response manner, after adjusting for covariates.  
Conclusion: Higher caffeine consumption was associated with higher levels of insomnia, 
poor sleep quality and higher levels of anxiety symptoms in PLWH. Although our 
previous studies have suggested a benefit of higher caffeine consumption on markers of 
HIV disease progression, in vulnerable patients, high doses of caffeine can aggravate 
existing psychological conditions. Effective interventions to reduce caffeine intake in this 
population need to be developed and tested in future large scale studies.  
Keywords: Modified Caffeine Consumption Questionnaire (MCCQ), HIV infection, 
Pittsburg Insomnia Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI) and 
Generalized Anxiety Disorder-7 (GAD-7)  
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INTRODUCTION  
According to the 2013 CDC estimates, about 1.2 million people were living with 
HIV/AIDS (PLWH) in United States. In Miami-Dade County, there were 26,760 
PLWH.1  PLWH report deteriorated sleep quality, increased periods of insomnia, post 
morning sleepiness, cognitive impairments, and chronic fatigue.2-6 Sleep quality 
measured by the Pittsburgh Sleep Quality Index (PSQI) was significantly lower in 
PLWH, when compared to the general population, after adjusting for other co-morbidities 
and over-the-counter sleep medications.4  In another study among clinically stable 
PLWH, it was found that poor sleep quality and increased psychological distress scores 
were associated with lower CD4 cell counts and higher HIV viral load after adjusting for 
the effects of ART.7  In a  study conducted to identify the correlates of sleep quality in 
PLWH, using the “Symptom Experience Dimension” of the revised “UCSF Symptom 
Management Conceptual Model”, the variables significantly affecting sleep quality were 
trait and state anxiety scores, general well-being scores, length of time living with HIV 
disease and diagnosis of clinical depression.5 The length of time living with HIV disease 
strongly correlated with worst sleep quality measured by the Pittsburg Sleep Quality 
Index (PSQI) questionnaire after adjusting for other predictor variables mentioned 
above.5  Another study done among 146 clinically stable PLWH showed that stress levels 
measured by State and Trait Anxiety (STA) Questionnaires were significantly associated 
with deteriorated sleep quality, after adjusting for covariates such as age, sex, ART, other 
medications, substance use and income.8  Similarly, better sleep quality, measured by the 
PSQI and Pittsburg Insomnia Rating Scale (PIRS) was associated with  better cognitive 
performance on tasks of attention, frontal/executive functions, and psychomotor/motor 
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speeds in PLWH, after adjusting for medications, alcohol consumption and drug use.6 
Additionally this study reported that more than one third of the PLWH participants were 
chronically and severely sleep deprived.6  
In a study that investigated the effects of caffeine on cognitive and psychomotor 
performance and sleep quality at night, in HIV non-infected participants, it was observed 
that caffeine in doses of 250 mg/day, irrespective of sources, significantly decreased the 
initial critical flicker fusion threshold (CFFT) scores which signifies higher levels of 
neuronal excitability after adjusting for age, BMI, exercise, gender, body composition 
measures and lifestyle factors.9 In a randomized double-blind study of 72 HIV non-
infected participants with various forms of anxiety disorders, oral administration of 480 
mg/day of caffeine provoked acute stress responses measured through State and Trait 
Anxiety Questionnaires.10 General stress levels estimated by the State and Trait Anxiety 
Questionnaires, were substantially higher in subjects administered 480 mg/day of 
caffeine when compared to control solutions after adjusting for gender, age, educational 
level, occupation and anxiolytic medications. Four hundred and eighty mg of caffeine 
precipitated panic attacks in 60.7% all of the participants in the experimental arm of the 
study. This study concluded that higher doses of caffeine (480 mg/day) precipitated 
anxiety and panic attacks even in HIV non-infected volunteers.10  
    Caffeine intake also affected sleep quality as reported by a study conducted 
among 88 HIV-positive participants.11 In this study, sleep quality was measured by the 
Revised Pittsburg Sleep Quality Index (RPSQI) Questionnaire. Mean caffeine intake of 
the sample was 476 mg/day or 2.4 times the US consumption average of 200 mg/day. It 
was found that subjects having high levels of caffeine consumption (>400 mg/day) 
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reported poor PSQI scores.11 Within one month, subjects who reduced their baseline 
caffeine consumption by 90% or higher, showed significant improvements in PSQI 
scores after adjusting for covariates such as sleep medications, other co-morbidities and 
substance use.  
In summary, the literature shows that caffeine consumption is associated with 
compromised sleep quality, altered sleep patterns, increased periods of insomnia, and 
increased stress and anxiety symptoms. All these parameters could produce adverse 
effects on disease progression in PLWH.7 The specific aim of the current study was to 
explore whether caffeine consumption affected sleep quality, insomnia levels and anxiety 
symptoms in a convenience sample of 130 participants (65 consuming ≤ 250 mg/day and 
65 consuming > 250 mg/day of caffeine) recruited from the Miami Adult Studies of HIV 
(MASH) cohort.  We also observed for the effects of sleep quality, insomnia and anxiety 
symptoms on immunological and virologic markers of HIV disease progression. 
METHODS 
Study Design and Setting 
The present study recruited a convenience sample of 130 participants (65 consuming ≤ 
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which 
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10 
years at the FIU research clinic in the Borinquen Health Care Center (BHCC).  The 
BHCC provides comprehensive range of health and social services to a culturally diverse 
low income community. The recruitment for the present study took place from February 
to July 2014. The present study included a baseline and 3-month follow-up visits, and 
participants received $5 as partial reimbursement for their time and efforts, for each of 
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the two visits. The initial screening included detailed explanation of the study as well as 
obtaining informed voluntary written consent for participation. In order to obtain a study 
sample of 128 participants as estimated in our sample size calculations, we screened a 
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants. 
The present study also included secondary analysis of relevant variables collected for the 
MASH cohort studies. Data collected during the baseline and 3-month visits were used 
for the analyses of descriptive and inferential statistics. The inclusion and exclusion 
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable 
to our current study. The additional inclusion criteria for participants in the present study 
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a 
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion 
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical 
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or 
mal-absorption syndromes. The Institutional Review Board at Florida International 
University approved the study protocol and research procedures. 
Measures 
The questionnaires used in the present study were previously field tested and validated in 
several large scale studies.12-15 However, we pre-tested these questionnaires on 15 
participants from the MASH cohort to ascertain their applicability and we determined 
that revisions were not necessary for the questionnaires. 
Caffeine consumption questionnaire: We used the Modified Caffeine Consumption 
Questionnaire (MCCQ) developed by Preston et al. in the year 1998.16 This questionnaire 
is easy to understand, compact, organized and reported adequate compliance, validity and 
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reliability.16 This questionnaire was field tested and validated in many large scale studies 
and adequately reflected average daily caffeine consumption levels.12 It includes a total 
of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the counter 
medications’ and ‘Prescription medications’. This questionnaire also included ‘Total 
caffeine consumption per day’ by adding these individual sources. Caffeine consumption 
was analyzed both as a continuous variable and a categorical variable.  
For both naturally occurring and artificially added caffeine sources, FDA 
considers 400 mg/day (7 cups of Coffee) to be generally safe and not associated with any 
dangerous side effects.17,18  The World Health Organization (WHO) defines caffeine 
overuse as daily consumption beyond 500 mg/d.19,20  Beyond this level caffeine produces 
visible adverse effects collectively known as ‘Caffeinism’. The World Health 
Organization (WHO) has also cautioned that these adverse effects could be precipitated at 
much lower doses depending on the physiological profiles of individuals as well as the 
genetic makeup of the population. 19,20 The International Classification of Diseases (ICD) 
manual considers caffeine consumption above 250 mg/day to be associated with many 
mental and behavioral disorders though it is inconclusive whether such effects would be 
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally 
safe and above this level to be associated with many adverse effects such as withdrawal, 
addiction, irritability and craving.21 Summarizing these cutoffs, we concluded that 
caffeine consumption below 250 mg/day that is equivalent to 4 cups of coffee, 
irrespective of the sources is generally safe and not associated with adverse effects. In 
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this study, caffeine categories included low (≤250 mg/day, within safe levels) and high 
(>250 mg/day, beyond safe levels) based on these recommendations. 
The Pittsburg Insomnia Rating Scale (PIRS): The PIRS is a 66-item self-report 
questionnaire that measures the subjective levels of insomnia experienced over the past 
seven days.13 This questionnaire consists of four components: Distress Score; Sleep 
Parameter Score; Quality of Life Score; and Total Insomnia Score. The ‘Distress Score’ 
equals the total of first 46 questions each rated on a 0-3 scale and higher scores indicate 
increased levels of subjective distress symptoms experienced by the participants. 
Similarly, the ‘Sleep Parameter Score’ totals questions 47 to 56, each rated on a 0-3 scale 
and higher scores signify poor sleep quality. The ‘Quality of Life Sore’ sums questions 
57 to 65, and higher scores signify poor quality of life.  The ‘The Global PIRS Score’ 
sums all the 65 questions and higher scores represent increased subjective reports of 
insomnia. The original study validating the questionnaire13 also recommends scores 0-50 
as ‘No Insomnia’, scores 51-100 as ‘Moderate Insomnia’ and scores greater than 100 as 
‘Severe Insomnia’.13  The PIRS questionnaire showed excellent internal consistency, test-
retest reliability and discriminative validity in a mixed sample of 456 normal adult 
participants between 18 and 85 years in the original study. The original study also 
reported a Cronbach's alpha coefficient of 0.88 indicating high internal consistency and 
an intra-class correlation of 0.89 indicating good test-retest reliability.13 The original 
study also reported a sensitivity of 83.4% and a specificity of 88.6% for the 
questionnaire.13 In the present study the global PIRS scores were analyzed as both 
continuous and categorical variables. The global PIRS score categories included: ≤50 (No 
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Insomnia), 51-100 (Moderate Insomnia), and >100(Severe Insomnia) as recommended in 
the original study.13 
The Pittsburg Sleep Quality Index questionnaire (PSQI): The PSQI is a 19-item self-
report questionnaire that measures self-reported quality of sleep over the past 30 days.14 
This questionnaire includes seven individual components: Sleep Duration; Sleep 
Disturbance; Sleep Latency; Days Dysfunction due to Sleepiness; Sleep Efficiency; 
Overall Sleep Quality; and Need Meds to Sleep. Each component is rated on a 0–3 scale, 
with higher scores signifying worsening outcomes. ‘Sleep Duration’ is calculated using 
question 4 and represents the total number hours slept per day. ‘Sleep Disturbance’ is 
calculated by summarizing individual scores in questions 5b to 5j and represents various 
factors like bad dreams, pain, breathing problems etc. that have impaired the quality of 
sleep. ‘Sleep Latency’ represents the total time spent awake on bed trying to sleep each 
day and is calculated using the questions 2 and 5 with necessary re-coding. ‘Days 
Dysfunction due to Sleepiness’ is calculated from questions 8 and 9 and represents daily 
problems related to sleep, such as having trouble staying awake or having enough 
enthusiasm to get things done. ‘Sleep Efficiency’ is calculated from questions 1 and 3 
and represents the ratio of actual number of hours of sleep, given the number of hours 
spent in bed. ‘Overall Sleep Quality’ is calculated from question 6 and represents general 
sleep quality over the past month.  ‘Need Meds to Sleep’ is calculated from question 7 
and represents use of sleep medications over the past month. These seven component 
scores are added to obtain a global PSQI score which ranges from 0 to 21 and higher 
scores represent worsening sleep quality. According to the original study a global PSQI 
score of 5 or greater represents poor sleep quality.14 However other studies recommend 
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scores 0-5 as good sleep quality, 6-10 as poor sleep quality and greater than 10 as worst 
sleep quality.22,23 This questionnaire had good internal consistency, test-retest reliability, 
and discriminative validity in the original study with a sample of 168 participants aged 19 
to 83 years.14 The original study also reported a Cronbach's alpha coefficient of 0.83 
indicating high internal consistency and an intra-class correlation of 0.85 indicating good 
test-retest reliability.14,24 The original study also reported a sensitivity of 89.6% and a 
specificity of 86.5% for the questionnaire.14,24 In the current study the global PSQI scores 
were analyzed as both continuous and categorical variables. The global PSQI score 
categories included: ≤5 (Good Sleep Quality), 6-10 (Poor Sleep Quality), and >10 (Worst 
Sleep Quality).23,24 
The Generalized Anxiety Disorder-7 (GAD-7) questionnaire: The GAD-7 is a 7-item 
self-reported questionnaire for screening and evaluating the severity of generalized 
anxiety symptoms over the past two weeks.15 Although primarily developed for 
measuring generalized anxiety disorder, studies have also reported good sensitivity and 
specificity for many other anxiety and panic disorders.25 There are seven questions about 
anxiety symptoms each rated on a 0-3 scale representing the options ‘not at all’, ‘several 
days’ , ‘more than half the days’ , and ‘nearly every day’. The total scores range from 0 
to 21 and higher scores represent greater anxiety levels. GAD-7 had shown good internal 
consistency, test-retest reliability, and discriminative validity in the original study of 
2470 participants aged 19 to 95 years.15 The original study of this questionnaire reported 
a Cronbach's alpha coefficient of 0.92 indicating very high internal consistency and an 
intra-class correlation of 0.83 indicating good test-retest reliability.15 The original study 
also reported a sensitivity of 89% and a specificity of 82% for the questionnaire.15 In the 
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current study, the GAD-7 scores were analyzed as both continuous and categorical 
variables. The GAD-7 score categories included: ≤5 (Minimal Anxiety), 6-10 (Mild 
Anxiety), 11-15 (Moderate Anxiety) and >15 (Severe Anxiety), as recommended in the 
original study.15 
Immunological and virologic variables: CD4 counts, viral loads and other clinical 
variables are determined for the participants’ healthcare visits by their primary health 
care physicians. The MASH cohort studies collected and documented these reports after 
appropriate medical release forms were signed by the participants. The MASH studies 
also paid a compensation of $15 every six months to motivate participants towards timely 
submission of medical records and lab reports, which included CD4 counts and viral 
load. In the current chapter, CD4 counts and viral loads were analyzed as continuous 
variables and transformed into CD4 square root and log10 viral load to ensure normal 
distribution and better model fit criteria. 
Control Variables 
Demographic and socioeconomic information: Demographic and socioeconomic 
information used in this study were collected by the MASH studies. Information used for 
the current study included age, gender, ethnicity, education and income levels. A number 
of health and lifestyle related factors such as tobacco use, alcohol consumption and illicit 
drug use were also gathered from the MASH data repository. These controlled variables 
were selected based on studies associating them with sleep quality and anxiety 
disorders.13-16,25-27  
ART medications: We obtained information about types of the antiretroviral medications 
prescribed and administered by their physicians during the MASH cohort visits. We 
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adjusted the analyses for these variables because some of the antiretroviral medications 
are associated with sleep and anxiety disorders.26-28 
Statistical Analysis 
Field data were collected in paper based questionnaires and later entered into RedCap 
database, then imported into SPSS version 21 for Windows (Armonk, NY: IBM Corp) 
and merged into a single dataset for analysis. Descriptive statistics were used to 
understand the population characteristics and were expressed in terms of means, standard 
deviations and percentages. The characteristics of the population were shown for all the 
participants and separated based on low and high intakes of caffeine using the cutoff 
points: >250 mg/day for high intake; and ≤250 mg/day for low or no intake as described 
in the Methods section above.17,18,19,20 T-tests and chi square tests were used to describe 
differences in demographics, health and lifestyle characteristics, and individual 
components and global scores of  PIRS, PSQI and GAD-7 questionnaires, with respect to 
low and high levels of caffeine consumption. Paired sample t-tests were used to measure 
differences in levels of caffeine consumption as well as the individual components and 
global scores of PIRS, PSQI and GAD-7 questionnaires, between the baseline and 3-
month visits. Linear regression was used to estimate the strength of association between 
caffeine consumption and the individual components and global scores of PIRS, PSQI 
and GAD-7 questionnaires. Assumptions of linear regression were followed prior to 
analyses. Linear mixed models (LMM) were used to determine the overtime changes in 
the strength of these associations. For parameter estimation in LMM models restricted 
maximum likelihood (REML) was used. Multinomial logistic regressions were used to 
determine the associations between high and low caffeine intake groups with respect to 
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different categories of global scores of PIRS, PSQI and GAD-7 questionnaires. Linear 
Regression was also used to estimate the strength of association between global scores of 
PIRS, PSQI and GAD-7 questionnaires and the markers of HIV disease progression 
(CD4 counts and viral load). Linear Mixed Models were used to estimate the changes 
over time in the strength of these associations. For Linear and Logistic Regressions and 
Linear Mixed Model analysis, we initially used crude models and subsequently adjusted 
for the covariates already described in the methodology. These covariates were also 
tested for significant associations with the outcome variables using bivariate analysis 
before being incorporated into the models. To increase the validity of the models, 
multicollinearity among covariates was tested prior to the analyses. Adjusted models 
included non-missing values for all independent variables included in the models. 
Statistical significance was set at P<0.05 for all the analyses.  
RESULTS  
Demographic and Socio-economic Characteristics  
A total of 130 participants were included in the study and 79 (60.8%) were men. 
The mean age was 47.89 ± 6.37 years. Most of the participants were African Americans 
(75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and other races 
constituted 4.6 percent. About 24% of the participants had college education, while 
45.4% were high school graduates and 30.8% has some form of primary education. All 
participants had incomes under the level of poverty and the mean income was $495.91± 
465.887. There were no significant differences in any socio-demographic variables 
between low and high levels of caffeine consumption in both baseline and follow-up 
visits (Table-1A, 1B). 
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Health/lifestyle Characteristics  
Sixty one percent of the participants reported smoking within the past six weeks 
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive 
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and 
65.8% tested positive for illicit drug use during the follow-up visit.  
All participants were on ART during both visits. Antiretroviral therapy took many 
forms, 58.5% were on NRTI, 13.1% were on NNRTI and 47.7% were on PI in several 
combinations, 26.2% of the participants were using a one-pill multi-drug combination 
such as Atripla, Truvada and Combivir during the baseline visit. At the 3-month visit, 
63.8% were on NRTI, 13.8% were on NNRTI and 47.7% were on PI, and 25.4% were on 
a one-pill multi-drug combination during the follow-up visit. There were no significant 
differences in the distribution of these variables between low and high levels of caffeine 
consumption in both baseline and follow-up visits (Tables 2 and 3). 
Caffeine Consumption from Different Sources 
Total caffeine consumption was 337.63 ± 304.97 mg/day at baseline (Range: 0-
1,498 mg/day), and 281.04 ± 260.85 mg/day (Range: 0-1,175 mg/day) at the 3-months 
follow-up. Coffee constituted the largest source of caffeine and mean consumption levels 
were 161.26± 194.95 mg/day at baseline, and 190.40 ± 205.03 mg/day at follow-up. 
Caffeinated soft drinks constituted the second largest source of caffeine and mean 
consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66 ± 83.78 mg/day at 
follow-up. There were no significant differences between baseline and follow-up visits 
with respect to total caffeine consumption or caffeine from most of the sources. However, 
there was significant decrease in consumption of caffeinated soft drinks (63.23 ± 92.98 
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vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs. 9.61 ± 65.32, P=0.005) 
and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the baseline to the follow-up 
visits (Table-4).  For all other sources of caffeine in the questionnaire, except the ones 
enlisted in Table 4, participants reported none to negligible levels of consumption at both 
the visits. 
The Individual Components and Global PIRS, PSQI and GAD-7 Scores 
Independent sample t-tests showed that most of the individual components and 
global scores of PIRS, PSQI and GAD-7 questionnaires did not differ significantly 
between the groups who consumed <250 mg of caffeine per day versus ≥ 250 mg/day, in 
the baseline as well as 3-month follow-up visit. However, ‘Distress Score’ (31.44 ± 23.92 
vs 72.33 ± 28.75, P=0.002), ‘The Global PIRS Scores’ (45.89 ± 133.13 vs 105.75 ± 
41.12, P=0.002), ‘Days Dysfunction due to Sleepiness’ (0.60 ± 0.63 vs 1.89 ± 0.85, 
P=0.002),  and ‘Overall Sleep Quality Derangements’ (0.58 ± 0.63 vs 1.74 ± 0.85, 
P=0.002), were significantly higher in  those who consumed ≥ 250 mg/day when 
compared to those who consumed <250 mg of caffeine per day (Tables 5, 6,8,9, 11,12). 
 Paired sample t-tests comparing the baseline and 3-month visits also showed that 
most of the individual components and global scores of PIRS, PSQI and GAD-7 
questionnaires did not differ significantly between the visits. ‘Sleep Disturbance’ (1.55 ± 
0.74 vs 1.32 ± 0.83, P=0.019), ‘Sleep Latency’ (1.54 ± 1.05 vs 1.16 ± 0.89, P=0.001), 
‘Sleep Efficiency’ (0.68 ± 0.96 vs 0.19 ± 0.53, P<0.001) and ‘Global PSQI’ (7.98 ± 5.59 
vs 6.61 ± 4.87, P=0.031), however, were significantly higher during the baseline visit 
when compared to follow-up visits (Tables 7, 9, 10, and 13).  
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Relationship between Caffeine Intake and PIRS Variables 
Caffeine consumption as a continuous variable was significantly associated with 
Distress Score (β=1.506, P=0.048), Quality of Life Score (β=1.784, P=0.001), and global 
PIRS Score (β=1.776, P=0.046), after adjusting for age, gender, race/ethnicity, education, 
income, and time from diagnosis of HIV, drug use, smoking status, alcohol use, different 
types of ART medications and use of sleep medications (Table 14). Linear Mixed Model 
analysis for the effect of caffeine intake on changes in these scores, between the two 
study visits, showed significantly increased Distress Score (β=1.347, P=0.036), Quality 
of Life Sore (β=1.767, P=0.006) and Global PIRS Score (β=1.678, P=0.047), with 
increasing caffeine consumption, in a dose-response manner, after adjusting for the same 
covariates (Table 15). Multinomial logistic regressions showed that the odds of having 
moderate insomnia were 9 times higher in participants consuming > 250 mg of caffeine 
per day, when compared to participants consuming ≤250 mg per day, after adjusting for 
the same covariates (OR=9.321, 95%CI: 3.324 -21.402, P=0.018).  Similarly, the odds of 
having severe insomnia were 17 times higher in participants consuming > 250 mg of 
caffeine per day, when compared to participants consuming ≤250 mg per day, after 
adjusting for the same covariates (OR=17.9558, 95%CI: 10.153 -94.512, P=0.003). 
These odds also increased in significance, when changes over the three month period 
were considered (Table 16 and 17).  
Relationship between Caffeine Intake and PSQI Variables 
Caffeine intake as a continuous variable was significantly associated with Sleep 
Duration (β=1.199, P=0.049), Days Dysfunction due to Sleepiness (β=1.250, P=0.043), 
Overall Sleep Quality (β=2.248, P=0.001), and Global PSQI scores (β=2.587, P=0.038), 
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after adjusting for covariates such as age, gender, race/ethnicity, education, income, and 
time from diagnosis of HIV, drug use, smoking status, alcohol use and different types of 
ART medications (Table 18). Linear Mixed Model analysis for the effect of caffeine 
intake on changes in these scores, between the two study visits, showed significantly 
worse domains of ”Sleep Duration” (β=1.345, P=0.042), “Sleep Disturbance” (β=1,505, 
P=0.032), “Sleep Latency” (β=1.323, P=0.023), “Days Dysfunction Due to Sleepiness” 
(β=1.353, P=0.036), “Sleep Efficiency” (β=1.212, P=0.025), “Need Meds to Sleep” 
(β=1.494, P=0.049) and “Global PSQI Scores” (β=2.594, P=0.0006), with increasing 
caffeine consumption, in a dose-response manner, after adjusting for the same covariates 
(Table 19).  
Multinomial logistic regressions showed that the odds of having poor sleep 
quality was 18 times higher in participants consuming >250 mg of caffeine per day when 
compared to participants consuming ≤250 mg per day after adjusting for the same 
covariates (OR=18.659, 95%CI: 8.016 -165.741, P=0.013). Similarly the odds of having 
extremely low sleep quality was 19 times higher in participants consuming >250 mg of 
caffeine per day when compared to participants consuming ≤250 mg per day after 
adjusting for the same covariates (OR= 19.060, 95%CI: 16.906 -186.786, P=0.008). 
When changes over the three month period were considered, the odd ratios for these 
variables became more significant (Table 20 and 21). 
Relationship between Caffeine Intake and GAD-7 Variables 
Caffeine intake as a continuous variable was significantly associated with GAD-7 
Score (β=1.674, p=0.027), after adjusting for covariates such as age, gender, 
race/ethnicity, education, income, and time from diagnosis of HIV, drug use, smoking 
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status, alcohol use, different types of ART medications and use of sleep medications 
(Table 22).  Linear mixed model analysis for the effect of caffeine intake on changes in 
GAD-7 scores, between the two study visits, showed significantly increased scores 
(β=0.937, P=0.048) with increasing caffeine consumption, in a dose-response manner, 
after adjusting for the same covariates (Table 23). Multinomial logistic regressions 
showed that the odds of having mild anxiety was 5 times higher in participants 
consuming >250 mg of caffeine per day, when compared to participants consuming ≤250 
mg per day after adjusting for the same covariates. (OR=5.107, 95%CI: 1.568 -33.499, 
P=0.027). Similarly the odds of having moderate anxiety was 6 times greater (OR= 
6.091, 95%CI: 2.333 -35.841, P=0.002) and the odds of having severe anxiety was 17 
times greater (OR= 17.185, 95%CI: 5.185 -88.185, P=0.001) in participants consuming 
>250 mg of caffeine per day, when compared to participants consuming ≤250 mg per day 
after adjusting for the same covariates. These odds also increased in significance, when 
changes over the three month period were considered (Tables 24 and 25).   
Relationship between Global PIRS, Global PSQI, GAD-7 and Immunological and 
Virologic Markers of Disease Progression 
Linear regression showed that global PIRS scores were significantly associated 
with lower CD4 cell counts (β=-1.202, P=0.015) after adjusting for time from diagnosis 
of HIV, drug use, smoking status, alcohol use and different types of ART medications. 
Similarly global PSQI scores (β=-1.149, P=0.036) and GAD-7 scores (β=-1.122, 
P=0.031) were significantly associated with lower CD4 cell counts after adjusting for the 
same covariates (Table 26). 
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Linear regression showed that global PIRS scores was significantly associated 
with higher HIV viral load (β=1.949, P=0.045) after adjusting for time from diagnosis of 
HIV, drug use, smoking status, alcohol use and different types of ART medications. 
Similarly global PSQI scores (β=1.988, P=0.031) and GAD-7 scores (β=1.269, P=0.029) 
were significantly associated with higher HIV viral load after adjusting for the same 
covariates (Table 26). However, linear mixed model analysis showed that these 
associations diminished and lost insignificance overtime (Table 27). 
DISCUSSION 
The characteristics of our population were epidemiologically similar to those 
described by others in Miami-Dade County.29,30 More than half of the participants were 
consuming alcohol and smoking cigarettes, and 48.2% had a positive urine toxicology 
result for illicit drugs.  
            The relationship between caffeine consumption and sleep quality, insomnia and 
anxiety scores, were also expected, as caffeine consumption has been associated with 
poor sleep quality and worsening anxiety symptoms in other studies on non-HIV infected 
participants.31-34  There are also studies stating that HIV infected patients have 
deteriorated sleep quality, increased periods of insomnia, post morning sleepiness, 
cognitive impairments, increased anxiety symptoms and tiredness.2-6,35-38 However, 
studies associating caffeine consumption to these adverse effects are rare in HIV positive 
populations. Currently, only one study on HIV positive patients reports adverse effects of 
caffeine consumption on sleep quality and general wellbeing.11 This study, however, was 
limited due to its small sample size (N=88) and very high mean caffeine consumption 
levels (476 mg/day), which was about 2.4 times the average consumption in United 
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States. Though many studies have associated caffeine intake with impaired sleep quality 
in HIV non-infected populations,4,5,39-43 our study is the among the few that investigated 
the association between high caffeine consumption and sleep quality and anxiety 
symptoms in a population of clinically stable PLWH.   
               We found that caffeine intake adversely affected many parameters of sleep and 
anxiety measured by PIRS, PSQI and GAD-7 questionnaires, adjusting for income, years 
since diagnosis of HIV, substance abuse and ART. Our analyses were adjusted by these 
variables because the literature reported their associations with poor sleep quality.44-47 
Our findings suggest that the adverse effects of caffeine on sleep and anxiety levels were 
mild but compounded by medication side effects, cocaine and amphetamine use, which 
have stronger effects on sleep disturbances and anxiety.  
            We also found that worsening sleep and anxiety scores measured through PIRS, 
PSQI and GAD-7 questionnaires were associated with lower CD4 counts and higher HIV 
viral load after adjusting for the covariates associated with HIV disease progression.48-50 
Similar findings are also reported in another study in PLWH, where poor sleep quality 
and worsening psychological distress scores were associated with lower CD4 cell counts 
and higher HIV viral loads.7 Nevertheless, comparability with our study is limited, 
because this study used a sample of PLWH beginning to show symptoms of AIDS, 
whereas, our participants were clinically stable HIV positive participants receiving ART. 
The deleterious effects of poor sleep quality and higher psychological distress scores on 
HIV disease progression, would have been more prominent in PLWH who were 
beginning to show symptoms of AIDS, compared to our stable HIV positive participants 
receiving ART, because recovery of the immune function and controlled viral loads are 
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only attained with ART.51 Our study findings are unique because we explored the adverse 
effects of sleep loss and anxiety symptoms in the absence of advanced HIV disease 
progression.   
           In spite of the findings in this study, we have to acknowledge some of its 
limitations.  The current study enrolled a convenience sample of 130 PLWH, thus the 
results may not be generalizable. Participating in the baseline could also have influenced 
the outcomes in the follow-up visit, as the participants could have been affected by an 
“Interpersonal Expectancy Bias,” 52 by which they would have responded what they 
believed the investigators wanted to hear or the investigators would have recorded what 
they wanted to report. 
Furthermore, the survey instruments used in the study do not measure the 
outcomes within the same time frame. PIRS measured insomnia levels over the past one 
month, GAD-7 measured anxiety symptoms over the past two weeks, PSQI measured 
sleep quality over the past week and MCCQ measured caffeine consumption over the 
past 24 hours.  Furthermore these instruments are self-reported measures and susceptible 
to memory and recall biases.  
Large scale studies should be done with controlled dietary and lifestyle factors, as 
well as controlled study settings, to overcome the limitations of our study. Though, our 
findings showed that caffeine intake adversely affected sleep quality and anxiety 
symptoms, and, in turn, adversely affected HIV disease progression, these findings 
should be confirmed by such large scale studies.   
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption 
Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Baseline 
Total Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 47.57±6.81 48.00±6.15 0.706 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
40 (61.5%) 
25 (38.5%) 
 
39 (60.0%) 
26 (40.0%) 
0.857 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
3 (4.6%) 
7 (10.8%) 
55 (84.6%) 
0 (0.0%) 
 
4 (6.2%) 
15 (23.1%) 
43 (66.2%) 
3 (4.6%) 
0.057 
Education in years, 
N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
24 (36.9%) 
29 (44.6%) 
12 (18.5%) 
 
 
16 (24.6%) 
30 (46.2%) 
19 (29.2%) 
0.202 
Income in dollars 
per month 
 
495.91 ± 
465.887 
464.00 ± 
419.667 
527.34 ± 
508.637 
0.442 
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Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption 
Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables    
 
 
 
 
 
 
 
 
 
 
Variables 
Follow-up 
Total Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 46.63±7.33 48.87±5.38 0.490 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
43 (68.3%) 
20 (31.7%) 
 
36 (53.7%) 
31 (46.3%) 
0.090 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
4 (6.3%) 
9 (14.3%) 
50 (79.4%) 
0 (0.0%) 
 
3(4.5%) 
13 (19.4%) 
48 (71.6%) 
3 (4.6%) 
0.285 
Education in years, 
N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
21 (33.3%) 
29 (46.0%) 
13 (20.6%) 
 
 
19 (28.4%) 
30 (44.8%) 
18 (26.9%) 
0.670 
Income in dollars 
per month 
 
495.91 ± 
465.887 
498.80 ± 
511.708 
492.89 ± 
416.619 
0.943 
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Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels  
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables 
ART: Antiretroviral therapy. 
 
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
 P-
value 
Smoking 
cigarettes 
Yes 
No 
 
80 (63.5%) 
46 (36.5%) 
 
39 (60.9%) 
25 (39.1%) 
 
41 (66.1%) 
21 (33.9%) 
0.582 
Alcohol use 
Yes 
No 
 
73 (57.9%) 
53 (42.1%) 
 
36 (56.3%) 
28 (43.8%) 
 
37 (59.7%) 
25 (40.3%) 
0.721 
Drug use 
Yes 
No 
 
53 (48.2%) 
57 (51.8%) 
 
25 (43.9%) 
32 (56.1%) 
 
28 (52.8%) 
25 (47.2%) 
0.445 
Marijuana 
Yes 
No 
 
44 (33.8%) 
86 (66.2%) 
 
21 (32.3%) 
44 (67.7%) 
 
23 (35.4%) 
42 (64.6%) 
0.853 
Cocaine 
Yes 
No 
 
41 (31.5%) 
89 (68.5%) 
 
19 (29.2%) 
46 (70.8%) 
 
22 (33.8%) 
43 (66.2%) 
0.706 
Other Drugs 
Yes 
No 
 
10 (9.1%) 
100 (90.9%) 
 
6 (10.5%) 
51 (89.5%) 
 
4 (7.5%) 
49 (92.5%) 
0.744 
ART     
Multi-combination 
Yes 
No 
 
34 (26.2%) 
96 (73.8%) 
 
22 (33.8%) 
43 (66.2%) 
 
12 (18.5%) 
53 (81.5%) 
0.072 
NRTI 
Yes 
No 
 
76 (58.5%) 
54 (41.5%) 
 
40 (61.5%) 
25 (38.5%) 
 
36 (55.4%) 
29 (44.6%) 
0.594 
NNRTI 
Yes 
No 
 
17 (13.1%) 
113 (86.9%) 
 
10 (15.4%) 
55 (84.6%) 
 
7 (10.8%) 
58 (89.2%) 
0.604 
PI 
Yes 
No 
 
62 (47.7%) 
68 (52.3%) 
 
34 (52.3) 
31 (47.7%) 
 
28 (43.1%) 
37 (56.9%) 
0.380 
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Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests all variables. 
ART: Antiretroviral therapy.  
 
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-
value 
Smoking 
cigarettes 
Yes 
No 
 
79 (63.2%) 
46 (36.8%) 
 
41 (68.3%) 
19 (31.7%) 
 
38 (58.5%) 
27 (41.5%) 
0.271 
Alcohol use 
Yes 
No 
 
76 (60.3%) 
50 (39.7%) 
 
34 (56.7%) 
26 (43.3%) 
 
42 (63.6%) 
24 (36.4%) 
0.469 
Drug use 
Yes 
No 
 
79 (65.8%) 
41 (34.2%) 
 
45 (75.0%) 
15 (25.0%) 
 
34 (56.7%) 
26 (43.3%) 
0.054 
Marijuana 
Yes 
No 
 
67 (55.8%) 
53 (44.2%) 
 
38 (63.3%) 
22 (36.7%) 
 
29 (48.3%) 
31 (51.7%) 
0.141 
Cocaine 
Yes 
No 
 
48 (40.0%) 
72 (60.0%) 
 
29 (48.3%) 
31 (51.7%) 
 
19 (31.7%) 
41 (68.3%) 
0.093 
Other drugs 
Yes 
No 
 
13 (10.9%) 
106 (89.1%) 
 
6 (10.0%) 
54 (90.0%) 
 
7 (11.9%) 
52 (88.1%) 
0.496  
ART     
Multi-
combination 
Yes 
No 
 
33 (25.4%) 
97 (74.6%) 
 
20 (31.7%) 
43 (68.3%) 
 
13 (19.4%) 
54 (80.6%) 
0.113 
NRTI 
Yes 
No 
 
83 (63.8%) 
47 (36.2%) 
 
40 (63.5%) 
23 (36.5%) 
 
43 (64.2%) 
24 (35.8%) 
1.000 
NNRTI 
Yes 
No 
 
18 (13.8%) 
112 (86.2%) 
 
9 (14.3%) 
54 (85.7%) 
 
9 (13.4%) 
58 (86.6%) 
1.000 
PI 
Yes 
No 
 
62 (47.7%) 
68 (52.3%) 
 
28 (44.4%) 
35 (55.6%) 
 
34 (50.7%) 
33 (49.3%) 
0.488 
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Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
 
Table 5: Baseline PIRS Variables by Caffeine Consumption Levels  
 
Variables Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-value 
Distress Score 31.44 ± 23.92 72.33 ± 28.75 0.002* 
Sleep Parameter Score 7.56 ± 5.38 17.96 ± 7.28 0.035* 
Quality of Life Score 6.87 ± 5.41 15.44 ± 6.43 0.588 
The Global PIRS Score 45.89 ± 133.13 105.75 ± 41.12 0.002* 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
 
 
 
 
 
 
Food source Baseline Follow-up P-value 
Coffee 161.26 ± 194.95 190.40 ± 205.03 0.206 
De-Caffeinated coffee 0.83 ± 9.21 0.03 ± 0.43 0.329 
Expresso 14.40 ± 64.35 13.92 ± 57.82 0.942 
Tea 34.70 ± 64.32 31.58 ± 59.36 0.640 
Green tea 7.34 ± 62.93 4.20 ± 21.62 0.594 
Energy drinks 46.32 ± 134.42 9.61 ± 65.32 0.005* 
Hot cocoa 1.03 ± 5.00 0.00 ± 0.00 0.020* 
Caffeinated soft drinks 63.23 ± 92.98 29.66 ± 83.78 <0.0001* 
Chocolate candy bars 3.69 ± 13.81 2.00 ± 17.93 0.402 
Anacin  0.24 ± 2.80 0.00 ± 0.00 0.319 
Appetite control pills  4.61 ± 39.10 0.00 ± 0.00 0.181 
Total 337.63 ± 304.97 281.04 ± 260.85 0.890 
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Table 6: Follow-Up PIRS Variables by Caffeine Consumption Levels  
 
Variables Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-value 
Distress Score 24.77 ± 20.98 85.70 ± 22.52 0.543 
Sleep Parameter Score 3.53 ± 5.81 20.34 ± 6.14 0.022* 
Quality of Life Score 4.50 ± 5.30 17.85 ± 4.46 0.001* 
The Global PIRS 
Score 
32.82 ± 30.10 128.89 ± 31.24 0.449 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
 
 
Table 7: Mean Scores of PIRS Variables: Baseline and Follow-Up Visit  
 
Variables BL FU P-value 
PIRS SCORES 
Distress Score 51.89 ± 33.39 56.17 ± 37.48 0.331 
Sleep Parameter Score 12.76 ± 8.24 12.20 ± 10.32 0.622 
Quality of Life Sore 11.16 ± 7.32 11.38 ± 8.27 0.817 
The Global PIRS Score 75.82 ± 47.81 79.76 ± 54.97 0.537 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
 
 
 
Table 8: Baseline PSQI Variables by Caffeine Consumption Levels  
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
Variables Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-value 
Sleep Duration 0.03 ± 0.17 1.14 ± 0.98 0.068 
Sleep Disturbance 1.08 ± 0.32 2.03 ± 0.74 0.039* 
Sleep Latency 0.72 ± 0.62 2.35 ± 0.69 0.059 
Days Dysfunction due to 
Sleepiness 
0.60 ± 0.63 1.89 ± 0.85 0.002* 
Sleep Efficiency 0.22 ± 0.57 1.15 ± 1.04 0.568 
Overall Sleep Quality 0.58 ± 0.63 1.74 ± 0.85 0.002* 
Need Meds to Sleep 0.52 ± 0.61 1.89 ± 0.86 0.588 
Global PSQI 3.75 ± 2.55 12.20 ± 4.51 0.039* 
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Table 9: Follow-Up PSQI Variables by Caffeine Consumption Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
Table 10: Mean Scores of PSQI Variables: Baseline and Follow-Up Visit  
 
Variables BL FU P-value 
PSQI SCORES    
Sleep Duration 0.58 ± 0.89 0.48 ± 0.79 0.292 
Sleep Disturbance 1.55 ± 0.74 1.32 ± 0.83 0.019* 
Sleep Latency 1.54 ± 1.05 1.16 ± 0.89 0.001* 
Days Dysfunction due to 
Sleepiness 
1.25 ± 0.98 1.22 ± 1.02 0.852 
Sleep Efficiency 0.68 ± 0.96 0.19 ± 0.53 <0.0001* 
Overall Sleep Quality 1.16 ± 0.94 1.14 ± 1.01 0.851 
Need Meds to Sleep 1.21 ± 1.01 1.08 ± 0.90 0.299 
Global PSQI 7.98 ± 5.59 6.61 ± 4.87 0.031* 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
 
Table 11:  Baseline GAD-7 Scores by Caffeine Consumption Levels  
 
Variables Low caffeine intake  
(≤250 mg/d) 
High caffeine intake  
(>250 mg/d) 
P-value 
GAD-7 scores 4.42 ± 3,441 12.78 ± 5.014 0.024* 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
Variables Low 
caffeine 
intake  
(≤250 mg/d) 
High 
caffeine 
intake  
(>250 mg/d) 
P-value 
Sleep Duration 0.19 ± 0.56 0.76 ± 0.87 0.046* 
Sleep Disturbance 0.68 ± 0.66 1.93 ± 0.43 0.532 
Sleep Latency 0.57 ± 0.79 1.72 ± 0.57 0.579 
Days Dysfunction due to 
Sleepiness 
0.41 ± 0.75 1.99 ± 0.53 0.002* 
Sleep Efficiency 0.10 ± 0.46 0.28 ± 0.57 0.041* 
Overall Sleep Quality 0.29 ± 0.60 1.94 ± 0.54 0.002* 
Need Meds to Sleep 0.38 ± 0.65 1.75 ± 0.53 0.598 
Global PSQI 2.62 ± 3.35 10.36 ± 2.53 0.001* 
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Table 12: Follow-Up GAD-7 Scores by Caffeine Consumption Levels  
 
Variables Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-value 
GAD-7 scores 3.41 ± 1.272 14.03 ± 0.361 0.043* 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
Table 13: Mean GAD-7 Scores: Baseline and Follow-Up Visit  
 
Variables BL FU P-value 
GAD-7 Score 8.60 ± 5.999 8.88 ± 6.450 0.711 
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
  
 
Table 14: Linear Regression of the Effect of Caffeine Consumption on  
PIRS Variables  
 
PIRS Varables Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Distress Score 1.088 1.006 0.239 1.506 1.103 0.048* 
Sleep Parameter 
Score 
1.022 1.001 0.599 1.890 1.096 0.586 
Quality of Life 
Score 
1.018 1.001 0.002* 1.784 1.226 0.001* 
The Global PIRS 
Score a 
1.128 1.057 0.048* 1.776 1.120 0.046* 
aModel R2 = 0.213, F (16) = 28.367, P= 0.042.   
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
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Table 15: Linear Mixed Model (LMM) Analysis of Overtime Changes in PIRS Variables 
due to Caffeine Consumption  
 
PIRS variables Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Distress Score 1.095 1.004 0.045* 1.347 1.200 0.036* 
Sleep Parameter 
Score 
1.256 1.127 0.587 1.304 1.183 0.045* 
Quality of Life 
Score 
1.202 1.114 0.046 1.767 1.168 0.006* 
The Global PIRS 
Score a 
1.141 1.070 0.035* 1.678 1.010 0.047* 
aModel: -2 Restricted Log Likelihood = 1952.149; Akaike’s Information Criteria (AIC) = 
1956.149; Schwarz’s Bayesian Criteria (BIC) = 1962.725. 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
 
 
Table 16:  Baseline Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on Global PIRS Score Categories  
 
 Unadjusted Adjusted† 
Caffeine 
intake 
OR 95% CI P-
value 
OR 95% CI P-
value 
 PIRS ≤50 (No Insomnia) versus PIRS 51-100 (Moderate Insomnia) 
Low 
High 
Ref 
4.395 
Ref 
(0.436 –25.689) 
 
0.190 
Ref 
9.321 
Ref 
(3.324-21.402) 
 
0.018* 
 PIRS ≤50 (No Insomnia) versus PIRS >100 (Severe Insomnia) 
Low 
High 
Ref 
9.314 
Ref 
(0.928 –35.245) 
 
0.095 
Ref 
17.958 
Ref 
(10.153 – 94.512) 
 
0.003* 
 R2 = 0.176 (Cox and Snell), 0.188 (Nagelkerke). χ2 (32) = 42.679, P=0.031 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
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Table 17: Over Time Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on Global PIRS Score Categories  
 
 Unadjusted Adjusted† 
Caffeine 
intake 
OR 95% CI P-
value 
OR 95% CI P-
value 
 PIRS ≤50 (No Insomnia) versus PIRS 51-100 (Moderate Insomnia) 
Low 
High 
Ref 
3.469 
Ref 
(0.369-13.535) 
 
0.130 
Ref 
15.550 
Ref 
(4.982 -96.042) 
 
0.019* 
 PIRS ≤50 (No Insomnia) versus PIRS >100 (Severe Insomnia) 
Low 
High 
Ref 
9.667 
Ref 
(0.965-963.457) 
 
0.110 
Ref 
23.988 
Ref 
(8.245 – 5.652) 
 
0.013* 
R2 = 0.170 (Cox and Snell), 0.181 (Nagelkerke). χ2 (30) = 37.654, P=0.034 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
 
 
Table 18: Linear Regression of the Effect of Caffeine Consumption on PSQI Variables  
 
PSQI Variables Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Sleep Duration 1.194 1.220 0.568 1.199 1.228 0.049* 
Sleep Disturbance 1.201 1.124 0.564 1.932 1.380 0.540 
Sleep Latency 1.271 1.188 0.786 1.258 1.015 0.548 
Days Dysfunction 
due to Sleepiness 
1.259 1.173 0.239 1.250 1.193 0.043* 
Sleep Efficiency 2.157 2.430 0.568 2.195 1.263 0.049* 
Overall Sleep 
Quality 
2.239 2.175 0.002* 2.248 2.182 0.001* 
Need Meds to 
Sleep 
1.268 1.176 0.987 1.274 1.197 0.589 
Global PSQI a 2.159 1.812 0.048* 2.587 1.058 0.038* 
aModel R2 = 0.191, F (15) = 26.491, P= 0.034.   
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
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Table 19: Linear Mixed Model (LMM) Analysis of Overtime Changes in PSQI Variables 
due to Caffeine Consumption  
  
PSQI variables Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Sleep Duration 1.162 1.054 0.450 1.345 1.134 0.042* 
Sleep Disturbance 1.216 1.112 0.570 1.505 1.122 0.032* 
Sleep Latency 1.245 1.154 0.568 1.323 1.170 0.023* 
Days Dysfunction 
due to Sleepiness 
1.263 1.146 0.460 1.353 1.161 0.036* 
Sleep Efficiency 1.104 1.016 0.450 1.212 1.178 0.025* 
Overall Sleep 
Quality 
1.256 1.143 0.570 1.575 1.152 0.058 
Need Meds to 
Sleep 
1.258 1.136 0.470 1.494 1.147 0.049* 
Global PSQI a 2.150 1.067 0.048* 2.594 1.190 0.006* 
aModel: -2 Restricted Log Likelihood = 1074.021; Akaike’s Information Criteria (AIC) = 
1078.021; Schwarz’s Bayesian Criteria (BIC) = 1084.608. 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
 
Table 20: Baseline Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on Global PSQI Score Categories  
 
 Unadjusted Adjusted† 
Caffe-
ine 
intake 
OR 95% CI P-value OR 95% CI P-
value 
 PSQI ≤5 (Good Sleep Quality) versus PSQI 6-10 (Poor Sleep Quality) 
Low 
High 
Ref 
2.585 
Ref 
(0.625 - 93.988) 
 
0.058 
Ref 
18.659 
Ref 
(8.016 -165.741) 
 
0.013* 
 PSQI ≤5 (Good Sleep Quality) versus PSQI >10 (Worst Sleep Quality) 
Low 
High 
Ref 
3.899 
Ref 
(1.609 -193.863) 
 
0.047* 
Ref 
19.060 
Ref 
(16.906-186.786) 
 
0.008* 
R2 = 0.218 (Cox and Snell), 0.218 (Nagelkerke). χ2 (28) = 44.688, P =0.038 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
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Table 21:  Over Time Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on Global PSQI Score Categories  
 
 Unadjusted Adjusted† 
Caffeine 
intake 
OR 95% CI P-
value 
OR 95% CI P-
value 
 PSQI ≤5 (Good Sleep Quality) versus PSQI 6-10 (Poor Sleep Quality) 
Low 
High 
Ref 
2.994 
Ref 
(0.382 – 7.067) 
 
0.509 
Ref 
33.577 
Ref 
(24.695 -82.962) 
 
0.039* 
 PSQI ≤5 (Good Sleep Quality) versus PSQI >10 (Worst Sleep Quality) 
Low 
High 
Ref 
3.470 
Ref 
(0.627 - 2.939) 
 
0.870 
Ref 
65.201 
Ref 
(49.882-96.662) 
 
0.015* 
R2 = 0.165 (Cox and Snell), 0.174 (Nagelkerke). χ2 (30) = 29.596, P =0.042 
†Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug, 
tobacco and alcohol use, sleep medications and types of ART medication. 
*Significant 
 
Table 22: Linear Regression of the Effect of Caffeine Consumption on GAD-7 Scores  
 
Generalized 
Anxiety  
Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
GAD-7 Score a 0.963 1.375 0.674 1.647 0.917 0.027* 
aModel R2 = 0.182, F (17) = 22.279, P = 0.039.   
†Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
 
Table 23: Linear Mixed Model (LMM) Analysis of Over Time Changes in GAD-7 
Scores due to Caffeine Consumption  
 
Generalized 
Anxiety 
Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
GAD-7 Score a 0.917 0.848 0.569 0.937 0.218 0.048* 
aModel: -2 Restricted Log Likelihood = 1096.531; Akaike’s Information Criteria (AIC) = 
1100.531; Schwarz’s Bayesian Criteria (BIC) = 1107.087. 
†Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant
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Table 24: Baseline Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on GAD-7 Score Categories  
 
 Unadjusted Adjusted† 
Caffeine 
intake 
OR 95% CI P-
value 
OR 95% CI P-
value 
 GAD-7 Scores  ≤5 (Minimal Anxiety) versus GAD-7 Scores 6-10 (Mild 
Anxiety) 
Low 
High 
Ref 
1.150 
Ref 
(0.387 – 7.009) 
 
0.482 
Ref 
5.107 
Ref 
(1.568 -33.499) 
 
0.027* 
 GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 11-15 
(Moderate Anxiety) 
Low 
High 
Ref 
4.714 
Ref 
(0.578 – 8.734) 
 
0.160 
Ref 
6.091 
Ref 
(2.333 – 35.841) 
 
0.002* 
 GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 15-20 
(Severe Anxiety) 
Low 
High 
Ref 
5.904 
Ref 
(0.714 – 9.150) 
 
0.080 
Ref 
17.185 
Ref 
(5.185 -88.185) 
 
0.001* 
R2 = 0.167 (Cox and Snell), 0.172 (Nagelkerke). χ2 (48) = 42.416, P =0.035 
†Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
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Table 25: Over Time Multinomial Logistic Regression of the Effect of Caffeine 
Consumption Levels on GAD-7 Score Categories  
  
 Unadjusted Adjusted† 
Caffei-
ne 
intake 
OR 95% CI P-
value 
OR 95% CI P -value 
 GAD-7 ≤5 Scores (Minimal Anxiety) versus GAD-7 Scores 6-10 (Mild 
Anxiety) 
Low 
High 
Ref 
1.160 
Ref 
(0.387 –17.009) 
 
0.482 
Ref 
12.107 
Ref 
(1.568-33.499) 
 
0.037* 
 GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 10-15 
(Moderate Anxiety) 
Low 
High 
Ref 
2.714 
Ref 
(0.578 –28.734) 
 
0.316 
Ref 
22.911 
Ref 
(6.333-53.841) 
 
0.033* 
 GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 15-20 
(Severe Anxiety) 
Low 
High 
Ref 
3.222 
Ref 
(0.906 –29.063) 
 
0.179 
Ref 
32.185 
Ref 
(7.185-87.185) 
 
0.002* 
R2 = 0.173 (Cox and Snell), 0.180 (Nagelkerke). χ2 (42) = 46.202, P =0.043 
†Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
 
Table 26: Linear Regression Analysis of the Effect of Global PIRS, Global PSQI and 
GAD-7 Scores on Immunological and Virologic Markers of Disease Progression  
 
 Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Global PIRS a 
CD4 square root -0.913 0.128 0.316 -1.202 0.649 0.015* 
Log10 Viral load 1.659 0.735 0.698 1.949 0.933 0.045* 
Global PSQI b 
CD4 square root  -0.782 0.110 0.479 -1.149 0.931 0.036* 
Log10 Viral load  1.176 0.924 0.741 1.988 0.828 0.031* 
GAD-7 c 
CD4 square root -0.476 0.239 0.643 -1.122 0.964 0.031* 
Log10 Viral load 1.508 1.219 0.417 1.269 0.425 0.029* 
aModel R2 = 0.187, F (14) = 32.390, P = 0.041. 
bModel R2 = 0.188, F (14) = 28.833, P =0.046. 
cModel R2 = 0.220, F (14) = 20.862, P = 0.014.   
†Model adjusted for time from diagnosis of HIV, drug use, smoking status, alcohol use 
and different types of ART medications. *Significant
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Table 27: Linear Mixed Model Analysis of Over Time Changes in Immunological and 
Virologic Markers of Disease Progression due to Global PIRS, Global PSQI and GAD-7 
Scores   
 
 Unadjusted Adjusted† 
 Beta SE P-value Beta SE P-value 
Global PIRS a 
CD4 square root  -0.643 0.126 0.817 -0.923 0.680 0.732 
Log10 Viral load 0.848 0.714 0.732 1.213 0.615 0.890 
Global PSQI b 
CD4 square root  -0.537 0.638 0.401 -1.081 0.722 0.260 
Log10 Viral load 0.918 0.814 0.201 1.013 0.716 0.429 
GAD-7 c 
CD4 square root  -0.366 0.152 0.900 -1.011 0.583 0.838 
Log10 Viral load 0.960 0.811 0.608 0.984 0.213 0.880 
aModel: -2 Restricted Log Likelihood = 1146.722; Akaike’s Information Criteria (AIC) = 
1150.722; Schwarz’s Bayesian Criteria (BIC) = 1157.005. 
bModel: -2 Restricted Log Likelihood = 1140.831; Akaike’s Information Criteria (AIC) 
=1144.831; Schwarz’s Bayesian Criteria (BIC) = 1151.115. 
cModel: -2 Restricted Log Likelihood = 1142.502; Akaike’s Information Criteria (AIC) = 
1146.502; Schwarz’s Bayesian Criteria (BIC) = 1152.785. 
† Model adjusted for time from diagnosis of HIV, drug use, smoking status, alcohol use 
and different types of ART medications. 
 
 
 
 
 
 
 
 
 
 
 
 166 
 
References 
1. Federal Department of Health. HIV Disease: United States vs Florida. 
2014; http://www.floridahealth.gov/diseases-and-
conditions/aids/surveillance/_documents/fact-sheet/2014/2014-us-vs-fl-fact-
sheet.pdf. Accessed December 20, 2014. 
 
2. Cohen FL, Ferrans CE, Vizgirda V, Kunkle V, Cloninger L. Sleep in men and 
women infected with human immunodeficiency virus. Holistic Nursing Practice. 
1996;10(4):33-43. 
 
3. Nokes KM, Kendrew J. Sleep quality in people with HIV disease. Journal of the 
Association of Nurses in AIDS Care. 1996;7(3):43-50. 
 
4. Nokes KM, Chidekel JH, Kendrew J. Exploring the complexity of sleep 
disturbances in persons with HIV/AIDS. Journal of the Association of Nurses in 
AIDS Care. 1999;10(3):22-29. 
 
5. Nokes KM, Kendrew J. Correlates of sleep quality in persons with HIV disease. 
Journal of the Association of Nurses in AIDS Care. 2001;12(1):17-22. 
 
6. Gamaldo CE, Gamaldo A, Creighton J, et al. Evaluating sleep and cognition in 
HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2013;63(5):609-
616. 
 
7. Motivala SJ, Hurwitz BE, Llabre MM, et al. Psychological distress is associated 
with decreased memory helper T-cell and B-cell counts in pre-AIDS HIV 
seropositive men and women but only in those with low viral load. Psychosomatic 
Medicine. 2003;65(4):627-635. 
 
8. Vosvick M, Gore-Felton C, Ashton E, et al. Sleep disturbances among HIV-
positive adults: the role of pain, stress, and social support. Journal of 
Psychosomatic Research. 2004;57(5):459-463. 
 
9. Hindmarch I, Rigney U, Stanley N, Quinlan P, Rycroft J, Lane J. A naturalistic 
investigation of the effects of day-long consumption of tea, coffee and water on 
alertness, sleep onset and sleep quality. Psychopharmacology. 2000;149(3):203-
216. 
 
10. Nardi AE, Lopes FL, Freire RC, et al. Panic disorder and social anxiety disorder 
subtypes in a caffeine challenge test. Psychiatry Research. 2009;169(2):149-153. 
 
11. Dreher HM. The effect of caffeine reduction on sleep quality and well-being in 
persons with HIV. Journal of Psychosomatic Research. 2003;54(3):191-198. 
 
 167 
 
12. United States Food and Drug Administration. FDA to investigate added caffeine. 
2013; http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM350
740.pdf. Accessed October 20, 2014. 
 
13. Moul D, Pilkonis P, Miewald J, Carey T, Buysse D. Preliminary study of the test-
retest reliability and concurrent validities of the Pittsburgh Insomnia Rating Scale 
(PIRS). Paper presented at: Sleep2002. 
 
14. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh 
Sleep Quality Index: a new instrument for psychiatric practice and research. 
Psychiatry Research. 1989;28(2):193-213. 
 
15. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing 
generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. 
2006;166(10):1092-1097. 
16. Preston JD, O'Neal JH, Talaga MC. Consumer's Guide to Psychiatric Drugs. New 
Harbinger Publications, Inc; 1998. 
 
17. United States Food and Drug Administration. Database of Select Committee on 
GRAS Substances (SCOG) Reviews: Caffeine. 
2006; http://www.accessdata.fda.gov/scripts/fcn/fcnDetailNavigation.cfm?rpt=sco
gsListing&id=42. Accessed Spetember 12, 2014. 
 
18. United States Food and Drug Administration. FDA to investigate added caffeine. 
2013; http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM350
740.pdf. Accessed September 2 2013. 
 
19. World Health Organization. Lexicon of alcohol and drug terms published by the 
World Health Organization. Accessed September 2 2013. 
 
20. World Health Organization. Mental and behavioural disorders F15. International 
Statistical Classification of Diseases and Related Health Problems. 2010;Chapter 
5(Mental and behavioural disorders due to use of other stimulants, including 
caffeine.). 
 
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders. Vol Fifth ed2013. 
 
22. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh sleep 
quality index. Journal of Psychosomatic Research. 1998;45(1):5-13. 
 
 
 
23. Fichtenberg NL, Putnam SH, Mann NR, Zafonte RD, Millard AE. Insomnia 
screening in postacute traumatic brain injury: utility and validity of the Pittsburgh 
 168 
 
Sleep Quality Index. American Journal of Physical Medicine & Rehabilitation. 
2001;80(5):339-345. 
 
24. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test–retest 
reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. 
Journal of Psychosomatic Research. 2002;53(3):737-740. 
 
25. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in 
primary care: prevalence, impairment, comorbidity, and detection. Annals of 
Internal Medicine. 2007;146(5):317-325. 
26. Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B. Changes in sleep quality 
and brain wave patterns following initiation of an efavirenz‐containing triple 
antiretroviral regimen. HIV Medicine. 2006;7(4):243-247. 
 
27. Dorey‐Stein Z, Amorosa VK, Kostman JR, Lo Re V, Shannon RP. Severe Weight 
Gain, Lipodystrophy, Dyslipidemia, and Obstructive Sleep Apnea in a Human 
Immunodeficiency Virus‐Infected Patient Following Highly Active Antiretroviral 
Therapy. Journal of the Cardiometabolic Syndrome. 2008;3(2):111-114. 
 
28. Morrison MF, Petitto JM, Have TT, et al. Depressive and anxiety disorders in 
women with HIV infection. American Journal of Psychiatry. 2002;159(5):789-
796. 
 
29. Moss T, Martin CW, Klausner JD, Brown BJ. Integration of Screening for 
Syphilis, Hepatitis C, and Other Sexually Transmitted Infections with HIV 
Testing in a Community-Based HIV Prevention Program in Miami, Florida. 
LGBT Health. 2014;1(2):82-85. 
 
30. Wawrzyniak AJ, Rodríguez AE, Falcon AE, et al. Association of Individual and 
Systemic Barriers to Optimal Medical Care in People Living With HIV/AIDS in 
Miami-Dade County. JAIDS Journal of Acquired Immune Deficiency Syndromes. 
2015;69:S63-S72. 
 
31. Penetar D, McCann U, Thorne D, et al. Caffeine reversal of sleep deprivation 
effects on alertness and mood. Psychopharmacology. 1993;112(2-3):359-365. 
 
32. Griffiths RR, Woodson PP. Reinforcing effects of caffeine in humans. Journal of 
Pharmacology and Experimental Therapeutics. 1988;246(1):21-29. 
 
33. Wesensten N, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. 
Maintaining alertness and performance during sleep deprivation: modafinil versus 
caffeine. Psychopharmacology. 2002;159(3):238-247. 
 
34. Wesensten NJ. Legitimacy of concerns about caffeine and energy drink 
consumption. Nutrition Reviews. 2014;72(suppl 1):78-86. 
 169 
 
 
35. Taibi DM. Sleep disturbances in persons living with HIV. Journal of the 
Association of Nurses in AIDS Care. 2013;24(1):S72-S85. 
 
36. Lee KA, Gay C, Portillo CJ, et al. Types of sleep problems in adults living with 
HIV/AIDS. Journal of Clinical Sleep Medicine: JCSM: official publication of the 
American Academy of Sleep Medicine. 2012;8(1):67. 
 
37. Taibi DM, Price C, Voss J. A pilot study of sleep quality and Rest–Activity 
patterns in persons living with HIV. Journal of the Association of Nurses in AIDS 
Care. 2013;24(5):411-421. 
38. Webel AR, Moore SM, Hanson JE, Patel SR, Schmotzer B, Salata RA. Improving 
sleep hygiene behavior in adults living with HIV/AIDS: a randomized control 
pilot study of the SystemCHANGE TM–HIV intervention. Applied Nursing 
Research. 2013;26(2):85-91. 
 
39. Gallego L, Barreiro P, del Río R, et al. Analyzing sleep abnormalities in HIV-
infected patients treated with Efavirenz. Clinical Infectious Diseases. 
2004;38(3):430-432. 
 
40. Hudson AL, Portillo CJ, Lee KA. Sleep disturbances in women with HIV or 
AIDS: efficacy of a tailored sleep promotion intervention. Nursing Research. 
2008;57(5):360-366. 
 
41. Lee KA, Portillo CJ, Miramontes H. The influence of sleep and activity patterns 
on fatigue in women with HIV/AIDS. Journal of the Association of Nurses in 
AIDS Care. 2001;12:19-27. 
 
42. Robbins JL, Phillips KD, Dudgeon WD, Hand GA. Physiological and 
psychological correlates of sleep in HIV infection. Clinical Nursing Research. 
2004;13(1):33-52. 
 
43. Cruess DG, Antoni MH, Gonzalez J, et al. Sleep disturbance mediates the 
association between psychological distress and immune status among HIV-
positive men and women on combination antiretroviral therapy. Journal of 
Psychosomatic Research. 2003;54(3):185-189. 
 
44. Patel NP, Grandner MA, Xie D, Branas CC, Gooneratne N. Sleep disparity" in the 
population: poor sleep quality is strongly associated with poverty and ethnicity. 
BMC Public Health. 2010;10(1):475-485. 
 
45. Roehrs T, Burduvali E, Bonahoom A, Drake C, Roth T. Ethanol and sleep loss: a" 
dose" comparison of impairing effects. SLEEP-NEW YORK THEN 
WESTCHESTER-. 2003;26(8):981-985. 
 
 170 
 
46. Moldofsky H, Gilbert R, Lue FA, MacLean AW. Sleep-related violence. Sleep. 
1995;18(9):731-739. 
 
47. Christian J. Fatigue, sleep disturbance, disability, and indices of progression of 
HIV infection. Am J Psychiatry. 1992;1:49. 
 
48. Schneider M, Chersich M, Neuman M, Parry C. Alcohol consumption and 
HIV/AIDS: the neglected interface. Addiction. 2012;107(8):1369-1371. 
 
49. Darke S, Swift W, Hall W, Ross M. Drug use, HIV risk-taking and psychosocial 
correlates of benzodiazepine use among methadone maintenance clients. Drug 
and Alcohol Dependence. 1993;34(1):67-70. 
 
50. Nieman RB, Fleming J, Coker RJ, Harris JW, Mitchell DM. The effect of 
cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. 
Aids. 1993;7(5):705-710. 
 
51. Lyles RH, Muñoz A, Yamashita TE, et al. Natural history of human 
immunodeficiency virus type 1 viremia after seroconversion and proximal to 
AIDS in a large cohort of homosexual men. Journal of Infectious Diseases. 
2000;181(3):872-880. 
 
52. Rosenthal R, Rubin DB. Interpersonal expectancy effects: The first 345 studies. 
Behavioral and Brain Sciences. 1978;1(03):377-386. 
 
 
 171 
 
CHAPTER-VI: CAFFEINE INTAKE AND ITS ASSOCIATION WITH 
NUTRITIONAL PARAMETERS IN MIAMI ADULT STUDIES OF HIV (MASH) 
COHORT—AN OBSERVATIONAL STUDY 
ABSTRACT  
Introduction: In a number of studies, people living with HIV (PLWH) have reported 
inadequate dietary intakes and compromised body compositions measures even when 
they were on ART. Additionally, weight-loss and reduced body fat reserves were 
associated with accelerated HIV-disease progression.  Although the literature abounds on 
studies on caffeine consumption and its relationship with changes in bodyweight and 
body composition in healthy populations, similar studies in PLWH are few.  
Methods: We examined the impact of high caffeine consumption on dietary intake and 
body composition measures in a convenience sample of 130 HIV+ participants (65 
consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) recruited from the 
Miami Adult Studies on HIV (MASH) cohort.  This study included a baseline and a 3-
month follow-up visits. After obtaining written informed consent, caffeine consumption 
was estimated using Modified Caffeine Consumption Questionnaire (MCCQ). 
Information on demographics, anthropometries, body composition measures, substance 
use, 24-hour dietary recall, Food Security Scores and antiretroviral therapy (ART) were 
obtained from the MASH cohort database.  T-tests and chi-square were used to describe 
demographics and health and lifestyle characteristics. Linear regressions were used to 
analyze baseline data for the effects of caffeine intake on the outcome variables. Linear 
Mixed Models were used to estimate the effect of caffeine consumption on these 
parameters over time.   
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Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were males and 
75.4% were African-Americans. All participants were on antiretroviral treatment (ART) 
throughout the study. Mean caffeine intake at the baseline was 161.26 ± 194.95 mg/day 
(3-8 cups of coffee) (Range: 0 mg-1498 mg/day) and did not change significantly at the 
3-month visit.  Fat (93.43 ± 48.484 vs 170.94 ± 44.585, P=0.048), carbohydrate (259.15 
± 132.242 vs 341.83 ± 133.437, P=0.048) and protein (85.24 ± 40.866 vs 94.82 ± 54.556, 
P=0.046) intakes were significantly lower in participants consuming > 250 mg of 
caffeine/day, compared to those who consumed ≤ 250 mg of caffeine/day. Higher 
caffeine consumption was also associated with lower fat mass (β=-0.994, P=0.042), 
lower caloric intakes (β=-1.643, P=0.042) and lower fat consumption (β=-1.902, 
P=0.044), in conjunction with the use of other anorexic agents such as cocaine use and 
amphetamine after adjusting for HIV viral load and ART medications.  
Conclusion: Higher caffeine consumption was associated with lower dietary intakes of 
macronutrients and lower fat reserves. These associations also became weaker or 
disappeared when adjusting for, or excluding, the use of other anorexic and stimulant 
drugs such as cocaine and methamphetamine, suggesting that caffeine may worsen the 
action of these drugs. Future large scale studies are needed to understand the level of 
caffeine’s influences on these health and nutritional outcomes. 
Keywords: Modified Caffeine Consumption Questionnaire (MCCQ), HIV infection, 
Body Mass Index (BMI), Lean Body Mass (LBM). 
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INTRODUCTION 
With significant improvements in availability and accessibility of combination 
ART, HIV is currently a chronic disease with decreasing incidence, increasing prevalence 
and 97% decrease in progression to AIDS and death, thereby increasing the number of 
people living with HIV (PLWH).1 According to CDC’s estimates in 2013,  there were 
about 1.2 million PLWH in the US2  and 26,760 of them were living in Miami.3  
Most of the PLWH in Miami live in marginalized neighborhoods with limited 
resources.4 Many socioeconomic factors such as homelessness, illegal commercial sex, 
drug abuse, alcohol addiction, extreme tobacco use and criminalization act as barriers for 
access to nutritious foods and supplements and compliance with ART.5-10 Though the 
majority of the MASH cohort, from which our participants were recruited, received social 
security benefits and some forms of food assistance, many experience food insecurity.10 
Food insecurity and decreased food intake are associated with uncontrolled HIV viral 
load and increased mortality even in participants on ART.11,12  Similarly weight loss and 
lower BMI are associated with faster disease progression as measured by lower CD4 cell 
counts and uncontrolled HIV viral load even in PLWH on ART.13-15  
Caffeine shows anorexic, lipolytic and thermogenic effects due to its inhibitory 
action on  cAMP degradation pathway, as well as increased cAMP generation via 
stimulation of beta-adrenergic receptors.16 In a double blind placebo controlled study on 
healthy volunteers, caffeine intake (100, 200 and 400 mg/day) produced a positive and 
dose-dependent increase in resting energy expenditures (REE), (r = 0.86; P< 0.001), after 
controlling for plasma lactate levels and plasma triglyceride levels.17 In another double 
blind placebo controlled study on the supplement Meltdown®, containing caffeine (400 
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mg/pill), participants who were administered the supplement once per day, recorded 
higher Area Under the Curve (AUC) for serum norepinephrine levels (NE), glycerol, free 
fatty acids (FFA), and basal metabolic rate (BMR) compared to placebo, indicating 
increased Resting Energy Expenditures (REE).18 Similar effects were reported in another 
study where 450 mg/day of caffeine produced higher AUC for resting oxygen uptake 
(VO2), which is also a measure of REE.19  Caffeine at a dose of 700 mg/day also 
produced 2-fold increase in lipid turnover (P < 0.005), increased thermic effect (P < 
0.001), and 2.3 times increased oxidative free fatty acid (FFA) disposal (P < 0.01) 
compared to placebo pills, indicating increased REE and lipid breakdown.16  
  Caffeine consumption (250 mg/day) was also associated with lower plasma 
levels of antioxidant trace elements such as Zinc And Selenium after controlling for 
dietary intakes, age, physical activity and substance use.20 This relationship also showed 
a dose-response pattern, with lower caffeine consumption associated with decreased 
depletion of antioxidant trace elements.20     
In summary, the literature supports that caffeine acted as an anorexic agent, 
increased energy expenditure, precipitated weight loss, and depleted antioxidant 
nutrients. Such effects could be detrimental to PLWH, because many of them already 
experience food scarcity and insecurity.10 Our study evaluated the effects of caffeine 
consumption on nutrient intake, body composition and nutritional indicators in a group of 
PLWH who were recruited from the MASH cohort. This study also examined the 
relationship between food security scores and caffeine consumption levels. In addition, 
this study also examined the net effects of body composition measures and macronutrient 
intakes on markers of HIV disease progression (CD4 counts and viral load).  
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METHODS 
Study Design and Setting 
The present study recruited a convenience sample of 130 participants (65 consuming ≤ 
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which 
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10 
years at the FIU research clinic in the Borinquen Health Care Center (BHCC).  The 
BHCC provides comprehensive range of health and social services to a culturally diverse 
low income community. The recruitment for the present study took place from February 
to July 2014. The present study included a baseline and a 3-month follow-up visit, and 
participants received $5 as partial reimbursement for their time and efforts, for each of 
the two visits. The initial screening included detailed explanation of the study as well as 
obtaining informed voluntary written consent for participation. In order to obtain a study 
sample of 128 participants as estimated in our sample size calculations, we screened a 
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants. 
The present study also included secondary analysis of relevant variables collected for the 
MASH cohort studies. Data collected during the baseline and 3-month visits were used 
for the analyses of descriptive and inferential statistics. The inclusion and exclusion 
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable 
to our current study. The additional inclusion criteria for participants in the present study 
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a 
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion 
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical 
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or 
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mal-absorption syndromes. The Institutional Review Board at Florida International 
University approved the study protocol and research procedures.  
Survey Instruments, Outcome Measures and Variables 
The questionnaires used in the present study were previously field tested and validated in 
several large scale studies.21-24 However, we pre-tested these questionnaires on 15 
participants from the MASH cohort to ascertain their applicability and we determined 
that revisions were not necessary for the questionnaires. 
Caffeine consumption questionnaire: We used the Modified Caffeine Consumption 
Questionnaire (MCCQ) developed by Preston et al in the year 1998.25 This questionnaire 
is easy to understand, compact, organized and reports adequate compliance, validity and 
reliability.25 This questionnaire was field tested and validated in several large scale 
studies and adequately reflected average daily caffeine consumption levels.21 It includes a 
total of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the 
counter medications’ and ‘Prescription medications’. This questionnaire also included 
‘Total caffeine consumption per day’ by adding these individual sources. Caffeine 
consumption was analyzed both as a continuous variable and a categorical variable.  
             For both naturally occurring and artificially added caffeine sources, FDA 
considers 400 mg/day (6-7 cups of coffee) to be generally safe and not associated with 
any dangerous side effects.26,27  The World Health Organization (WHO) defines caffeine 
overuse as daily consumption beyond 500 mg/d.28,29  Beyond this level caffeine produces 
visible adverse effects collectively known as ‘caffeinism’. The World Health 
Organization (WHO) has also cautioned that these adverse effects could be precipitated at 
much lower doses depending on the physiological profiles of individuals as well as the 
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genetic makeup of the population.28,29 The International Classification of Diseases (ICD) 
manual considers caffeine consumption above 250 mg/day to be associated with many 
mental and behavioral disorders though it is inconclusive whether such effects would be 
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally 
safe and above this level to be associated with many adverse effects such as withdrawal, 
addiction, irritability and craving.30 Summarizing these cutoffs, we concluded that 
caffeine consumption below 250 mg/day that is equivalent to 4 cups of coffee, 
irrespective of the sources is generally safe and not associated with adverse effects. In 
this study, caffeine categories included low (≤250 mg/day, within safe levels) and high 
(>250 mg/day, beyond safe levels) based on these recommendations. 
Nutritional Status Assessment 
Dietary intakes: All research personnel in the MASH cohort studies were trained to 
obtain 24-hour dietary recalls, which were used to estimate daily dietary and nutrient 
consumption by the participants. During each MASH cohort study visit, participants were 
queried about foods and beverages consumed on the day prior to the visit. All details 
including cooking methods, amount consumed, additional ingredients and seasonings and 
food brands were recorded to ensure comprehensiveness of the obtained information. We 
also used props like food models and measuring cups to ensure accuracy of the amounts 
and volumes consumed and to provide cues for better recall of consumed foods. We used 
Nutribase Professional Software Version 9 (Cybersoft Inc, 2011), into which all the 
collected information were entered to obtain a detailed estimation of kilocalories, 
macronutrients and micronutrients consumed by the participants. Adequacy of nutrient 
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intakes were determined using the Daily Values (DV), developed by the FDA by 
combining two sets of reference values, the Daily Reference Values (DRV) and the 
Reference Daily Intakes (RDI), to include a comprehensive list of all essential nutrients, 
including the nutrients for which Recommended Dietary Allowances (RDA) are not 
established.31 
Body composition measures: In the MASH cohort studies, after screening the 
participants, height was recorded immediately using a stadiometer, calibrated according 
to the instructions in the user’s manual. Height was recorded to the nearest 0.5 inch after 
removing shoes, socks and other footwear. Height was recorded only once to ensure that 
it was uniform and there were no minor variations during every successive visit. Weight 
was measured every visit to the nearest 0.1 lbs. using a standard weighing machine which 
was calibrated and maintained throughout the study. Participants were requested to 
remove their watches, shoes, mobile phones or other heavy materials possessed by them. 
The data so obtained, along with age, were entered into the bio-impedance machine 
(Biodynamics-450)32 to obtain several body composition measures, including body cell 
mass, extracellular mass, lean body mass (LBM), fat mass, body mass index (BMI) and 
intracellular and extracellular fluid levels. In addition, we also obtained the waist-to-hip 
ratio using a non-stretchable tape to measure the waist and hip circumferences at the 
narrowest levels of the waist and widest levels of the hip.  
Biochemical indicators: Nutritional biomarkers which included serum albumin, 
hemoglobin and hematocrit were obtained at the semiannual MASH visits . In addition, 
participants provided their most recent laboratory reports from their regular treatment 
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visits. The MASH cohort studies also collected other relevant laboratory and clinical data 
after the participants signed a medical release form.  
Immunological and virologic variables: CD4 counts, viral loads and other clinical 
variables were obtained from participants’ medical charts and collected by the MASH 
cohort study after appropriate medical release by the participants. In the current research, 
CD4 counts and viral loads were analyzed as continuous variables and transformed into 
CD4 square root and log10 viral load to ensure normal distribution and better model fit 
criteria. 
Control Variables 
Demographic and socioeconomic information: Demographic variables used for the 
current study included age, gender, race/ethnicity, education and income levels. A 
number of health and lifestyle related factors such as tobacco use, alcohol consumption, 
and illicit drug use were also obtained from the MASH data repository. All these 
variables were controlled in our analysis based on studies associating these variables with 
adverse health and nutritional outcomes in HIV.33-46 
ART medications: We obtained information about types of the antiretroviral medications 
prescribed by their physicians during the MASH cohort visits. We controlled for these 
variables because some of the antiretroviral medications were associated with altered 
nutrition and body composition measures.47-49 
Statistical Analysis 
Field data were collected in paper based questionnaires and later entered into RedCap 
database, imported into SPSS version 21 for Windows (Armonk, NY: IBM Corp), and 
merged into a single dataset for analysis. Descriptive statistics used to understand the 
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characteristics of the cohort were expressed in terms of means, standard deviations and 
percentages and were separated based on low and high intakes of caffeine using the 
cutoff points: > 250 mg/day for high intake; and ≤ 250 mg/day for low or no intake. T-
tests and chi square tests were used to compare the differences in demographics, health 
and lifestyle characteristics, nutrient intakes and percentages of participants who were not 
meeting the Daily Values (DV) for the nutrients, between the low and high caffeine 
groups. Paired sample t-tests were used to understand the changes in caffeine and nutrient 
intakes between the baseline and 3-month visits. Linear regression analyses were used to 
estimate the strength of the association of caffeine intake as a continuous variable with 
body composition measures; nutritional status indicators, dietary intakes and food 
security scores. Assumptions of linear regression were followed prior to analyses. Linear 
mixed models (LMM) were used to determine the changes in these associations over 
time. For parameter estimation in LMM models, Restricted Maximum Likelihood 
(REML) was used. Multinomial logistic regressions were used to determine the strength 
of associations between different categories of caffeine intake (low and high) and 
different categories of food insecurity measured through FSQ scores. Linear Regression 
was also used to estimate the strength of association between body composition, dietary 
intakes and food security scores and the markers of HIV disease progression (CD4 counts 
and viral load). Linear Mixed Models were used to estimate the changes over time in the 
strength of these associations. For both liner and logistic regressions, as well as liner 
mixed model analysis, we initially used crude models and subsequently adjusted for 
covariates such as age, gender, race/ethnicity, grades of schooling, income, time from 
diagnosis of HIV, drug use, alcohol use, smoking and different types of antiretroviral 
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medications, based on studies associating these risk factors with adverse health and 
nutritional outcomes in HIV.33-49  These covariates were also tested for significant 
associations with the outcome variables using bivariate analysis before being 
incorporated into the models. To increase the validity of the models, mutlicollinearity 
among covariates was tested prior to the analyses. Adjusted models included non-missing 
values for all independent variables included in the models. Statistical significance was 
set at P < 0.05 for all the analyses. 
RESULTS 
Demographic and Socio-economic Characteristics  
A total of 130 participants were included in the study and 79 (60.8%) were men. 
The mean age of the sample was 47.89 ± 6.37 years. Most of the participants were 
African Americans (75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and 
other races were 4.6 percent. Less than one fourth (23.8%) of the participants had college 
education, while 45.4% were high school graduates and 30.8% has some form of primary 
education. All participants had incomes under the level of poverty and the mean income 
was $495.91± 465.887. There were no significant differences in any socio-demographic 
variables between low and high levels of caffeine consumption in both baseline and 
follow-up visits (Table-1A, 1B). 
Health/lifestyle Characteristics  
Sixty one percent of the participants reported smoking within the past six weeks 
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive 
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and 
65.8% tested positive for illicit drug use during the follow-up visit.  
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All participants were on ART during the entire duration of the study. 
Antiretroviral therapy took many forms, 58.5% were on NRTI, 13.1% were on NNRTI 
and 47.7% were on PI in several combinations, 26.2% of the participants were using a 
one-pill multi-drug combination such as Atripla, Truvada and Combivir during the 
baseline visit. At the 3-month visit, 63.8% were on NRTI, 13.8% were on NNRTI and 
47.7% were on PI, and 25.4% were on a one-pill multi-drug combination. There were no 
significant differences in the distribution of these variables between low and high levels 
of caffeine consumption in both baseline and follow-up visits, or in the distribution of 
these variables between baseline and follow-up visits (Tables 2 and 3). 
Caffeine Consumption from Different Sources 
The mean total caffeine consumption from all sources was 337.63 ± 304.97 mg/day 
(Range: 0-1,498 mg/day) at baseline, and 281.04 ± 260.85 mg/day (Range: 0-1,175 
mg/day) at follow-up. Coffee constituted the largest source of caffeine and mean 
consumption levels were 161.26 ± 194.95 mg/day at baseline, and 190.40 ± 205.03 
mg/day at follow-up. Caffeinated soft drinks constituted the second largest source of 
caffeine and mean consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66 
± 83.78 mg/day at follow-up. There were no significant differences between baseline and 
follow-up visits with respect to total caffeine consumption or caffeine from most of the 
sources. However, there was significant decrease in consumption of caffeinated soft 
drinks (63.23 ± 92.98 vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs. 
9.61 ± 65.32, P=0.005) and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the 
baseline to the follow-up visits (Table 4).  For all other sources of caffeine in the 
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questionnaire, except the ones enlisted in Table 4, participants reported none to negligible 
levels of consumption at both the visits. 
Dietary Intakes by Caffeine Consumption Status  
During the baseline visit, total fat (93.43 ± 48.484 vs 170.94 ± 44.585, P=0.048), 
carbohydrate (259.15 ± 132.242 vs 341.83 ± 133.437, P=0.048) and protein intakes 
(85.24 ± 40.866 vs 94.82 ± 54.556, P=0.046) were significantly lower in participants 
consuming > 250 mg of caffeine per day, compared to participants consuming ≤ 250 mg 
of caffeine per day (Table 5). Similarly intakes of Sodium, Chloride, Potassium, Calcium, 
Magnesium, Phosphorus, Vitamin C, Thiamine, Riboflavin, Niacin, Vitamin B6, Vitamin 
B12, Iron, Zinc and Selenium were also significantly lower in high caffeine consumers 
compared to low caffeine consumers (Table 5). During the follow-up visits, total calories 
(1858.27 ± 932.055 vs 2100.52 ± 1127.868, P=0.017), carbohydrate (151.32 ± 116.795 
vs 255.27 ± 152.914, P=0.042), protein (43.48 ± 37.841 vs 86.49 ± 42.173, P=0.017) and 
fat intake (77.52 ± 56.469 vs 183.72 ± 68.771, P=0.026) were significantly lower in high 
caffeine consumers compared to low caffeine consumers (Table 6). Total intakes of 
Cholesterol, Sodium, Potassium, Thiamine, Riboflavin, Niacin, and Vitamin B6 were also 
significantly lower in high caffeine group compared to low caffeine group (Table 6).  
However, there were no significant differences in any nutrient intakes between baseline 
and follow-up visit (Table 7). During the baseline visit, nutrient intakes were below Daily 
Values (DV), for many micronutrients (Table 8). All participants reported nutrient 
intakes below DV for chromium, molybdenum, and chloride. More than 90% of the 
participants reported consumption below DV for Potassium, Vitamin D, Vitamin E, 
Vitamin K, Pantothenic Acid, Iodine, Copper, and Manganese. For many of the 
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remaining nutrients, 50.0% to 87.7% of the participants reported consumption below DV 
(Table 8). For total fat, Saturated Fat, Sodium, and protein, less than 50% of participants 
reported consumption below DV (Table 8). For most of the nutrients, there were no 
significant differences between low and high caffeine consumers with respect to the 
proportion of participants failing to meet the DV, except Sodium (24.6% vs 10.8%, 
P=0.039). Similar trends were observed in follow-up visit (Table 9). More than 99% of 
the participants reported consumption below DV for Chromium, Molybdenum and 
Chloride. Similar to baseline findings, only for total fat, saturated fat, Sodium, and 
protein, less than 50% of participants reported consumption below DV. For many 
nutrients there were no significant differences between low and high caffeine consumers 
with respect to proportion of participants failing to meet the DV, except for total fat 
(38.1% vs 56.7%,  P=0.034) which was higher in participants consuming ≤ 250 mg of 
caffeine per day.  
Relationship between Caffeine Consumption and Body Composition Measures and 
Biochemical Indicators  
 Mean BMI for this cohort was 26.81 ± 7.82 kg/m2 and mean waist to hip ratio was 0.93. 
Higher caffeine consumption was associated with lower fat mass (β=-0.994, P=0.042) 
after adjusting for time from diagnosis of HIV, drug use, smoking status, alcohol use and 
different types of ART medications (Table 10). Linear mixed model analysis showed that 
this relationship increased overtime (β=-1.987, P=0.035), after adjusting for the same 
covariates (Table 11). Though BMI was not significantly different between low and high 
caffeine consuming participants, when caffeine was combined with cocaine and 
amphetamine to form a composite measure of total anorectic agents, we found that BMI 
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(27.70 ± 7.332 vs 25.51 ± 6.461, P=0.046) was significantly lower and HIV viral load 
(3.23 ± 1.465 vs 2.09 ± 1.137, P=0.000) was significantly higher in those who consumed 
high caffeine, and reported cocaine and amphetamine use. Similarly linear regression 
analysis also showed that the effect of cocaine on BMI (β=-2.502, P=0.013) decreased 
upon adjusting for caffeine (β=-2.352, P=0.046), thus justifying that caffeine 
compounded the weight loss effects of other powerful anorectic agents such as cocaine. 
Relationship between Dietary Intakes and Caffeine Consumption 
Higher caffeine intake was significantly associated with lower total caloric intake (β=-
1.643, P=0.042) and lower calories from fat (β=-1.902, P=0.044), after adjusting for time 
from diagnosis of HIV, drug use, smoking status, alcohol use and different types of ART 
medications (Table 12). Linear Mixed Models for the effects of caffeine on macronutrient 
consumption over time showed no associations (Table 13).  
Relationship between Body Composition and Macronutrient Intake and CD4 Count 
and Viral Load 
No associations were found between body composition measures or macronutrient 
intakes and CD4 counts and HIV viral load (Table 14, 16). Linear mixed models for the 
effects of body composition measures and macronutrient intakes on CD4 counts and viral 
load over time, also showed no associations (Table 15, 17).   
DISCUSSION 
During the baseline and follow-up visits, PLWH reported inadequate intakes for 
many nutrients, such as, total energy, carbohydrate, protein, fat, and many electrolytes, 
vitamins and minerals. All participants had incomes below the poverty level and more 
than half of them were consuming alcohol, smoking cigarettes, and had positive urine 
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toxicology result for illicit drugs. Poverty, substance abuse and dependence could have 
adversely influenced their dietary intake and food purchasing potential, which is 
supported by previous reports.50 A study done among 459 men and 212 women, living 
with HIV, found that food insecurity was associated with poverty and substance use. One 
in four participants in this study reported alcohol and tobacco purchase with resources 
allocated for food.50 
 In our study, caffeine consumption was associated with decreased dietary intakes 
for several nutrients and decreased fat mass. Caffeine also contributed to the weight loss 
effects of other powerful anorectic agents such as cocaine and amphetamine. These 
adverse associations of caffeine were superimposed on the already inadequate diet 
recorded for most participants.  Adverse effects of caffeine on energy deficits and weight 
loss were observed in many non-HIV infected populations.51-54 In a long-term follow-up 
study of eighteen years, conducted in 1333 males and 4085 females with type-2 diabetes, 
there was a strong association between caffeine consumption (> 4 cups/day which is 
approximately >240 mg caffeine/day) and weight loss after controlling for age, baseline 
body weight, insulin and anti-diabetic drugs, physical activity and lifestyle factors.51  
Further analysis of the same study found a dose–response relationship between caffeine 
intake and weight loss.51 In a systematic review of twenty studies on the protective 
effects of caffeine in diabetes, twelve studies reported weight loss due to caffeine 
consumption.52  This review also stated an estimated 100 kcal/day increased energy 
deficits due to habitual consumption of 7 cups of coffee (400 mg caffeine/day).52  Eight 
of these twenty studies also reported a dose-response relationship between caffeine intake 
and weight loss.52  
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Our study also reported that total fat mass was adversely affected by caffeine 
consumption. Probable mechanisms include increased basal energy expenditures (BEE) 
and the thermogenic effects of caffeine.54 Similar mechanisms were reported in a study 
done in young healthy women, where, caffeine increased BEE, even in the presence of 
genetic abnormalities predisposing to decreased BEE. The Arg allele in the beta-3 
adrenergic receptor gene (beta-3-AR) is a marker for obesity-related traits, and mutations 
in this gene leads to decreased BEE.54 In a group of women showing beta-3-AR 
Trp64Arg abnormalities, and consequently decreased BEE, an average early morning 
dose of  250 mg/day of caffeine, produced significant increase in BEE, measured by 
indirect open-circuit calorimeter at four intervals during the day, after controlling for age, 
physical activity, height, blood pressure, dietary intakes of fat, proteins, carbohydrates, 
cholesterol, fiber, BMI and lifestyle factors.54 This study showed that caffeine, 
independent of genetic predispositions to gain weight, increased resting energy 
expenditure leading to significant fat loss.54  
Our study did not find any association between body composition measures, CD4 
cell count and HIV viral load. However, higher total fat mass and higher BMI have been 
associated with better immunological and virologic profiles. Such beneficial effects were 
reported by Jones et al.,13 in a study among 871 HIV positive women followed for three 
years. Cross sectional analysis, survival analysis and longitudinal analysis revealed that, 
all five HIV disease severity outcomes such as CD4 cell count and viral load; time to ﬁrst 
occurrence of CD4 cell count ≤200 cells/mm3; ﬁrst occurrence of CD4 cell count ≤100 
cells/mm3; ﬁrst occurrence of  other infection/malignancy; and HIV-related deaths, were 
significantly delayed in women in the obese group (BMI≥35 kg/m2),  after controlling for 
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ART status, baseline BMI, baseline CD4 cell counts, attrition due to death and 
progression to AIDS, age and lifestyle factors.13  A longitudinal study conducted among 
125 HIV-1 seropositive drug users on ART showed that non-obese individuals reported 
25% decline in CD4 cell counts, compared to 18% decline in obese patients (P<0.004), 
over a period of 18 months.55 This study also showed that BMI was inversely associated 
with time towards progression to AIDS and death, after controlling for covariates such as 
ART and drug use. This study states that HIV infection constitutes a chronic hyper-
metabolic state with increased demands on existing fat reserves, which if not replenished, 
would aggravate the process of wasting.55 Many other studies have also reported that 
resting metabolic rate (RMR) was significantly higher in HIV positive patients compared 
to healthy controls, leading to energy deficits and wasting.56-58 The importance of 
preserving healthy BMI in PLWH is adequately emphasized in a review by Langford et 
al.,59 which summarized that BMI <20.3 kg/m2 in men and <18.5 kg/m2 in women were 
strong indicators of mortality due to HIV, in many racially diverse populations. This 
review also stated that BMI values 17–18 kg/m2 and < 16 kg/m2 increased the risk for 
progression to AIDS by twice and 5 times, respectively, and that BMI <18.5 kg/m2 was as 
useful as clinical staging and serological and immunological markers for decisions about 
ART initiations.59 All these studies justify the need to prevent weight loss; especially loss 
of fat mass in HIV positive patients. Therefore, high caffeine intake, a known anorectic, 
should be prevented in PLWH reporting decreased BMI, fat mass and signs of wasting. 
Our study also found that caffeine consumption was associated with lower intakes 
of several micronutrients such as Vitamin C, Thiamin, Riboflavin, Niacin, Vitamin B6, 
Vitamin B12, Iron, Zinc and Selenium.  This is consistent with previous findings reported 
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in a study of 225 HIV positive participants, where caffeine at a level of 115 mg/day was 
associated with decreased plasma levels of Zinc, after controlling for age, gender, CD4 
count, viral load and ART.20  Though the mechanisms for such findings are unclear, 
decreased dietary intakes could have precipitated such events, as supported by our study. 
Future large studies should investigate such effects to understand the bio-chemical 
mechanisms for such micronutrient depletions. Similar to what we observed in our study, 
a study by Laurie et al.,60 on 264 HIV positive and 127 un-infected participants, reported 
significantly lower intakes of Vitamin C and Vitamin E, in HIV positive participants, 
when compared to un-infected participants, after controlling for several dietary, 
behavioral and lifestyle factors. Furthermore, deficiencies of micronutrients such as Zinc 
and Selenium  have been independently associated with accelerated HIV disease 
progression and mortality risks,61,62 and caffeine intake is one more factor that could 
affect this relationship.  
In spite of the findings in this study, we have to acknowledge some of its 
limitations.  The current study enrolled a consecutive convenient sample of 130 HIV 
positive participants and the generalizability is weak. Participating in the baseline could 
also have influenced the outcomes in the follow-up visit, as the participants could have 
been affected by an “Interpersonal Expectancy Bias,” 63 by which they would have 
responded what they believed the investigators wanted to hear or the investigators would 
have recorded what they wanted to report. In addition, the 24-hour dietary recall used for 
assessing nutrient consumption is a self-reported parameter and subject to memory and 
recall biases. 
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Large scale studies should be conducted with controlled dietary and lifestyle 
factors, as well as controlled study settings, to overcome the limitations of our study. 
Though, our findings showed that caffeine intake adversely affected dietary intakes of 
several nutrients and body composition measures and, in turn, adversely affected HIV 
disease progression, these findings should be confirmed by such large scale studies. 
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption 
Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
Baseline 
Total Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 47.57±6.81 48.00±6.15 0.706 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
40 (61.5%) 
25 (38.5%) 
 
39 (60.0%) 
26 (40.0%) 
0.857 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
3 (4.6%) 
7 (10.8%) 
55 (84.6%) 
0 (0.0%) 
 
4 (6.2%) 
15 (23.1%) 
43 (66.2%) 
3 (4.6%) 
0.057 
Education in years, 
N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
24 (36.9%) 
29 (44.6%) 
12 (18.5%) 
 
 
16 (24.6%) 
30 (46.2%) 
19 (29.2%) 
0.202 
Income in dollars 
per month 
 
495.91 ± 
465.887 
464.00 ± 
419.667 
527.34 ± 
508.637 
0.442 
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Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption 
Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous 
variables   
 
Variables 
Follow-up 
Total Low 
caffeine 
intake  
(≤250 
mg/d) 
High 
caffeine 
intake  
(>250 
mg/d) 
P-value 
Age in years 
(Mean±SD) 
47.89 ± 6.37 46.63±7.33 48.87±5.38 0.490 
Gender, N (%) 
Male 
Female 
 
79 (60.8%) 
51 (39.2%) 
 
43 (68.3%) 
20 (31.7%) 
 
36 (53.7%) 
31 (46.3%) 
0.090 
Ethnicity, N (%) 
White 
Hispanic 
Black 
Other 
 
7 (5.4%) 
22 (16.9%) 
98 (75.4%) 
3 (2.3%) 
 
4 (6.3%) 
9 (14.3%) 
50 (79.4%) 
0 (0.0%) 
 
3(4.5%) 
13 (19.4%) 
48 (71.6%) 
3 (4.6%) 
0.285 
Education in years, 
N (%) 
<12 
12 
>12 
 
 
40 (30.8%) 
59 (45.4%) 
31 (23.8%) 
 
 
21 (33.3%) 
29 (46.0%) 
13 (20.6%) 
 
 
19 (28.4%) 
30 (44.8%) 
18 (26.9%) 
0.670 
Income in dollars 
per month 
 
495.91 ± 
465.887 
498.80 ± 
511.708 
492.89 ± 
416.619 
0.943 
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Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels  
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables 
ART: Antiretroviral therapy.  
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
 P-
value 
Smoking cigarettes 
Yes 
No 
 
80 (63.5%) 
46 (36.5%) 
 
39 (60.9%) 
25 (39.1%) 
 
41 (66.1%) 
21 (33.9%) 
0.582 
Alcohol use 
Yes 
No 
 
73 (57.9%) 
53 (42.1%) 
 
36 (56.3%) 
28 (43.8%) 
 
37 (59.7%) 
25 (40.3%) 
0.721 
Drug use 
Yes 
No 
 
53 (48.2%) 
57 (51.8%) 
 
25 (43.9%) 
32 (56.1%) 
 
28 (52.8%) 
25 (47.2%) 
0.445 
Marijuana 
Yes 
No 
 
44 (33.8%) 
86 (66.2%) 
 
21 (32.3%) 
44 (67.7%) 
 
23 (35.4%) 
42 (64.6%) 
0.853 
Cocaine 
Yes 
No 
 
41 (31.5%) 
89 (68.5%) 
 
19 (29.2%) 
46 (70.8%) 
 
22 (33.8%) 
43 (66.2%) 
0.706 
Other Drugs 
Yes 
No 
 
10 (9.1%) 
100 
(90.9%) 
 
6 (10.5%) 
51 (89.5%) 
 
4 (7.5%) 
49 (92.5%) 
0.744 
ART     
Multi-combination 
Yes 
No 
 
34 (26.2%) 
96 (73.8%) 
 
22 (33.8%) 
43 (66.2%) 
 
12 (18.5%) 
53 (81.5%) 
0.072 
NRTI 
Yes 
No 
 
76 (58.5%) 
54 (41.5%) 
 
40 (61.5%) 
25 (38.5%) 
 
36 (55.4%) 
29 (44.6%) 
0.594 
NNRTI 
Yes 
No 
 
17 (13.1%) 
113 
(86.9%) 
 
10 (15.4%) 
55 (84.6%) 
 
7 (10.8%) 
58 (89.2%) 
0.604 
PI 
Yes 
No 
 
62 (47.7%) 
68 (52.3%) 
 
34 (52.3) 
31 (47.7%) 
 
28 (43.1%) 
37 (56.9%) 
0.380 
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Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine 
Consumption Levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests all variables. 
ART: Antiretroviral therapy.  
 
 
Variables Total Low caffeine 
intake  
(≤250 mg/d) 
High caffeine 
intake  
(>250 mg/d) 
P-
value 
Smoking 
cigarettes 
Yes 
No 
 
79 (63.2%) 
46 (36.8%) 
 
41 (68.3%) 
19 (31.7%) 
 
38 (58.5%) 
27 (41.5%) 
0.271 
Alcohol use 
Yes 
No 
 
76 (60.3%) 
50 (39.7%) 
 
34 (56.7%) 
26 (43.3%) 
 
42 (63.6%) 
24 (36.4%) 
0.469 
Drug use 
Yes 
No 
 
79 (65.8%) 
41 (34.2%) 
 
45 (75.0%) 
15 (25.0%) 
 
34 (56.7%) 
26 (43.3%) 
0.054 
Marijuana 
Yes 
No 
 
67 (55.8%) 
53 (44.2%) 
 
38 (63.3%) 
22 (36.7%) 
 
29 (48.3%) 
31 (51.7%) 
0.141 
Cocaine 
Yes 
No 
 
48 (40.0%) 
72 (60.0%) 
 
29 (48.3%) 
31 (51.7%) 
 
19 (31.7%) 
41 (68.3%) 
0.093 
Other drugs 
Yes 
No 
 
13 (10.9%) 
106 
(89.1%) 
 
6 (10.0%) 
54 (90.0%) 
 
7 (11.9%) 
52 (88.1%) 
0.496  
ART     
Multi-combination 
Yes 
No 
 
33 (25.4%) 
97 (74.6%) 
 
20 (31.7%) 
43 (68.3%) 
 
13 (19.4%) 
54 (80.6%) 
0.113 
NRTI 
Yes 
No 
 
83 (63.8%) 
47 (36.2%) 
 
40 (63.5%) 
23 (36.5%) 
 
43 (64.2%) 
24 (35.8%) 
1.000 
NNRTI 
Yes 
No 
 
18 (13.8%) 
112 
(86.2%) 
 
9 (14.3%) 
54 (85.7%) 
 
9 (13.4%) 
58 (86.6%) 
1.000 
PI 
Yes 
No 
 
62 (47.7%) 
68 (52.3%) 
 
28 (44.4%) 
35 (55.6%) 
 
34 (50.7%) 
33 (49.3%) 
0.488 
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Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit  
All variables reported as mean ± SD 
Note: P-values correspond to t-tests for all variables 
*Significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Food source Baseline Follow-up P-value 
Coffee 161.26 ± 194.95 190.40 ± 205.03 0.206 
De-Caffeinated coffee 0.83 ± 9.21 0.03 ± 0.43 0.329 
Expresso 14.40 ± 64.35 13.92 ± 57.82 0.942 
Tea 34.70 ± 64.32 31.58 ± 59.36 0.640 
Green tea 7.34 ± 62.93 4.20 ± 21.62 0.594 
Energy drinks 46.32 ± 134.42 9.61 ± 65.32 0.005* 
Hot cocoa 1.03 ± 5.00 0.00 ± 0.00 0.020* 
Caffeinated soft drinks 63.23 ± 92.98 29.66 ± 83.78 <0.0001* 
Chocolate candy bars 3.69 ± 13.81 2.00 ± 17.93 0.402 
Anacin  0.24 ± 2.80 0.00 ± 0.00 0.319 
Appetite control pills  4.61 ± 39.10 0.00 ± 0.00 0.181 
Total 337.63 ± 304.97 281.04 ± 260.85 0.890 
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Table 5: Baseline: Mean Nutrient Intakes by Levels of Caffeine Consumption  
 
Nutrient Caffeine intake P-valuea 
Low High 
Total Calorie 1911.84 ± 1045.674 2038.36 ± 945.830 0.791 
Total 
Carbohydrate  
341.83 ± 133.437 259.15 ± 132.242 0.048* 
Protein  94.82 ± 54.556 85.24 ± 40.866 0.046* 
Total Fat 170.94 ± 44.585 93.43 ± 48.484 0.048* 
Saturated Fat  23.02 ± 15.899 24.51 ± 16.667 0.602 
Cholesterol  359.27 ± 286.033 374.97 ± 304.754 0.762 
Dietary Fiber  12.18 ± 9.783 13.06 ± 9.346 0.599 
Sodium  3932.89 ± 2666.521 3177.54 ± 1756.021 0.016* 
Chloride 8.93 ± 4.000 5.23 ± 4.172 0.032* 
Potassium 1751.09 ± 1245.598 1437.63 ± 999.103 0.018* 
Calcium  999.60 ± 466.681 651.53 ± 448.444 0.049* 
Magnesium 177.62 ± 38.055 144.61 ± 84.679 0.010* 
Phosphorus  856.29 ± 549.057 760.73 ± 491.577 0.030* 
Vitamin A† 6259.44 ± 10687.908 5503.70 ± 10197.283 0.475 
Vitamin C† 110.38 ± 141.475 61.68 ± 71.914 0.029* 
Vitamin D† 77.13 ± 92.950 75.54 ± 93.053 0.659 
Vitamin E† 1.12 ± 5.307 1.53 ± 4.980 0.266 
Vitamin K† 23.67 ± 29.992 30.22 ± 69.443 0.631 
Thiamin  2.33 ± 1.762 1.08 ± 0.714 0.028* 
Riboflavin 2.47 ± 1.037 1.29 ± 1.286 0.037* 
Niacin  26.95 ± 13.737 17.14 ± 13.124 0.044* 
Vitamin B6 1.44 ± 1.168 1.01 ± 0.904 0.022* 
Folate  268.90 ± 226.207 258.16 ± 207.074 0.778 
Vitamin B12 13.91 ± 4.189 5.75 ± 2.452 0.046* 
Pantothenic 
Acid  
3.57 ± 2.192 3.57 ± 2.985 0.994 
Iodine†  4.39 ± 7.979 4.74 ± 33.746 0.994 
Iron  34.46 ± 9.319 25.80 ± 11.356 0.046* 
Zinc  9.13 ± 1.774 4.64 ± 1.753 0.027* 
Selenium  76.61 ± 5.797 45.27 ± 5.837 0.029* 
Copper† 0.77 ± 0.688 1.19 ± 4.261 0.426 
Manganese  1.42 ± 1.419 1.59 ± 1.343 0.487 
Chromium†  1.11 ± 6.354 0.41 ± 2.603 0.975 
Molybdenum† 0.65 ± 3.705 0.31 ± 2.481 0.555 
All variables reported as mean ± SD 
a P-values correspond to t- tests for all variables 
†Mann-Whitney U test was used for comparison because the variables were not normally 
distributed.  
*Significant 
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Table 6:  Follow-up: Mean Nutrient Intakes by Levels of Caffeine Consumption  
 
Nutrient Caffeine intake P-valuea 
Low High 
Total Calorie 2100.52 ± 1127.868 1858.27 ± 932.055 0.017* 
Total 
Carbohydrate  
255.27 ± 152.914 151.32 ± 116.795 0.042* 
Protein  86.49 ± 42.173 43.48 ± 37.841 0.017*  
Total Fat 183.72 ± 68.771 77.52 ± 56.469 0.026*  
Saturated Fat† 30.45 ± 35.212 44.84 ± 178.663 0.121 
Cholesterol  419.85 ± 347.931 300.71 ± 227.419 0.024* 
Dietary Fiber† 13.45 ± 18.933 13.06 ± 7.673 0.163 
Sodium  3911.67 ± 1857.343 3239.20 ± 2049.984 0.018* 
Chloride†  42.54 ± 212.929 15.22 ± 70.847 0.638 
Potassium 1482.16 ± 1264.208 666.63 ± 598.147 0.036* 
Calcium  689.22 ± 480.232 705.43 ± 37.815 0.857 
Magnesium 165.88 ± 109.738 169.48 ± 122.184 0.897 
Phosphorus  818.62 ± 587.809 771.74 ± 508.395 0.627 
Vitamin A†  5285.28 ± 13851.995 5153.94 ± 12370.864 0.334 
Vitamin C†  65.42 ± 91.662 79.52 ± 84.668 0.150 
Vitamin D† 96.57 ± 107.881 75.12 ± 91.308 0.293 
Vitamin E† 4.58 ± 19.808 2.00 ± 8.892 0.241 
Vitamin K† 24.76 ± 36.634 31.95 ± 56.458 0.993 
Thiamin  2.16 ± 1.055 1.05 ± 0.681 0.044* 
Riboflavin 12.54 ± 1.755 8.24 ± 2.521 0.036* 
Niacin  18.69 ± 5.191 5.61 ± 1.769 0.034* 
Vitamin B6 2.34 ± 1.446 1.38 ± 0.875 0.048*  
Folate†  288.24 ± 297.962 286.71 ± 178.391 0.180 
Vitamin B12† 6.84 ± 30.140 4.04 ± 9.221 0.672 
Pantothenic acid  3.99 ± 3.748 3.27 ± 1.868 0.176 
Iodine† 6.06 ± 25.970 2.27 ± 11.227 0.402 
Iron  17.31 ± 7.898 14.67 ± 8.972 0.285 
Zinc  9.61 ± 3.021 7.91 ± 5.847 0.244 
Selenium  71.57 ± 52.860 69.47 ± 59.698 0.833 
Copper† 1.63 ± 6.081 20.54 ± 161.78 0.958 
Manganese† 1.97 ± 5.313 23.98 ± 184.300 0.212 
Chromium†  3.51 ± 14.574 11.52 ± 83.442 0.668 
Molybdenum†   3.48 ± 13.972 1.18 ± 5.810 0.392 
All variables reported as mean ± SD 
a P-values correspond to t- tests for all variables 
†Mann-Whitney U test was used for comparison because the variables were not normally 
distributed 
*Significant 
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Table 7: Differences in Mean Nutrient Intake between Baseline and Follow-Up Visit  
 
Nutrient  P-
value BL FU 
Total Calorie 1981.84 ± 1024.674 2098.84 ± 1032.674 0.838 
Total Carbohydrate  250.49 ± 132.610 253.23 ± 134.986 0.835 
Protein  84.72 ± 48.069 84.95 ± 39.887 0.962 
Total Fat 72.18 ± 46.411 80.52 ± 62.563 0.143 
Saturated Fat  23.77 ± 16.242 37.87 ± 13.305 0.214 
Cholesterol  367.12 ± 94.499 358.45 ± 97.012 0.788 
Dietary Fiber  12.62 ± 9.540 13.25 ± 4.228 0.671 
Sodium  3105.22 ± 2250.051 3274.32 ± 1951.772 0.401 
Chloride 120.62 ± 29.820 128.46 ± 56.673 0.058 
Potassium 1594.36 ± 1135.664 1577.23 ± 1134.212 0.889 
Calcium  625.57 ± 456.621 697.58 ± 408.816 0.183 
Magnesium 161.11 ± 115.273 167.73 ± 117.936 0.674 
Phosphorus  808.51 ± 521.298 794.46 ± 546.676 0.810 
Vitamin A  5881.57 ± 1411.824 5217.59 ± 1058.457 0.656 
Vitamin C  86.03 ± 14.427 72.69 ± 18.067 0.247 
Vitamin D 76.34 ± 42.644 85.52 ± 49.874 0.419 
Vitamin E 1.32 ± 0.130 3.25 ± 1.189 0.168 
Vitamin K 26.95 ± 5.381 28.46 ± 4.842 0.808 
Thiamin  1.21 ± 0.345 1.11 ± 0.880 0.462 
Riboflavin 1.38 ± 0.167 4.99 ± 1.299 0.320 
Niacin  18.04 ± 13.413 27.41 ± 11.594 0.296 
Vitamin B6 1.22 ± 0.062 1.36 ± 0.182 0.298 
Folate  263.53 ± 216.077 287.45 ± 242.801 0.371 
Vitamin B12 4.83 ± 1.192 5.40 ± 1.957 0.811 
Pantothenic acid  3.57 ± 2.608 3.62 ± 2.944 0.880 
Iodine  3.07 ± 2.483 4.11 ± 1.805 0.707 
Iron  15.13 ± 10.369 15.95 ± 10.032 0.588 
Zinc  8.88 ± 2.737 8.73 ± 2.154 0.868 
Selenium  75.94 ± 56.600 70.49 ± 56.280 0.360 
Copper  9.98 ± 3.048 11.38 ± 6.183 0.309 
Manganese  1.50 ± 0.379 3.31 ± 2.339 0.311 
Chromium  8.76 ± 4.849 7.64 ± 3.667 0.200 
Molybdenum  6.48 ± 3.145 12.29 ± 8.603 0.060 
All variables reported as mean ± SD. 
Note: P-values correspond to t- tests for all variables 
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Table 8: Baseline, PLWH with Nutrient Intakes below Daily Values (DV) by Levels of 
Caffeine Consumption  
  
Nutrient Total Caffeine intake P-value 
 Low High 
Total Calorie 70 (53.8%) 36 (55.4%) 34 (52.3%) 0.860 
Total Carbohydrate  92 (70.8%) 45 (69.2%) 47 (72.3%) 0.700 
Protein  29 (22.7%) 18 (28.1%) 11 (17.2%) 0.139 
Total Fat 61 (47.3%) 33 (50.8%) 28 (43.8%) 0.425 
Saturated Fat  58 (46.4%) 32 (50.8%) 26 (41.9%) 0.321 
Cholesterol  71 (54.6%) 36 (55.4%) 35 (53.8%) 0.860 
Dietary Fiber  114 (87.7%) 56 (86.2%) 58 (89.2%) 0.593 
Sodium  23 (17.7%) 16 (24.6%) 7 (10.8%) 0.039* 
Chloride† 130 (100%) 65 (100%) 65 (100%) N/A 
Potassium 119 (91.5%) 57 (87.7%) 62 (95.4%) 0.115 
Calcium  106 (81.5%)  54 (83.1%) 52 (80.0%) 0.651 
Magnesium 126 (96.9%) 62 (95.4%) 64 (98.5%) 0.310 
Phosphorus  93 (71.5%) 43 (66.2%) 50 (76.9%) 0.174 
Vitamin A  95 (73.1%) 45 (69.2%) 50 (76.9%) 0.323 
Vitamin C  73 (56.2%) 31 (47.7%) 42 (64.6%) 0.052 
Vitamin D 127 (97.7%) 64 (98.5%) 63 (96.9%) 0.559 
Vitamin E 127 (97.7%) 63 (96.9%) 64 (98.5%) 0.599 
Vitamin K 119 (91.5%) 59 (90.8%) 60 (92.3%) 0.753 
Thiamin  96 (73.8%) 46 (70.8%) 50 (76.9%) 0.425 
Riboflavin 88 (68.8%) 41 (63.1%) 47 (74.6%) 0.160 
Niacin  81 (62.8%) 39 (60.9%) 42 (64.6%) 0.666 
Vitamin B6 102 (78.5%) 47 (72.3%) 55 (84.6%) 0.088 
Folate  106 (81.5%) 53 (81.5%) 53 (81.5%) 1.000 
Vitamin B12 108 (84.4%) 52 (81.3%) 56 (87.5%) 0.330 
Pantothenic acid  127 (98.4%) 64 (98.5%) 63 (98.4%) 0.991 
Iodine  129 (00.2%) 65 (100%) 64 (98.5%) 0.315 
Iron  87 (68.0%) 46 (70.8%) 41 (65.1%) 0.490 
Zinc  106 (82.8%) 51 (81.0%) 55 (84.6%) 0.583 
Selenium  66(50.8%) 33 (50.8%) 33 (50.8%) 1.000 
Copper  126 (96.9%) 63 (96.9%) 63 (96.9%) 1.000 
Manganese  86 (66.2%) 47 (72.3%) 39 (60.0%) 0.138 
Chromium† 130 (100%) 65 (100%) 65(100%) N/A 
Molybdenum† 130 (100%) 65 (100%) 65 (100%) N/A 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables 
† Pearson’s Chi-Square test could not be done because all participants reported 
consumption below Daily Values (DV) for the nutrient. 
*Significant 
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Table 9: Follow-Up, PLWH with Nutrient Intakes below Daily Values (DV) by Levels of 
Caffeine Consumption  
 
Nutrient Total Caffeine intake P-value 
 Low High 
Total Calorie 72 (55.8%) 33 (52.4%) 39 (59.1%) 0.481 
Total Fat 62 (47.7%) 24 (38.1%) 38 (56.7%) 0.034* 
Saturated Fat  56 (43.1%) 25 (39.7%) 31 (46.3%) 0.449 
Cholesterol  72 (55.4%) 31 (49.2%) 41 (61.2%) 0.169 
Sodium  14 (10.8%) 6 (9.5%) 8 (11.9%) 0.657 
Potassium 121 (93.1%) 57 (90.5%) 64 (95.5%) 0.257 
Total 
Carbohydrate 
95 (73.1%) 43 (68.3%) 52 (77.6%) 0.229 
Dietary Fiber  119 (92.2%) 58 (92.1%) 61 (92.4%) 0.939 
Protein  19 (14.7%) 11 (17.5%) 8 (12.1%) 0.392 
Vitamin A  102 (78.5%) 52 (82.5%) 50 (74.6%) 0.273 
Vitamin C  76 (58.9%) 39 (62.9%) 37 (55.2%) 0.376 
Calcium  100 (76.9%) 48 (76.2%) 52 (77.6%) 0.848 
Iron  87 (66.9%) 40 (63.5%) 47 (70.1%) 0.420 
Vitamin D 129 (99.2%) 62 (98.4%) 67 (100%) 0.301 
Vitamin E 124 (95.4%) 60 (95.2%) 64 (95.5%) 0.938 
Vitamin K 119 (91.5%) 60 (95.2%) 59 (88.1%) 0.142 
Thiamin  100 (78.1%) 49 (79.0%) 51 (77.3%) 0.810 
Riboflavin 91 (71.7%) 43 (70.5%) 48 (72.7%) 0.780 
Niacin  78 (61.9%) 39 (65.0%) 39 (59.1%) 0.495 
Vitamin B6 95 (73.1%) 49 (77.8%) 46 (68.7%) 0.241 
Folate  104 (80%) 52 (82.5%) 52 (77.6%) 0.483 
Vitamin B12 109 (84.5%) 55 (87.3%) 54 (81.8%) 0.390 
Pantothenic acid  126 (97.7%) 59 (95.2%) 67 (100%) 0.068 
Phosphorus  91 (70.0%) 43 (68.3%) 48 (71.6%) 0.674 
Iodine  129 (99.2%) 62 (98.4%) 67 (100%) 0.301 
Magnesium 123 (94.6%) 59 (93.7%) 64 (95.5%) 0.637 
Zinc  109 (83.8%) 51 (81.0%) 58 (86.6%) 0.385 
Selenium  75 (57.7%) 35 (55.6%) 40 (59.7%) 0.633 
Copper  116 (89.2%) 54 (85.7%) 62 (92.5%) 0.210 
Manganese  81 (62.3%) 43 (68.3%) 38 (56.7%) 0.175 
Chromium  129 (99.2%) 63 (100%) 66 (98.5%) 0.330 
Molybdenum  129 (99.2%) 62 (98.4%) 67 (100%) 0.301 
Chloride† 130 (100%) 63 (100%) 67 (100%) N/A 
All variables reported as N (%) 
Note: P-values correspond to χ2 tests for all variables 
† Pearson’s Chi-Square test could not be done because all participants reported 
consumption below recommended daily values for the nutrient. 
*Significance
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Table 10: Linear Regression of the Effect of Caffeine Consumption on Body 
Composition Measures and Nutritional Indicators  
 
Body 
Composition 
Variables 
                 Unadjusted                      Adjusted† 
 β SE P-value β SE P-value 
Waist/Hip ratio -2.200 1.042 0.920 -2.345 1.190 0.573 
BMI lbs/in2 -0.001 0.002 0.648 -0.002 0.002 0.064 
LBM lbs  -0.001 0.007 0.885 0.002 0.007 0.761 
Fat mass lbsb -0.449 0.774 0.058 -0.994 0.737 0.042* 
Hemoglobin g/dl 0.027 0.007 0.706 -0.029 0.008 0.503 
Hematocrit % 0.001 0.002 0.708 -0.001 0.001 0.667 
Albumin g/dl 0.001 0.001 0.361 0.004 0.001 0.604 
aModel R2 = 0.187, F (16) = 25.075, P = .039.   
bModel R2 = 0.155, F (16) = 24.292, P = .034.   
†Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
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Table 11:  Linear Mixed Model (LMM) Analysis of Over Time Changes in Body 
Composition Measures and Nutritional Indicators due to Caffeine Consumption  
  
Body 
Composition 
Variables 
                 Unadjusted                      Adjusted† 
 β SE P-value β SE P-value 
Waist/Hip 
ratio 
0.268 0.875 0.113 0.389 0.987 0.095 
BMI lbs/in2b -1.310 0.870 0.647 0.987 0.910 0.532 
LBM lbs  -0.477 0.332 0.815 -0.363 0.377 0.338 
Fat mass lbs -0.001 0.003 0.958 -1.987 0.910 0.035* 
Hemoglobin 
g/dl 
-0.003 0.004 0.425 0.002 0.002 0.265 
Hematocrit % 0.0007 0.001 0.463 0.0004 0.0006 0.532 
Albumin g/dl 0.0002 0.0003 0.571 0.00020 0.0004 0.533 
aModel: -2 Restricted Log Likelihood = 1832.170; Akaike’s Information Criteria (AIC) = 
1836.170; Schwarz’s Bayesian Criteria (BIC) = 1842.716. 
bModel: -2 Restricted Log Likelihood = 1252.041; Akaike’s Information Criteria (AIC) = 
1256.014; Schwarz’s Bayesian Criteria (BIC) = 1262.539. 
†Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
 
Table 12: Linear Regression of the Effect of Caffeine Consumption on Macronutrient 
Consumption  
 
Macronutrient 
Intake 
Unadjusted Adjusted† 
β SE P-
value 
β SE P-value 
Total Kcala -1.071 1.208 0.644 -1.643 1.491 0.042* 
Kcal from Protein -0.065 0.056 0.247 -0.078 0.072 0.277 
Kcal from Carbs 0.604 0.152 0.692 -0.972 0.178 0.956 
Kcal from Fatsb  -1.043 0.121 0.647 -1.902 0.155 0.044* 
aModel R2 = 0.213, F (16) = 35.707, P= 0.038.   
bModel R2 = 0.185, F (16) = 30.681, P= .0.008. 
cModel R2 = 0.185, F (16) = 16.300, P= 0.022.  
†Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
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Table 13: Linear Mixed Model (LMM) Analysis of Over Time Changes in Macronutrient 
Consumption due to Caffeine Consumption  
 
Food Intake and 
Food Security 
Variables 
Unadjusted Adjusted† 
β SE P-
value 
β SE P-
value 
Total Kcal  -0.933 0.821 0.257 -0.402 0.942 0.670 
Kcal from Protein  0.013 0.049 0.784 0.039 0.058 0.506 
Kcal from Carbs   -0.099 0.108 0.361 -0.079 0.116 0.497 
Kcal from Fats  -0.895 0.991 0.367 -0.317 0.118 0.789 
aModel: -2 Restricted Log Likelihood = 1761.542; Akaike’s Information Criteria (AIC) = 
1765.542; Schwarz’s Bayesian Criteria (BIC) = 1772.088. 
†Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol 
consumption, smoking status and types of ART medications. 
*Significant 
 
 
Table 14: Linear Regression of the Effect of Body Composition Measures and 
Macronutrient Intake on CD4 Cell Count   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aModel R2 = 0.159, F (14) = 23.773, P= .047.   
bModel R2 = 0.174, F (14) = 16.379, P = .042. 
†Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use, 
HIV viral load. 
Body 
Composition, and 
Macronutrient 
consumption  
                 Unadjusted                      Adjusted† 
β SE P-
value 
β SE P-
value 
BMI lbs/in2a 1.225 1.010 0.643 1.568 1.149 0.325 
Fat mass lbsb 1.653 1.226 0.085 2.028 1.034 0.404 
Total Kcal   1.209 0.147 0.158 0.137 0.169 0.422 
Kcal from Protein -1.658 1.344 0.058 -0.005 0.004 0.202 
Kcal from Carbs   -1.103 1.012 0.391 -0.001 0.001 0.485 
Kcal from Fats  1.267 1.001 0.485 1.185 1.016 0.262 
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Table 15: Linear Regression of the Effect of Body Composition Measures and 
Macronutrient Intake on HIV Viral Load  
 
 
 
 
 
 
 
 
 
 
 
aModel: -2 Restricted Log Likelihood = 1129.609; Akaike’s Information Criteria (AIC) = 
1133.609; Schwarz’s Bayesian Criteria (BIC) = 1139.868. 
bModel: -2 Restricted Log Likelihood = 1136.666; Akaike’s Information Criteria (AIC) = 
1140.666; Schwarz’s Bayesian Criteria (BIC) = 1146.937. 
†Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use, 
HIV viral load. 
 
 
Table 16: . Linear Mixed Model (LMM) Analysis of Over Time Changes in CD4 Cell 
Counts due to changes in Body Composition Measures and Macronutrient intakes  
cModel R2 = 0.189, F (14) = 19.612, P = .036.   
dModel R2 = 0.182, F (14) = 18.560, P = .048.   
†Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use and 
CD4 cell counts. 
Body Composition, 
and Macronutrient 
consumption  
                 Unadjusted             Adjusted† 
β SE P-
value 
β SE P-value 
BMI lbs/in2a 0.151 0.076 0.068 0.972 0.486 0.567 
Fat mass lbsb 0.592 0.176 0.052 0.936 0.223 0.056 
Total Kcal   0.219 0.097 0.625 0.901 0.710 0.624 
Kcal from Protein  -0.786 0.153 0.609 -0.987 0.155 0.994 
Kcal from Carbs   -0.915 0.757 0.347 -0.934 0.857 0.517 
Kcal from Fats  0.930 0.765 0.226 0.965 0.794 0.827 
Body Composition, 
and Macronutrient 
consumption  
Unadjusted Adjusted† 
β SE P-
value 
β SE P-
value 
BMI lbs/in2c -0.048 0.023 0.142 -0.033 0.031 0.430 
Fat mass lbsd -0.010 0.005 0.248 -0.053 0.007 0.347 
Total Kcal  0.988 0.346 0.858 1.032 0.360 0.389 
Kcal from Protein  0.420 0.075 0.956 0.800 0.084 0.344 
Kcal from Carbs   0.780 0.258 0.764 0.835 0.308 0.257 
Kcal from Fats  -0.924 0.032 0.939 -0.930 0.035 0.390 
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Table 17: . Linear Mixed Model (LMM) Analysis of Over Time Changes in HIV Viral 
Load due to changes in Body Composition Measures and Macronutrient intakes  
cModel: -2 Restricted Log Likelihood = 1605.359; Akaike’s Information Criteria (AIC) = 
1609.359; Schwarz’s Bayesian Criteria (BIC) = 1615.595. 
dModel: -2 Restricted Log Likelihood = 1609.316; Akaike’s Information Criteria (AIC) = 
1613.316; Schwarz’s Bayesian Criteria (BIC) = 1619.564. 
†Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use and 
CD4 cell counts. 
 
 
Body Composition, 
and 
Macronutrient 
consumption 
                 Unadjusted             Adjusted† 
β SE P-value β SE P-value 
BMI lbs/in2c -0.463 0.026 0.324 -0.013 0.018 0.322 
LBM lbs  -0.304 0.380 0.793 -0.532 0.483 0.261 
Fat mass lbsd -0.810 0.472 0.456 -0.724 0.485 0.314 
Total Kcal -0.158 0.121 0.253 -0.586 0.123 0.845 
Kcal from Protein  -0.214 0.134 0.740 -0.189 0.035 0.922 
Kcal from Carbs   0.218 0.137 0.155 0.515 0.192 0.421 
Kcal from Fats  0.974 0.547 0.622 -0.834 0.851 0.851 
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CHAPTER-VII: SUMMARY AND CONCLUSIONS 
The present study characterized a consecutive convenience sample of 130 
PLWH (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of 
caffeine), recruited from the MASH cohort, and investigated for the effects of 
caffeine consumption on parameters of HIV disease progression crosssectionally 
and over time. Additionally, this study examined the effects of caffeine 
consumption on behavioral and nutritional parameters. The behavioral outcomes 
evaluated included sleep quality, insomnia levels and generalized anxiety 
symptoms. The nutritional parameters examined were nutrient intake, 
anthropometrics and body composition measures. Finally, this study explored the 
net combined impact of the behavioral and nutritional variables on HIV disease 
progression both crosssectionally and over time.   
The mean caffeine consumption for our cohort was 338 mg/day during the 
baseline visit and 281 mg/day during the 3-month follow-up visit, and was higher 
than US average of 200 mg/day during both the visits. 1-3 Caffeine intake from 
coffee was also higher than the US average of 135 mg/day during both visits. The 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) considers 
consumption below 250 mg/day to be generally safe and not associated with any 
adverse effect.4 Considering this recommendation, it is concerning that our cohort 
reported a higher than safe, mean levels of caffeine consumption during both the 
study visits.  
The majority of the demographic findings of the current study were 
epidemiologically similar to those described by others in Miami-Dade County.5,6 
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Most of the participants were African Americans (75.4%). All participants had 
incomes under the level of poverty and the mean income was $495.91± 465.887 
per month. More than half of the participants in our cohort were consuming 
alcohol and smoking cigarettes, and slightly less than half had a positive urine 
toxicology result for illicit drugs. Our results suggested that higher caffeine was 
associated with higher CD4 cell counts and lower viral load cross-sectionally, 
adjusting for co-variates such as age, gender, education, income, time from 
diagnosis of HIV, substance use, different types of ART medications, BMI and 
total fat mass.  Higher caffeine consumption was also associated with higher CD4 
cell counts and better control over viral loads, when observed over time after 3-
months, adjusting for the same covariates. Higher caffeine consumption was also 
associated with lower sleep quality, higher insomnia levels and higher generalized 
anxiety symptoms, both crosssectionally and over time, adjusting for the 
covariates. Approximately half of all participants reported inadequate dietary 
intakes for many micronutrients during both the visits, independent of the effects 
of caffeine. Higher caffeine intake was additionally associated with lower dietary 
intakes of many nutrients and lower fat mass. Our results were paradoxical 
because higher caffeine intakes were associated with improvements in parameters 
of disease progression, but indirectly also precipitated adverse outcomes, since 
higher caffeine intakes were associated with worsening behavioral and nutrition 
measures. High caffeine intakes seemed to improve the recuperation of CD4 cells 
and facilitated control over HIV viral load, whereas, caffeine also precipitated 
many adverse outcomes associated with HIV disease progression such as 
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worsening sleep quality, increased insomnia and generalized anxiety levels, and 
compromised dietary intakes and body composition measures and consequently 
worsening HIV disease progression. These paradoxical and inconsistent findings 
open new hypotheses for future large scale studies to shed light on other 
behavioral and bio-chemical mechanisms responsible for these findings.  
The majority of the adverse effects of caffeine became apparent, only after 
controlling for covariates associated with HIV disease progression, suggesting a 
mild but complex effects of caffeine on the adverse outcomes observed in this 
study.  Caffeine can only be implicated in mediating and moderating the adverse 
and beneficial effects of other co-variates (with higher β coefficients) such as 
cocaine and methamphetamine use and antiretroviral medications which have 
greater effects on HIV disease progression parameters.  
  Our study reported decrease in mean caffeine consumption from 338 
mg/day during baseline visit, to 281 mg/day during follow-up visit, though not 
statistically significant. Caffeine intakes from caffeinated soft drinks and energy 
drinks also decreased significantly, from 63 mg/day to 30 mg/day and 46 mg/day 
to 10 mg/day, respectively, from the baseline to the 3-month follow-up visit. Over 
three months, the effects of behavioral outcomes such as poor sleep quality, 
insomnia, and generalized anxiety symptoms, on CD4 counts and viral load 
diminished and lost statistical significance, thereby indicating decreasing effects 
of these behavioral outcomes on HIV disease progression. These observations 
could have been incidental findings or due to self-motivated changes in dietary 
and lifestyle factors, and better compliance to medications, ascribable to the 
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stimulant effect of caffeine, the free nutritional advice and counselling provided 
during the visits, which would have facilitated better immune recuperation and 
decreased disease progression. There is a possibility that such changes could also 
be due to the ‘Hawthorn Effect’, where participants improved their behaviors in 
response to the awareness of being observed by our study.7 These findings 
suggest other approaches for improving the health and nutritional outcomes in 
PLWH. In addition to restricted consumption of anorectic agents such as caffeine, 
improved nutritional advice, dietary counseling and lifestyle-modifications could 
be associated with alleviating some of the adverse outcomes reported in our study.   
Since almost half of the participants reported illicit drugs use and more 
than half of the participants reported alcohol use and smoking, the combined 
effects of these substances could far outweigh the adverse effects of caffeine, 
because many studies have associated substance use with adverse health and 
nutritional consequences in HIV.8-11 Alcohol, drug and smoking cessation 
interventions should accompany nutritional and dietary counseling initiatives in 
order to achieve better immunologic and virologic profiles and thereby adequate 
control over disease progression in this vulnerable population of PLWH. 
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CHAPTER VIII: STRENGTHS AND LIMITATIONS 
The greatest strength of our study is filling the gap in the literature on the 
health effects of caffeine in PLWH, by examining the relationship of caffeine 
consumption with parameters of disease progression, and with behavioral and 
nutritional outcomes in this vulnerable population. For the first time, we identified 
paradoxical findings in the relationship of caffeine intake with HIV disease 
progression.  
The current study followed a quasi-experimental design and gathered data 
from a baseline and 3-month follow-up visit, and two MASH cohort study visits. 
Because of the prospective observational characteristic of this study, changes in 
associations over time could be measured and a number of causal associations 
could be determined, controlling for the pertinent covariates. This greatly 
contributed to the strengths of the study, because, not only cross-sectional 
associations but also the causal effects with dose-response relationships were 
reported for many outcome variables. Large scale experimental and interventional 
studies planned in the future could benefit from our understandings on the effects 
of caffeine on the outcome variables researched in our study.  
Our study recorded one hundred percent response rates to all components 
and questionnaires for both the study visits, thereby eliminating non-response and 
attrition biases. All the questionnaires used in the current study were field tested 
and validated in large scale studies.1-5 Our participants were recruited from the 
MASH cohort and comprehensive protocols were already developed and 
instituted for the MASH studies, thereby greatly facilitating precise data 
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collecting procedures for the current study. All the data were collected and quality 
assured by trained dietitians, nutritionists and registered nurses with substantial 
experience in health-science research. Moreover, there were no adverse events or 
compromised participant compliance with the visits, during the entire duration of 
the current study. All these factors added to the validity and reliability of the data 
gathered during the study. 
In spite of the planned research design and implementation, there were 
some limitations. The current study enrolled a consecutive convenient sample of 
130 HIV positive participants from the MASH cohort, attending their treatment 
visits at BHCC. This sample of frequent health care utilizers would have been 
different form the population of PLWH in the United States. As this was not a 
random sample from the total population of PLWH, our findings are not 
generalizable, thus limiting the external validity of our study. In addition, many 
un-accounted confounders beyond the ones controlled in the current study and 
gathered in the MASH cohort studies, could have affected our results, thereby 
limiting the internal validity of our findings. Experimental designs such as 
randomized controlled trials, which have complete control over the study 
variables, a comparable control arm, and high internal validity, should be planned 
in the future to overcome these limitations and ascertain the findings of our study. 
In the current study, there were two time points when the data was 
gathered, and carryover effects from the initial baseline visit could have affected 
the outcomes during the follow-up visit. Since these participants were followed 
for a long time (2002 - 2014) for MASH cohort study visits, some carry-over 
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effects from the MASH cohort studies could have also affected the findings in our 
study. Biases such as the Pygmalion effect and the Golem effect,6 by which 
participants tend to improve or moderate their responses to the outcome measures, 
after learning about the expectations of the research and the research personnel, 
could have affected our study. Biases such as the Hawthorne effect,7 by which, 
participants could have modified their health and nutritional outcomes, because of 
being monitored by the studies, could have also affected our study findings. In 
addition, the participants could have been affected by an Interpersonal 
Expectancy Bias,8 by which, they would have responded what they believed the 
investigators wanted to hear, or the investigators would have recorded what they 
wanted to report. Such biases get adequately balanced and controlled in 
randomized control studies, due to the presence of a comparable control arm, and 
should be planned in the future to retest and establish the findings of our study.  
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CHAPTER IX: FUTURE RESEARCH 
Our study findings will serve as a preface for further investigations on the 
paradoxical effects of caffeine consumption in PLWH. Organizations such as 
United States Food and Drug Administration (USFDA) and Food and Agriculture 
Department (FAO), can plan and accomplish future large scale studies on the 
effects of caffeine consumption in PLWH and regulate caffeine consumption in 
this population of PLWH.  
Though caffeine and its health effects have been widely researched in 
several vulnerable populations such as students, business personnel, athletes, 
night shift workers, military personnel, geriatric population, frequent travelers and 
college and university professionals,1 similar studies are lacking in PLWH. Large 
scale studies should be planned in the future with greater sample size, better 
sample selection methods, other pertinent outcomes, and  longer study durations 
for confirming and explaining the findings of our study.  
We had primarily focused on HIV disease progression, sleep and 
generalized anxiety, and nutritional and body composition outcomes but did not 
consider other potential domains such neuro-hormonal changes, nerve conduction 
velocities, loco-motor stimulatory effects, simple reaction time, choice reaction 
time, state and trait anxiety, Critical Flicker Fusion Threshold (CFFT) and muscle 
sympathetic activity scores which are  sleep and stress related variables affected 
by caffeine consumption.2-7 These are open areas for research because they are 
extensions of our study findings, where caffeine produced sleep loss and 
heightened anxiety states. Though dependence, tolerance and withdrawal effects 
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of caffeine have been researched in healthy populations,8-11 similar studies are 
non-existent in PLWH and are open areas for future research.  
There are very few studies on the effect of caffeine consumption on 
parameters of disease progression and hence there is no scientific consensus on 
this topic. Our study included CD4 counts and viral loads as markers of disease 
progression and found conflicting evidences of caffeine being both beneficial and 
detrimental to these variables. Several other markers such as time to ﬁrst 
occurrence of CD4 cell count ≤100 cells/mm3; ﬁrst occurrence of other 
infection/malignancy; and HIV-related deaths,12 could not be considered due to 
the short duration of the study. These additional parameters could have aided a 
better understanding about the effects of caffeine on HIV disease progression and 
should be considered by future large scale studies. Other behavioral markers such 
as the effect of caffeine consumption on mood, physical activity, routine physical 
functioning and performance, should also be considered in future studies.   
Future bio-chemical investigations are also critical to explain the dose 
response relationship between increased caffeine consumption and increased CD4 
cells and more controlled viral load observed in the current study. Caffeine has 
been associated with changes in plasma levels of hormones such as nor-
epinephrine, epinephrine, prostaglandins, cortisol, testosterone, and insulin, and 
cytokines such as interleukins-6, interleukin-8, interleukin-18, 8-isoprostane, 
interferons, tumor necrosis factors, E-selectins, Hypoxia-Inducible Factor-1α, and 
Vascular Endothelial Growth Factor in many studies.13-22 To fully understand the 
relationship of caffeine with parameters of disease progression, behavioral and 
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nutritional factors and their inter-relationships, these biomarkers should be 
measured and controlled, because they could explain the detrimental and 
beneficial outcomes observed in our study. Future large scale studies with 
sufficient resources should be planned to answer the questions raised by the 
paradoxical outcomes of our study. Additionally caffeine consumption should be 
considered for both the beneficial and the adverse effects in PLWH, in order to 
derive recommendations on safe levels of consumption for this population. 
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